Anti-vla1 (cd49a) antibody pharmaceutical compositions

ABSTRACT

Formulations of anti-VLA-1 antibodies are described.

RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No.61/599,827, filed on Feb. 16, 2012, the entire content of which ishereby incorporated in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted in ASCII format via EFS-Web and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Feb. 13, 2013, isnamed C2095-7004WO_SL.txt and is 35,968 bytes in size.

BACKGROUND

Integrins are a superfamily of cell surface receptors that mediatecell-cell and cell-matrix adhesion. These heterodimeric proteins,composed of two noncovalently linked polypeptide chains, α and β,provide anchorage as well as signals for cellular growth, migration anddifferentiation during development and tissue repair. Integrins havealso been implicated in immune and inflammatory processes, which requirethe extravasation of cells out of blood vessels, into tissues andtowards the site of infection.

VLA-1 (also called α1β1) belongs to a class of integrins called VLA(“Very Late Antigen”) integrins. VLA-1 binds collagen (both types I andIV) and laminin, and has been implicated in cell adhesion and migrationon collagen; contraction and reorganization of collagen matrices; andregulation of expression of genes involved in extracellular matrixremodeling.

VLA-1 has been shown to be involved in the development of rheumatoidarthritis, a chronic inflammatory disease associated with boneresorption. Infiltrating T cells in the arthritic synovium of patientsexpress high levels of VLA-1, and its blockade with antibodiessignificantly reduces the inflammatory response and the development ofarthritis in animal models.

SUMMARY

The invention is based, at least in part, on the development offormulations containing high concentrations of anti-VLA-1 antibody. Someembodiments are particularly well suitable for delivery to a subject,such as a human, for example, a human patient, by subcutaneous (SC)delivery. The anti-VLA-1 antibody can be SAN-300, for example, and theantibody is at a concentration of about ≥100 mg/mL to about 225 mg/mL.The formulations provide a therapeutic effect for an inflammatory,immune, or autoimmune disorder. For example, the formulation can providea therapeutic effect for an inflammatory disorder, such as rheumatoidarthritis (RA).

In one aspect, the invention features an aqueous pharmaceuticalcomposition, such as a stable aqueous pharmaceutical composition,containing an anti-VLA-1 antibody at a concentration of ≥100 mg/mL, forexample, at least about 110 mg/mL, at least about 120 mg/mL, at leastabout 130 mg/mL, at least about 140 mg/mL, at least about 150 mg/mL, atleast about 160 mg/mL, at least about 170 mg/mL, at least about 180mg/mL, at least about 190 mg/mL, or at least about 200 mg/mL. In oneembodiment, the composition comprises an anti-VLA-1 antibody at aconcentration of less than about 200 mg/mL, less than about 205 mg/mL,less than about 210 mg/mL, less than about 215 mg/mL, less than about220 mg/mL or less than about 225 mg/mL. In another embodiment, thecomposition comprises an anti-VLA-1 antibody at a concentration of about155 mg/mL to about 165 mg/mL, about 165 mg/mL to about 175 mg/mL, about175 mg/mL to about 185 mg/mL, about 180 mg/mL to about 190 mg/mL, about185 mg/mL to about 195 mg/mL, about 195 mg/mL to about 205 mg/mL, about205 mg/mL to about 215 mg/mL or about 215 mg/mL to about 225 mg/mL. Inanother embodiment, the composition comprises an anti-VLA-1 antibody ata concentration of greater than about 100 mg/mL to about 225 mg/mL, suchas about 160 mg/mL to about 210 mg/mL, about 175 mg/mL to about 195mg/mL, or about 180 mg/mL to about 190 mg/mL.

In one embodiment, the aqueous pharmaceutical composition comprising ananti-VLA-1 antibody further comprises a buffer, such as an acetate,histidine, succinate, or phosphate buffer. The buffer can be at aconcentration of about 10 mM to about 50 mM, for example, about 20 mM toabout 40 mM, such as about 30 mM. For example, the composition cancontain a histidine buffer at a concentration of about 10 mM to about 50mM, for example, about 20 mM to about 40 mM, such as about 30 mM. In oneembodiment, the composition contains an acetate buffer at aconcentration of about 10 mM to about 50 mM, for example, about 20 mM toabout 40 mM, such as about 30 mM.

In another embodiment, the aqueous pharmaceutical composition furthercomprises an excipient, such as sorbitol, sodium chloride (NaCl),sucrose, trehelose, or mannitol. The composition can include anexcipient at a concentration of about 100 mM to about 300 mM, forexample, 110 mM to about 270 mM, about 120 mM to about 230 mM, or about130 mM to about 210 mM, about 170 mM to about 200 mM, or about 180 mM toabout 200 mM. For example, the composition can contain sorbitol at aconcentration of about 180 mM to about 300 mM, for example, about 200 mMto about 300 mM, about 200 mM to about 240 mM, about 230 mM to about 270mM, or about 240 mM to about 260 mM. In another example, the compositioncan contain NaCl at a concentration of about 100 mM to about 200 mM, forexample, about 110 mM to about 190 mM, about 120 mM to about 180 mM, orabout 130 mM to about 170 mM. In another example, the composition cancontain sucrose at a concentration of about 200 mM to about 240 mM,about 230 mM to about 270 mM, or about 240 mM to about 260 mM. Inanother example, the composition can contain trehalose at aconcentration of about 200 mM to about 240 mM, about 230 mM to about 270mM, or about 240 mM to about 260 mM. In yet another example, thecomposition can contain mannitol at a concentration of about 200 mM toabout 240 mM, about 230 mM to about 270 mM, or about 240 mM to about 260mM.

In another embodiment, the aqueous pharmaceutical composition furthercomprises a surfactant, such as a polysorbate, for example, polysorbate80 or polysorbate 20. In one embodiment, the concentration of surfactantis at a concentration of about 0.001% to about 0.5%, about 0.001% toabout 0.1%, for example, about 0.005% to about 0.05%, such as about0.01%.

As used herein, a “surfactant” is a substance that lowers surfacetension of a liquid, and are used to prevent surface adsorption and actas stabilizers against protein aggregation. Exemplary surfactantssuitable for use herein include, for example, polysorbate 80 (alsocalled Tween 80), polysorbate 20 (also called Tween 20). Othersurfactants of similar strength can also be used.

In yet another embodiment, the aqueous pharmaceutical composition has apH of about 4.5 to about 7, for example, pH of about 5 to about 7, pH ofabout 5 to about 6, pH of about 5.5 to about 7, or pH of about 5.5 toabout 6.5. In one embodiment composition has a pH of about 4.5, a pH ofabout 5, a pH of about 5.5, a pH of about 6, a pH of about 6.5, or a pHof about 7.

In one embodiment, the aqueous pharmaceutical composition comprises abuffer, an excipient, and a surfactant. For example, in one embodiment,the aqueous pharmaceutical composition comprises acetate, sorbitol, andpolysorbate 80. In one embodiment, acetate is at concentration of about20 mM to about 40 mM, sorbitol is at a concentration of about 180 mM toabout 240 mM, polysorbate 80 is at a concentration of about 0.005% toabout 0.05%, and the composition has pH of about 4.5 to about 6. Inanother embodiment, acetate is at concentration of about 20 mM to about40 mM, sorbitol is at a concentration of about 200 mM to about 300 mM,polysorbate 80 is at a concentration of about 0.0055% to about 0.05%,and the composition has pH of about 4.5 to about 5.5. In one embodiment,acetate is at a concentration of about 30 mM, sorbitol is at aconcentration of about 180 mM to about 250 mM, polysorbate 80 is at aconcentration of about 0.01%, and the formulation has pH of about 5.5.

In another embodiment, the composition comprises histidine, sorbitol,and polysorbate 20. For example, histidine is at a concentration ofabout 20 mM to about 40 mM, sorbitol is at a concentration of about 180mM to about 270 mM, polysorbate 20 is at a concentration of about 0.005%to 0.05%, and the composition has pH of about 6 to about 7. In oneembodiment, histidine is at a concentration of about 30 mM, sorbitol isat a concentration of about 180 mM to about 250 mM, polysorbate 20 is ata concentration of about 0.01% and the composition has pH of about 6.0.

In another embodiment, the aqueous pharmaceutical composition comprisesacetate, NaCl, and polysorbate 80. In one embodiment, acetate is at aconcentration of about 20 mM to about 40 mM, NaCl is at a concentrationof about 120 mM to about 180 mM, polysorbate 80 is at a concentration ofabout 0.005% to about 0.05%, and the composition has pH of about 4.5 toabout 6. In one embodiment, acetate is at a concentration of about 30mM, NaCl is at a concentration of about 150 mM, polysorbate 80 is at aconcentration of about 0.01%, and the formulation has pH of about 5.5.

In another embodiment, the composition comprises histidine, NaCl, andpolysorbate 20. For example, histidine is at a concentration of about 20mM to about 40 mM, NaCl is at a concentration of about 120 mM to about180 mM, polysorbate 20 is at a concentration of about 0.005% to about0.05%, and the composition has pH of about 6 to about 7. In oneembodiment, histidine is at a concentration of about 30 mM, NaCl is at aconcentration of about 150 mM, polysorbate 20 is at a concentration ofabout 0.01% and the composition has pH of about 6.0.

In another embodiment, the anti-VLA-1 antibody in the aqueouspharmaceutical composition is a monoclonal antibody. In anotherembodiment, the anti-VLA-1 antibody is a CDR-grafted antibody. In yetanother embodiment, the anti-VLA-1 antibody is a humanized antibody.

In another embodiment, the anti-VLA-1 antibody is a humanized monoclonalantibody, such as SAN-300. In another embodiment, the anti-VLA-1antibody is a variant of SAN-300. For example, in some embodiments, thelight chain variable region of the antibody has an amino acid sequencethat differs by one or more amino acid residues, but not more than 2amino acid residues, 3 amino acid residues, 4 amino acid residues, 5amino acid residues, or 6 amino acid residues of the light chainvariable region of SAN-300, and/or the heavy chain variable region hasan amino acid sequence that differs by one or more amino acid residues,but not more than 2 amino acid residues, 3 amino acid residues, 4 aminoacid residues, 5 amino acid residues, or 6 amino acid residues of theheavy chain variable region of SAN-300. In some embodiments, some or alldifferences are conservative changes.

In another embodiment, the anti-VLA-1 antibody has one or both of alight chain variable region having the amino acid sequence of SEQ IDNO:4 (FIG. 2A), and a heavy chain variable region having the amino acidsequence of SEQ ID NO:5 (FIG. 2B). In other embodiments, the anti-VLA-1antibody is a variant of one of these antibodies. For example, in someembodiments, the light chain variable region has an amino acid sequencethat differs by one or more amino acid residues, but not more than 2amino acid residues, 3 amino acid residues, 4 amino acid residues, 5amino acid residues, 6 amino acid residues, 7 amino acid residues, 8amino acid residues, 9 amino acid residues or 10 amino acid residuesfrom the sequence in SEQ ID NO:4, and/or the heavy chain variable regionhas an amino acid sequence that differs by one or more amino acidresidues, but not more than 2 amino acid residues, 3 amino acidresidues, 4 amino acid residues, 5 amino acid residues, 6 amino acidresidues, 7 amino acid residues, 8 amino acid residues, 9 amino acidresidues or 10 amino acid residues as defined by SEQ ID NO:5. In otherembodiments, the light chain variable region has an amino acid sequencethat is 80%, 85%, 90% or 95% identical with the sequence of SEQ ID NO:4,and/or the heavy chain variable region has an amino acid sequence thatis 80%, 85%, 90% or 95% identical with the sequence of SEQ ID NO:5.

In yet another embodiment, the anti-VLA-1 antibody has one or both of alight chain amino acid sequence of SEQ ID NO: 1 (FIG. 3), and a heavychain amino acid sequence of SEQ ID NO:2 (FIG. 4). In other embodiments,the VLA-1 antibody is a variant of one of these antibodies. For example,in some embodiments, the light chain of the antibody has an amino acidsequence that differs by one or more amino acid residues, but not morethan 2 amino acid residues, 3 amino acid residues, 4 amino acidresidues, 5 amino acid residues, 6 amino acid residues, 7 amino acidresidues, 8 amino acid residues, 9 amino acid residues or 10 amino acidresidues from the sequence of SEQ ID NO: 1, and/or the heavy chain ofthe antibody has an amino acid sequence that differs by one or moreamino acid residues, but not more than 2 amino acid residues, 3 aminoacid residues, 4 amino acid residues, 5 amino acid residues, 6 aminoacid residues, 7 amino acid residues, 8 amino acid residues, 9 aminoacid residues or 10 amino acid residues from the sequence of SEQ IDNO:2. In other embodiments, the light chain of the antibody has an aminoacid sequence that is 80%, 85%, 90% or 95% identical with the sequenceof SEQ ID NO: 1, and/or the heavy chain of the antibody has an aminoacid sequence that 80%, 85%, 90% or 95% identical with the sequence ofSEQ ID NO:2.

A first amino acid sequence “differs” or is “different” or displays a“difference” as compared to a second amino acid sequence when there is adifference in the identity of an amino acid (for example, a substitutionof a different amino acid for an amino acid in SEQ ID NO:4 or 5 referredto above), or a deletion or insertion. A difference can be, for example,in a framework region, a CDR, a hinge, or a constant region. Adifference can be internal or at the end of a sequence of protein. Insome embodiments, some or all differences are conservative changes ascompared to the recited sequence.

In another embodiment, the composition comprises less than 20 mMcitrate, and in another embodiment the composition is substantially freeof citrate. For example, the level of citrate comprises less than 20 mMcitrate, or the level of citrate is such that it has no effect on aproperty described herein, such as, injection site pain when embodimentsare administered to a subject.

In another embodiment, the aqueous pharmaceutical composition comprisingan anti-VLA-1 antibody is stable for at least 6 months, at least 12months, at least 18 months, at least 24 months, at least 30 months, orat least 36 months or longer (for example, at least 1 year, at least 2years, at least 3 years or longer). For example, the composition can bestable for at least 6 months, at least 12 months, at least 18 months, atleast 24 months, at least 30 months, at least 36 months or longer (forexample, at least 1 year, at least 2 years, at least 3 years, orlonger), at a temperature of about 2° C. to about 8° C. (for example,about 4° C., about 5° C.). In one embodiment, the composition is stablefor at least 24 months (at least 2 years) at a temperature of about 2°C. to about 8° C. In another embodiment, the composition is stable forat least 2 days, at least 3 days, at least 4 days, at least 5 days, atleast 6 days, or at least 7 days or longer (for example, at least oneweek, or at least 12 days or at least 14 days or longer) at ambienttemperature (about 20° C. to about 30° C., such as about 25° C.).

In one embodiment, less than about 1%, less than about 2%, less thanabout 5%, less than about 10%, or less than about 15% of the antibody inthe anti-VLA-1 antibody composition has aggregated after a period of 6months, 12 months, 18 months, 24 months, 30 months, or 36 months orlonger, such as after a period of 1 year, 2 years or 3 years or longer.In another embodiment, less than about 1%, less than about 2%, less thanabout 5%, less than about 10%, or less than about 15% of the antibody inthe anti-VLA-1 antibody composition has fragmented after a period of 6months, 12 months, 18 months, 24 months, 30 months, or 36 months orlonger, such as after a period of 1 year, 2 years, 3 years or longer.

In certain embodiments, aggregation or protein fragmentation is measuredby dynamic light scattering (DLS), size exclusion chromatography (SEC),color/clarity, UV light scattering or size exclusion chromatography. Inone embodiment, aggregation is measured by DLS. DLS can be performed bymethods known those of ordinary skill in the art such as thosedescribed, for example, in Nobbmann et al., “Dynamic Light Scattering asa Relative Tool for Assessing the Molecular Integrity and Stability ofMonoclonal Antibodies” Biotech. and Genetic Engineering Rev. 24:117-128,2007. In another embodiment, aggregation is measured by SEC. SEC can beperformed by methods known to those of ordinary skill in the art such asthose described, for example, in Skoog, D. A.; Principles ofInstrumental Analysis, 6th ed.; Thompson Brooks/Cole: Belmont, C A,2006, Chapter 28.

In one embodiment, less than about 1%, less than about 2%, less thanabout 5%, less than about 10%, less than about 15% or less than about20% of the antibody in the aqueous pharmaceutical composition hasundergone fragmentation after a period of 6 months, 12 months, 18months, 24 months, 30 months, or 36 months or longer (for example, aftera period of 1 year, 2 years, 3 years or longer).

In one embodiment, less than about 1%, less than about 2%, less thanabout 5%, less than about 10%, less than about 15% or less than about20% of the antibody in the aqueous pharmaceutical composition hasundergone deamidation after a period of 6 months, 12 months, 18 months,24 months, 30 months, or 36 months or longer (for example, after aperiod of 1 year, 2 years, 3 years or longer). In another embodiment,deamidation is assayed by measuring protein loss, such as byspectroscopy, for example, UV-Vis (“Ultraviolet-visible”) spectroscopy.Use of UV-Vis spectroscopy is reviewed in, for example, Schmid,“Biological Macromolecules: UV-visible spectrophotometry” Encyclopediaof Life Sciences, pp. 1-4, published online Apr. 19, 2001.

In one embodiment, anti-VLA-1 antibody in the aqueous pharmaceuticalcomposition exhibits less than a preselected level of aggregation whenthe formulation is stored in a closed container at about 2° C. to about8° C., such as at about 4° C., for a preselected period of time, such asafter storage for at least 30 days, at least 60 days, at least 90 days,at least 180 days, at least 1 year, at least 1.5 years, at least 2years, at least 2.5 years, at least 3 years or longer. In anotherembodiment, anti-VLA-1 antibody in the aqueous pharmaceuticalcomposition exhibits less than a preselected level of protein loss dueto aggregation when the formulation is stored in a closed container atabout 2° C. to about 8° C., for example, at about 4° C., for apreselected period of time. In one embodiment, the preselected level ofprotein loss is less than about 40%, less than about 35%, less thanabout 30%, less than about 20%, less than about 15%, less than about10%, less than about 8%, less than about 5%, less than about 3%, lessthan about 1%, or less than about 0.5%. In one embodiment, after 6months, one year, two years or three years, less than about 1%, lessthan about 2%, less than about 5%, less than about 10%, less than about15%, less than about 20%, less than about 30%, less than about 35%, orless than about 40% of the antibody in the formulation has undergoneaggregation.

Protein loss can be measured, for example, by spectroscopy, such as byUV-Vis spectroscopy. In certain embodiments, aggregation is measured bydynamic light scattering (DLS), color/clarity, UV light scattering orsize exclusion chromatography.

In another embodiment, anti-VLA-1 antibody in the aqueous pharmaceuticalcomposition exhibits less than a preselected level of protein loss whenthe formulation is subjected to a preselected number of freeze/thawcycles, for example, 2, 3, 4, 5, 6, 7, 8 or more freeze/thaw cycles. Inone embodiment, the preselected number of freeze/thaw cycles is 5. A“freeze/thaw cycle” is a sequence comprising at least one period inwhich the sample is a frozen solid followed by a period in which thesamples is a liquid, or a sequence comprising at least one period inwhich the sample is liquid followed by a period in which the samples isa frozen solid. The periods can be equal to, or longer than, forexample, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 45minutes, 60 minutes, or 120 minutes, 2 hours, 3 hours, 4 hours, 6 hours,24 hours, 48 hours, or 3 days, 5 days, 10 days, or 20 days in length.The liquid and solid periods need not be of the same length. The solidperiods can be held at 0° C. or less, for example, −10° C., −20° C.,−30° C., −40° C., −60° C., or −80° C. The solid period can be at least,for example, 2 hours, 3 hours, 4 hours, or more. The solid period can befollowed by thawing, for example, at 18° C., 20° C., 23° C., or higher,until melted. The sample can remain melted for 20 minutes, 30 minutes,one hour, or two hours or longer, prior to freezing the sample again, tobegin another freez/thaw cycle. The sample can be stored in the frozenstate or in the melted state between freeze/thaw cycles. In oneembodiment, the preselected level of protein loss following 2, 3, 4, 5,6, 7, 8 or more freeze/thaw cycles is, for example, less than about 40%,less than about 35%, less than about 30%, less than about 20%, less thanabout 15%, less than about 10%, less than about 8%, less than about 5%,less than about 3%, less than about 1%, or less than about 0.5%. Proteinloss can be measured, for example, by UV-Vis spectroscopy.

In yet another embodiment, anti-VLA-1 antibody in the aqueouspharmaceutical composition exhibits less than a preselected level ofprotein loss when the formulation is subjected to photo stress, such aswhen the composition is stored in a closed container at 2° C. to 8° C.,for example, 4° C., and exposed to 1.2 lux hours white light and then200W/m² UV energy. In one embodiment, the preselected level of proteinloss is less than about 40%, less than about 35%, less than about 30%,less than about 20%, less than about 15%, less than about 10%, less thanabout 8%, less than about 5%, less than about 3%, less than about 1%, orless than about 0.5%. Protein loss can be measured, for example, byUV-Vis spectroscopy.

In another embodiment, anti-VLA-1 antibody in the aqueous pharmaceuticalcomposition exhibits less than a preselected level of protein loss whenthe formulation is subjected to agitation, for example, shaking at 550rpm, 600 rpm, 650 rpm, 700 rpm, 750 rpm, or faster, for a preselectedperiod of time, such as for 1 day, 2 days, 3 days, 4 days, 5 days orlonger (for example, for 24 hours, 48 hours, 72 hours, 96 hours, 120hours or longer at room temperature. In one embodiment, the preselectedlevel of protein loss is less than about 40%, less than about 35%, lessthan about 30%, less than about 20%, less than about 15%, less thanabout 10%, less than about 8%, less than about 5%, less than about 3%,less than about 2%, less than about 1.5%, less than about 1%, less thanabout 0.5%, or less than about 0.25%. Protein loss can be measured, forexample, by UV-Vis spectroscopy.

In one embodiment, anti-VLA-1 antibody in the aqueous pharmaceuticalcomposition exhibits less than a preselected level of protein loss whenthe formulation is subjected to a preselected level of oxidation stress.The preselected level of oxidation stress can be provided by thepresence of hydrogen peroxide at a final concentration of 0.04% (v/v)with incubation at 37° C. for a preselected period of time, such as for2 hours, 3 hours, 4 hours, 5 hours, or 6 hours or longer. In oneembodiment, the preselected level of protein loss is less than about35%, less than about 30%, less than about 25%, less than about 20%, lessthan about 15%, or less than about 10%. Protein loss can be measured,for example, by UV-Vis spectroscopy.

In one embodiment, the anti-VLA-1 antibody in the aqueous pharmaceuticalcomposition exhibits less than a preselected level of protein loss whenthe formulation is subjected to a preselected level of deamidationstress. The preselected level of deamidation can be provided by raisingthe pH of the composition, such as to a pH 29, such as in the presenceof Tris (tris(hydroxymethyl)aminomethane) buffer, and then incubatingthe composition at about 25° C. for a preselected period of time, suchas for 2 days, 3 days, 4 days, 5 days, 6 days or longer. In oneembodiment, the preselected level of protein loss is less than about20%, less than about 15%, less than about 10%, less than about 5%, lessthan about 3%, or less than about 1%. Protein loss can be measured, forexample, by UV-Vis spectroscopy.

In one embodiment, the aqueous pharmaceutical composition comprising ananti-VLA-1 antibody formulation is for subcutaneous (SC) administration.

In one embodiment, the aqueous pharmaceutical composition has asyringeability for patient self administration to a subcutaneous site.For example, the aqueous composition, when disposed in a syringesuitable for subcutaneous delivery can be expelled and thereby injectedinto a subcutaneous site of the patient, using pressure sufficient todepress the plunger for patient self administration. The pressure, or“plunger force” can be, for example, equal to or less than 4 lbs. In oneembodiment, the plunger force will allow delivery of a unit dosage in 10seconds or less. In another embodiment, about 1 mL of an aqueouspharmaceutical composition, disposed in a syringe having a needle of apreselected gauge, can be expelled at a preselected rate with a plungerforce of no more than a preselected amount. In another embodiment, about2 mL of aqueous pharmaceutical composition, disposed in a syringe havinga needle of a preselected gauge, can be expelled at a preselected ratewith a plunger force of no more than a preselected amount. For example,about 1 mL aqueous pharmaceutical composition, disposed in a syringehaving a 25 gauge needle, a 27 guage needle, or a 30 guage needle can beexpelled at 10 mL/minute with a plunger force of no more than 4 lbs.

As used herein, a “unit dosage” is an amount suitable for administrationat one time. The unit dosage can provide a therapeutically effectiveamount of anti-VLA-1 antibody, for example an amount of anti-VLA-1antibody to relieve one or more symptoms of an inflammatory disorder,such as one or more symptoms of arthritis or IBD.

In one embodiment, the aqueous pharmaceutical composition comprising ananti-VLA-1 antibody has a viscosity suitable for subcutaneous deliverywith a syringe, such as a viscosity of less than 21 cP (centipoises),less than 18 cP, less than 15 cP, less than 14 cP, such as at 3 rpm, 5rpm, 7 rpm, or 9 rpm. In one embodiment, the composition has a viscosityof about 10 cP to about 20 cP, about 10 cP to about 15 cP, about 10 cPto about 14 cP, or for example, 10 cP to 13 cP, at for example 3 rpm, 5rpm, 7 rpm, or 9 rpm.

“Viscosity” is a measure of the resistance of a fluid that is beingdeformed by either shear or tensile stress. A thicker substance hashigher resistance, and thus higher viscosity, than a thinner substance.

In one embodiment, the aqueous pharmaceutical composition is foradministration by a healthcare professional.

In one aspect, the invention features an aqueous pharmaceuticalcomposition comprising an anti-VLA-1 antibody comprising a light chainhaving the sequence of SEQ ID NO: 1 and a heavy chain having thesequence of SEQ ID NO:2; acetate at a concentration of about 10 mM toabout 50 mM; sorbitol at a concentration of about 180 mM to about 275mM; polysorbate 80 at 0.005% to 0.5%; and pH of about 4.5 to pH of about6.0. In one embodiment, the antibody concentration is ≥100 mg/mL toabout 225 mg/mL, for example, about 120 mg/mL to about 210 mg/mL, about140 mg/mL to about 200 mg/mL. In another embodiment, the antibody is ata concentration of about 155 mg/mL to about 195 mg/mL, about 160 mg/mLto about 190 mg/mL, or about 170 mg/mL to about 180 mg/mL. In someembodiments, the antibody is at a concentration of about 160 mg/mL,about 165 mg/mL, about 175 mg/mL, about 180 mg/mL or about 190 mg/mL.

In one embodiment, the aqueous pharmaceutical composition comprisesacetate at a concentration of about 20 mM to about 40 mM, for exampleabout 30 mM. In another embodiment, the aqueous pharmaceuticalcomposition contains sorbitol at a concentration of about 180 mM toabout 275 mM, for example, about 200 mM to about 240 mM. In oneembodiment, the aqueous pharmaceutical composition contains sorbitol ata concentration of about 250 mM. In one embodiment, the aqueouspharmaceutical composition contains polysorbate 80 at a concentration ofabout 0.005% to about 0.05%, such as at about 0.01%. In yet anotherembodiment, the aqueous pharmaceutical composition has a pH of about5.5.

In one embodiment, the aqueous pharmaceutical composition comprising ananti-VLA-1 antibody has an osmolality of about 80 mOsm/kg to about 500mOsm/kg, for example, about 100 mOsm/kg to about 450 mOsm/kg, about 150mOsm/kg to about 400 mOsm/kg, about 200 mOsm/kg to about 350 mOsm/kg,for example, about 280 mOsm/kg to about 350 mOsm/kg, for example, about300 mOsm/kg to about 325 mOsm/kg. In one example, the aqueouspharmaceutical composition comprising an anti-VLA-1 antibody has anosmolality of less than about 500 mOsm/kg, less than about 455 mOsm/kg,less than about 405 mOsm/kg, less than about 355 mOsm/kg, less thanabout 305 mOsm/kg, or less than about 255 mOsm/kg.

In another embodiment, the aqueous pharmaceutical composition containsan anti-VLA-1 antibody comprising a light chain having the sequence ofSEQ ID NO:1 and a heavy chain having the sequence of SEQ ID NO:2 at aconcentration of about 170 mg/mL to about 210 mg/mL. In one embodiment,the composition also includes acetate at a concentration of about 25 mMto about 35 mM, sorbitol at a concentration of about 180 mM to about 275mM, polysorbate 80 at a concentration of about 0.005% to about 0.02%,and a pH of about 5.5.

In one embodiment, the aqueous pharmaceutical composition includes ananti-VLA-1 antibody comprising a light chain having the sequence of SEQID NO:1 and a heavy chain having the sequence of SEQ ID NO:2 at aconcentration of about 185 mg/mL to about 195 mg/mL; acetate at aconcentration of about 30 mM; sorbitol at a concentration of about 250mM; polysorbate 80 at a concentration of about 0.01%; and a pH of about5.5.

In one embodiment, the aqueous pharmaceutical composition comprisesanti-VLA-1 antibody at a concentration of about 190 mg/mL.

In one aspect, the invention features an aqueous pharmaceuticalcomposition comprising an anti-VLA-1 antibody comprising a light chainhaving the sequence of SEQ ID NO: 1 and a heavy chain having thesequence of SEQ ID NO:2; acetate at a concentration of about 10 mM toabout 50 mM; NaCl at a concentration of about 120 mM to about 180 mM;polysorbate 80 at a concentration of about 0.005% to about 0.05%; and apH of about 4.5 to about 6.0. In one embodiment, the antibody is at aconcentration of ≥100 mg/mL to about 225 mg/mL, for example, about 120mg/mL to about 210 mg/mL, about 140 mg/mL to about 200 mg/mL. In anotherembodiment, the antibody is at concentration of about 155 mg/mL to about195 mg/mL, about 160 mg/mL to about 190 mg/mL, or about 170 mg/mL toabout 180 mg/mL. In some embodiments, the antibody is at a concentrationof about 160 mg/mL, about 165 mg/mL, about 175 mg/mL, about 180 mg/mL orabout 190 mg/mL.

In one embodiment, the aqueous pharmaceutical composition comprisesacetate at a concentration of about 20 mM to about 40 mM, for exampleabout 30 mM. In another embodiment, the aqueous pharmaceuticalcomposition contains NaCl at a concentration of about 130 mM to about170 mM, for example, about 140 mM to about 160 mM. In one embodiment,the aqueous pharmaceutical composition contains NaCl at a concentrationof about 150 mM. In one embodiment, the aqueous pharmaceuticalcomposition contains polysorbate 80 at a concentration of about 0.005%to about 0.05%, such as at about 0.01%. In yet another embodiment, theaqueous pharmaceutical composition has a pH of about 5.5.

In one embodiment, the aqueous pharmaceutical composition comprising ananti-VLA-1 antibody has an osmolality is 80 mOsm/kg to 350 mOsm/kg.

In another embodiment, the aqueous pharmaceutical composition containsan anti-VLA-1 antibody comprising a light chain having the sequence ofSEQ ID NO:1 and a heavy chain having the sequence of SEQ ID NO:2 at aconcentration of about 170 mg/mL to about 210 mg/mL. In one embodiment,the composition also includes acetate at a concentration of about 25 mMto about 35 mM, NaCl at a concentration of about 120 mM to about 180 mM,polysorbate 80 at a concentration of about 0.005% to about 0.02%, and apH of about 5.5.

In one embodiment, the aqueous pharmaceutical composition includes ananti-VLA-1 antibody comprising a light chain having the sequence of SEQID NO:1 and a heavy chain having the sequence of SEQ ID NO:2 at aconcentration of about 185 mg/mL to about 195 mg/mL; acetate at aconcentration of about 30 mM; NaCl at a concentration of about 150 mM;polysorbate 80 at about 0.01%; and a pH of about 5.5.

In one embodiment, the aqueous pharmaceutical composition comprisesanti-VLA-1 antibody at a concentration of about 190 mg/mL.

In one aspect, the invention features an aqueous pharmaceuticalcomposition comprising an anti-VLA-1 antibody comprising a light chainhaving the sequence of SEQ ID NO:1 and a heavy chain having the sequenceof SEQ ID NO:2; histidine at a concentration of about 10 mM to about 50mM; sorbitol at a concentration of about 180 mM to about 300 mM;polysorbate 20 at a concentration of about 0.005% to about 0.05%; and apH of about 5.5 to about 7.0. In one embodiment, the antibody is at aconcentration of ≥100 mg/mL to about 225 mg/mL, for example, about 120mg/mL to about 210 mg/mL, about 140 mg/mL to about 200 mg/mL. In anotherembodiment, the antibody is at a concentration of about 155 mg/mL toabout 195 mg/mL, about 160 mg/mL to about 190 mg/mL, or about 170 mg/mLto about 180 mg/mL. In some embodiments, the antibody is at aconcentration of about 160 mg/mL, about 165 mg/mL, about 175 mg/mL,about 180 mg/mL or about 190 mg/mL.

In one embodiment, the composition includes histidine at a concentrationof 20 mM to 40 mM, such as at a concentration of about 30 mM. In anotherembodiment, the composition comprises sorbitol at a concentration of 220mM to 280 mM, for example, 240 mM to 260 mM, such as about 250 mM. Inanother embodiment, the composition comprises polysorbate 20 at aconcentration of about 0.005% to 0.05%, such as about 0.01%. In anotherembodiment, the composition has a pH of about 6.0, and in yet anotherembodiment, the composition has an osmolality of about 280 mOsm/kg toabout 350 mOsm/kg.

In one embodiment, the aqueous pharmaceutical composition includes ananti-VLA-1 antibody comprising a light chain having the sequence of SEQID NO:1 and a heavy chain having the sequence of SEQ ID NO:2 at aconcentration of about 160 mg/mL to about 200 mg/mL; histidine at aconcentration of about 25 mM to about 35 mM histidine; sorbitol at aconcentration of about 240 mM to about 260 mM; polysorbate 20 at aconcentration of about 0.005% to about 0.02%; and a pH of about 6.

In another embodiment, the composition includes an anti-VLA-1 antibodycomprising a light chain having the sequence of SEQ ID NO: 1 and a heavychain having the sequence of SEQ ID NO:2 at a concentration of about 170mg/mL to about 180 mg/mL; histidine at a concentration of about 30 mM;sorbitol at a concentration of about 250 mM; polysorbate 20 at aconcentration of about 0.01%; and a pH of about 6.

In one embodiment, the composition includes antibody at a concentrationof about 180 mg/mL.

In one aspect, the invention features an aqueous pharmaceuticalcomposition comprising an anti-VLA-1 antibody comprising a light chainhaving the sequence of SEQ ID NO:1 and a heavy chain having the sequenceof SEQ ID NO:2; histidine at a concentration of about 10 mM to about 50mM; NaCl at a concentration of about 120 mM to about 180 mM; polysorbate20 at a concentration of about 0.005% to about 0.05%; and a pH of about5.5 to about 7.0. In one embodiment, the antibody concentration is at aconcentration of ≥100 mg/mL to about 225 mg/mL, for example, about 120mg/mL to about 210 mg/mL, or about 140 mg/mL to about 200 mg/mL. Inanother embodiment, the antibody concentration is about 155 mg/mL toabout 195 mg/mL, about 160 mg/mL to about 190 mg/mL, or about 170 mg/mLto about 180 mg/mL. In some embodiments, the antibody concentration isabout 160 mg/mL, about 165 mg/mL, about 175 mg/mL, about 180 mg/mL or190 mg/mL.

In one embodiment, the composition includes histidine at a concentrationof about 20 mM to about 40 mM, such as at a concentration of about 30mM. In another embodiment, the composition comprises NaCl at aconcentration of about 130 mM to about 170 mM, for example, about 140 mMto about 160 mM, such as about 150 mM. In another embodiment, thecomposition comprises polysorbate 20 at a concentration of about 0.005%to about 0.05%, such as about 0.01%. In another embodiment, thecomposition has a pH of about 6.0, and in yet another embodiment, thecomposition has an osmolality of about 280 mOsm/kg to about 350 mOsm/kg.

In one embodiment, the aqueous pharmaceutical composition includes ananti-VLA-1 antibody comprising a light chain having the sequence of SEQID NO:1 and a heavy chain having the sequence of SEQ ID NO:2 at aconcentration of about 160 mg/mL to about 200 mg/mL; histidine at aconcentration of about 25 mM to about 35 mM histidine; NaCl at aconcentration of about 140 mM to about 160 mM; polysorbate 20 at aconcentration of about 0.005% to about 0.02%; and a pH of about 6.

In another embodiment, the composition includes an anti-VLA-1 antibodycomprising a light chain having the sequence of SEQ ID NO: 1 and a heavychain having the sequence of SEQ ID NO:2 at a concentration of about 170mg/mL to about 180 mg/mL; histidine at a concentration of about 30 mM;NaCl at a concentration of about 150 mM; polysorbate 20 at about 0.01%;and a pH of about 6.

In one embodiment, the composition includes antibody at a concentrationof about 180 mg/mL.

In one aspect, the invention features an aqueous pharmaceuticalcomposition containing an anti-VLA-1 antibody in an amount effective fortreatment of inflammatory disease; and means for delivering theeffective amount of the antibody in a formulation suitable forsubcutaneous delivery.

In one aspect, the invention features a unit dosage form of an aqueouspharmaceutical composition described herein. In one embodiment, thecomposition includes about 200 mg of anti-VLA-1 antibody. In anotherembodiment, the composition includes an anti-VLA-1 antibody at about 155mg to about 165 mg, about 165 mg to about 175 mg, about 175 mg to about185 mg, about 185 mg to about 195 mg, about 195 mg to about 205 mg,about 205 mg to about 215 mg, or about 215 mg to about 225 mg. In oneembodiment, the composition includes anti-VLA-1 antibody at about 160 mgto about 210 mg of antibody, for example, about 180 mg or about 190 mg.

In one embodiment, the aqueous pharmaceutical composition containing ananti-VLA-1 antibody, when administered to a human will deliver about 2.0mg antibody per kg of body weight to about 4.0 mg antibody per kg ofbody weight to the human.

In another embodiment, the aqueous pharmaceutical composition has avolume of about 0.25 mL to about 1.5 mL, such as about 0.5 mL, about0.75 mL, or about 1.0 mL. In one embodiment, a unit dose delivers ananti-VLA-1 antibody at about 80 mg to about 315 mg, such as about 100mg, about 160 mg, about 180 mg, about 190 mg, about 210 mg, about 250mg, or about 300 mg.

In another aspect, the invention features a unit dose of an aqueousformulation of anti-VLA-1 antibody, where administration of the unitdose will deliver an anti-VLA-1 antibody at about 0.03 mg per kg bodyweight to about 10 mg per kg body weight, about 0.03 mg per kg bodyweight to about 6 mg per kg body weight, about 0.1 mg per kg body weightto about 6 mg per kg body weight, about 0.3 mg per kg body weight about6 mg per kg body weight, about 0.3 mg per kg body weight to about 3 mgper kg body weight, about 1 mg per kg body weight about 3 mg per kg bodyweight, about 2.0 mg per kg body weight to about 4.0 mg per kg bodyweight. For example, administration of the unit dose to a human willdeliver about 2.1 mg/kg, about 2.2 mg/kg, about 2.3 mg/kg, about 2.5mg/kg, about 2.8 mg/kg, about 3.0 mg/kg, about 3.1 mg/kg, about 3.2mg/kg, about 3.3 mg/kg, about 3.4 mg/kg, or about 3.6 mg/kg.

In one aspect, the invention features a plurality of unit dosage formsof an aqueous pharmaceutical composition described herein. In oneembodiment, the plurality is two.

In one embodiment, the plurality of unit dosage forms, when takentogether, comprise at least about 160 mg anti-VLA-1 antibody, at leastabout 170 mg anti-VLA-1 antibody, at least about 180 mg anti-VLA-1antibody, at least about 190 mg anti-VLA-1 antibody, at least about 200mg anti-VLA-1 antibody, at least about 300 mg anti-VLA-1 antibody, atleast about 400 mg anti-VLA-1 antibody, at least about 500 mg anti-VLA-1antibody, at least about 600 mg anti-VLA-1 antibody, at least about 700mg anti-VLA-1 antibody, at least about 800 mg anti-VLA-1 antibody, atleast about 900 mg anti-VLA-1 antibody, at least about 1000 mganti-VLA-1 antibody. In another embodiment, the plurality of unit dosageforms, when taken together, comprise about 155 mg anti-VLA-1 antibody toabout 165 mg anti-VLA-1 antibody, about 165 mg anti-VLA-1 antibody toabout 175 mg anti-VLA-1 antibody, about 175 mg anti-VLA-1 antibody toabout 185 mg anti-VLA-1 antibody, about 185 mg anti-VLA-1 antibody toabout 195 mg anti-VLA-1 antibody, about 195 mg anti-VLA-1 antibody toabout 205 mg anti-VLA-1 antibody, about 205 mg anti-VLA-1 antibody toabout 215 mg anti-VLA-1 antibody, about 215 mg anti-VLA-1 antibody toabout 225 mg anti-VLA-1 antibody. In yet another embodiment, theplurality of unit dosage forms, when taken together, include about 160mg anti-VLA-1 antibody to about 210 mg anti-VLA-1 antibody, for example,about 180 mg anti-VLA-1 antibody, or about 190 mg anti-VLA-1 antibody.

In one embodiment, the plurality of unit dosage forms, when takentogether, when administered to a human, will deliver about 0.03 mganti-VLA-1 antibody per kg of body weight to about 10.0 mg anti-VLA-1antibody per kg body weight.

In one embodiment, each of the plurality of unit dosage forms has avolume of about 0.25 mL to about 3 mL, for example, about 1 mL, about1.5 mL, about 2 mL, or about 2.5 mL.

In one embodiment, each dosage form can contain an equal amount ofantibody.

In one aspect, the invention features a kit comprising a unit dosageform as described herein.

In one aspect, the invention features a container, having disposedtherein, an aqueous pharmaceutical composition described herein. In oneembodiment, the container has disposed therein, a unit dosageformulation as described herein.

In one embodiment, the container is a delivery device, such as asyringe. In another embodiment, the container is suitable forsubcutaneous administration.

In one aspect, the invention features a method of administering anaqueous pharmaceutical composition described herein by activating adelivery device, and then administering the anti-VLA-1 antibody disposedin the delivery device to the patient.

In one embodiment, activating the device comprises one of more ofremoving the device from a packaging, removing a cover from the needleor orifice of the device, or shaking the device. In another embodiment,activating the device further includes inspecting the device for thepresence of precipitate, colored material, or turbidity, or opalescence.

In one embodiment, the patient, for example, a patient who has aninflammatory disorder, performs one or both steps of administering thecomposition.

In one embodiment the patient has arthritis, such as rheumatoidarthritis; inflammatory bowel disease; lupus; transplant rejection; orpsoriasis.

The invention features methods that optimize provision of a liquidformulation of an anti-VLA-1 antibody, such as SAN-300, to a patient.

In one embodiment, the method allows for a gradual increase in theconcentration of the antibody provided. This allows ramp-up of antibodyconcentration and can allow monitoring of the patient for tolerance,reactions and the like as the concentration is increased. For example,the method can start by providing SAN-300 to the patient at one or moreinitial or relatively low concentrations followed by providing SAN-300to the patient at a final, higher concentration. Exemplary formulationsfor the initial concentration will typically have an antibodyconcentration of less than about 80%, less than about 70%, less thanabout 50%, less than about 30%, less than about 20% or less than about10% of the final higher concentration. Typical initial concentrationscan be, for example, about 20 mg/mL, about 30 mg/mL, or about 40 mg/mL.Typical final concentrations will be, for example, about 150 mg/mL toabout 225 mg/mL, for example, about 160 mg/mL, about 170 mg/mL, about175 mg/mL, about 180 mg/mL, about 190 mg/mL, or about 200 mg/mL. In someembodiments, the patient will receive one, or a plurality ofadministrations at one or a plurality of initial concentrations. Forexample, in one embodiment, the patient will receive increasingconcentrations over a number of administrations. In some embodiments,the patient will receive 2, 3, 4, 5, 6, 7, or 8 administrations at oneor more initial concentrations prior to reaching the finalconcentration. For example, the patient will receive one or moreadministrations at a first initial concentration, and one or moreadministrations at a second higher concentration. In some embodiments,the patient is assessed after one or more administrations for symptoms,including adverse symptoms. In some embodiments, the patient isadministered a formulation having an increased concentration of SAN-300only after determining that the patient does not have an unacceptableadverse reaction to the previous administration.

In one embodiment, the anti-VLA-1 antibody composition is providedprepackaged in a container, which can be, for example, a deliverydevice, such as a syringe.

In another aspect, the invention features a method of instructing apatient in need of an anti-VLA-1 antibody therapy how to administer aformulation described herein. The method includes (i) providing thepatient with at least one unit dose of a formulation of an anti-VLA-1antibody described herein; and (ii) instructing the patient toself-administer the at least one unit dose subcutaneously. Anothermethod included in the invention is a method of treatment that includes(i) providing the patient with at least two unit doses of a formulationof anti-VLA-1 antibody; and (ii) instructing the patient toself-administer the unit doses subcutaneously, for example,subcutaneously, one dose at a time.

In one embodiment, the patient has an inflammatory, immune, orautoimmune disorder, such as an arthritic disorder, such as rheumatoidarthritis, juvenile arthritis, psoriatic arthritis, or ankylosingspondylitis; tissue or organ graft rejection or graft-versus-hostdisease; acute CNS injury, such as stroke or spinal cord injury; chronicrenal disease; allergy, such as allergic asthma; type 1 diabetes; aninflammatory bowel disorder, such as Crohn's disease or ulcerativecolitis; myasthenia gravis; fibromyalgia; an inflammatory/immune skindisorder, such as psoriasis, vitiligo, dermatitis, or lichen planus;systemic lupus erythematosus; Sjogren's Syndrome; a hematologicalcancer, such as multiple myeloma, leukemia, or lymphoma; a solid cancer,such as a sarcoma or carcinoma, such as of the lung, breast, prostate,or brain; or a fibrotic disorder, such as pulmonary fibrosis,myelofibrosis, liver cirrhosis, mesangial proliferativeglomerulonephritis, crescentic glomerulonephritis, diabetic nephropathy,or renal interstitial fibrosis.

In another aspect, the invention features a method of treating a patientby administering to the patient a composition containing an anti-VLA-1antibody in a formulation for subcutaneous administration, for example,a composition as described herein. In one embodiment, the patient has aninflammatory disorder, such as arthritis, for example, rheumatoidarthritis (RA); an inflammatory bowel disease; lupus; transplantrejection; psoriasis; fibrosis; or Crohn's disease. In anotherembodiment, the composition is administered as a regimen. In anotherembodiment, the method further includes selecting a patient suitable fortreatment with the composition. A patient suitable for treatment, forexample, has demonstrated a sign or symptom indicative of disease onset,such as a sign or symptom indicative of RA. In yet another embodiment,the method further includes administering to the patient a secondtherapeutic agent, such as an anti-inflammatory, an antihistamine, ananalgesic or a corticosteroid.

In one embodiment, the patient has rheumatoid arthritis, and is selectedon the basis that the patient has demonstrated an inadequate response toa prior alternate treatment for rheumatoid arthritis. A “prior alternatetreatment” refers to any treatment other than a treatment comprising ananti-VLA-1 antibody as described herein. The prior alternate treatmentfor rheumatoid arthritis can be, for example, a DMARD (Disease ModifyingAntirheumatic Drug) or a TNF-α (Tumor Necrosis Factor-α) inhibitor. TheDMARD can be, for example, methotrexate, leflunomide, sulfasalazine, orhydroxychloroquine. In one embodiment, the TNF-α inhibitor is anantibody, such as infliximab, adalimumab, certolizumab pegol, orgolimumab; or a fusion protein, such as etanercept. In anotherembodiment, the first therapeutic agent is an inhibitor of VLA-2, suchas an anti-VLA-2 antibody, for example GBR 500.

In one embodiment, the method of treating a patient further comprisesadministering to the patient a second therapeutic agent, such as acorticosteroid, an anti-inflammatory, an antihistamine or an analgesic,such as acetaminophen.

In another embodiment, the second therapeutic agent is a Bcell-depleting agent, such as an anti-CD20 antibody, for examplerituximab (Rituxan, Genentech, Inc., South San Francisco, Calif.; andIDEC Pharmaceutical, San Diego, Calif.). In yet another embodiment, thesecond therapeutic agent is an inhibitor of a Janus kinase (JAK) familymember or a Spleen tyrosine kinase (SYK) family member. JAK familymembers include JAK1, JAK2, JAK3 and TYK2, and SYK family membersinclude SYK and ZAP-70. In one embodiment, the second therapeutic agentis an inhibitor of JAK3, such as the small molecule inhibitor CP-690,550(tofacitinib). In another embodiment, the second therapeutic agent is aSYK inhibitor, such as the small molecule inhibitor R406, or its prodrugR788.

In one embodiment, the patient has an inflammatory bowel disease (IBD),and is selected on the basis that the patient has demonstrated aninadequate response to a prior alternate treatment for IBD. The prioralternate treatment for IBD can be, for example, an inhibitor of anintegrin, such as MAdCAM-1 (Mucosal Vascular Addressin Cell AdhesionMolecule-1, α4β7 integrin). The MAdCAM-1 inhibitor can be ananti-MAdCAM-1 antibody, such as vedolizumab (MLN0002, MillenniumPharmaceuticals, Cambridge, Mass.).

In another embodiment, a subject is treated with one or more therapeuticagents prior to receiving an anti-VLA-1 antibody therapy, such as aninfusion of an anti-VLA-1 therapy, such as to prevent or ameliorateadverse reactions to the anti-VLA-1 administration, for example, toprevent or ameliorate adverse events associated with infusion of ananti-VLA-1 antibody. For example, in one embodiment, pre-treatmentincludes administration of one or more of an analgesic, such asacetaminophen, an antihistamine, or a corticosteroid, such asmethylprednisolone.

In one embodiment, the pretreatment is administered 15 minutes to onehour or more, for example, 15 minutes, 30 minutes, 45 minutes, or onehour or more, prior to administration of the anti-VLA-1 antibody, suchas prior to infusion of the anti-VLA-1 antibody.

In one embodiment, a subject, such as an RA patient, is administered oneor both of acetaminophen and an antihistamine prior to administration ofan anti-VLA-1 antibody, such as prior to infusion with an anti-VLA-1antibody. In one embodiment, an RA patient is administered acorticosteroid (also called a glucocorticoid), such asmethylprednisolone, prior to treatment with an anti-VLA-1 antibody.

In one embodiment, the pretreatment is administered at a dose of fromabout 50 mg per 75 kg human to about 150 mg per 75 kg human. Forexample, the pretreatment, such as methylprenisolone administration, isdelivered at a dose or from about 50 mg per 75 kg human, about 75 mg per75 kg human, about 100 mg per 75 kg human, about 125 mg per 75 kg human,or about 150 mg per 75 kg human.

In another embodiment, the pretreatment is administered 15 minutes toone hour or more, for example, 15 minutes, 30 minutes, 45 minutes, orone hour or more prior to administration of the anti-VLA-1 antibody,such as prior to infusion of the anti-VLA-1 antibody.

The pretreatment can be administered, for example, by intravenousdelivery, such as by infusion.

In another aspect, the invention features a method of evaluating apatient by determining if the patient meets a preselected criterion, andif the patient meets the preselected criterion approving, providing,prescribing, or administering an anti-VLA-1 antibody formulationdescribed herein to the patient. In one embodiment, the preselectedcriterion is the failure of the patient to adequately respond to a prioralternate therapeutic treatment or regimen, such as for treatment of RA.In another embodiment, the criterion is as described in co-ownedapplication Ser. No. 61/498,263, filed Jun. 17, 2011, which is herebyincorporated by reference in its entirety.

In another aspect, the invention features a method of instructing arecipient on the administration of a formulation of SAN-300. The methodincludes instructing the recipient, such as an end user, that the drugshould be administered to a patient subcutaneously. In some embodiments,the end user is a patient, physician, retail or wholesale pharmacy,distributor, or pharmacy department at a hospital, nursing home clinicor HMO (Health Maintenance Organization).

In one aspect, the invention features a method of making an aqueouscomposition comprising about ≥100 mg/mL to about 225 mg/mL of ananti-VLA-1 antibody, for example, an aqueous composition describedherein, by combining antibody, buffer, excipient, and a surfactant inproportion to obtain an aqueous composition comprising ≥100 mg/mL toabout 225 mg/mL of the anti-VLA-1 antibody.

As used herein the term “excipient” is a pharmacologically inactivesubstance used as a carrier for the active ingredients of a medication.

In one embodiment, the buffer is histidine, and in another embodiment,the buffer is acetate. In another embodiment, the excipient is sorbitol,and in another embodiment, the excipient is sodium chloride. In yetanother embodiment, the surfactant is polysorbate 80, and in anotherembodiment the surfactant is polysorbate 20. In one embodiment thesurfactant is polysorbate 80, and in another embodiment the surfactantis polysorbate 20.

In another embodiment, the anti-VLA-1 antibody comprises a light chainhaving the sequence of SEQ ID NO:1 and a heavy chain having the sequenceof SEQ ID NO:2.

In another aspect, a method of distributing a composition describedherein is provided. The composition contains a formulation of SAN-300and is suitable for subcutaneous administration. The method includesproviding a recipient, such as an end user, with a package containingsufficient unit dosages of the drug to treat a patient for at least 6months, at least 12 months, at least 24 months, or at least 36 months.In some embodiments, the end user is a patient, a physician, a retail orwholesale pharmacy, a distributor, a pharmacy department at a hospital,a nursing home clinic or an HMO.

In another aspect, the invention features a method of evaluating thequality of a package or lot of packages of a composition describedherein containing an anti-VLA-1 antibody. The method includes, forexample, evaluating whether the package has expired. The expiration dateis at least 6 months, at least 12 months, at least 18 months, at least24 months, at least 36 months, or at least 48 months, for example,greater than 24 months or greater than 36 months, from a preselectedevent, such as manufacturing, assaying, or packaging. In someembodiments, a decision or step is taken as a result of the analysis.For example, the antibody in the package is used or discarded,classified, selected, released or withheld, shipped, moved to a newlocation, released into commerce, sold, or offered for sale, withdrawnfrom commerce or no longer offered for sale, depending on whether theproduct has expired.

In another aspect, the invention features a package containing at least2 unit doses of an aqueous composition containing an anti-VLA-1antibody. In one embodiment, all of the unit doses contain the sameamount of antibody, and in other embodiments, there are unit dosages oftwo or more strengths, or two or more different formulations. Forexample, different formulations can have different strengths or releaseproperties. In one embodiment, at least one dosage contains anti-VLA-1antibody at about 80 mg to about 315 mg, for example, about 100 mg,about 160 mg, about 180 mg, about 190 mg, about 210 mg, about 250 mg,about 300 mg, about 325 mg, about 350 mg, about 360 mg, about 400 mg,about 450 mg, or about 500 mg.

In another aspect, the invention includes a method of instructing arecipient on the administration of an aqueous formulation containinganti-VLA-1 antibody. The method includes instructing the recipient (forexample, an end user, patient, physician, retail or wholesale pharmacy,distributor, or pharmacy department at a hospital, nursing home clinicor HMO) that the antibody should be administered to a patient prior tothe expiration date. The expiration date is at least 6 months, at least12 months, at least 18 months, at least 24 months, at least 36 months,or at least 48 months, for example, greater than 18 months, greater than24 months or greater than 36 months, from a preselected event, such as amanufacturing, assaying, or packaging event. In one embodiment, therecipient also receives a supply of the antibody, such as a supply ofunit dosages of the antibody.

In another aspect, the invention features the use of a method or systemfor distributing a formulation described herein, monitoring or trackingthe provision of a formulation described herein to a pharmacy, infusioncenter, or patient, monitoring one or more patients, selecting patients,or compiling or reporting data on the use of a formulation describedherein.

In another aspect, the invention features a method of analyzing aproduct or a process, such as a manufacturing process. The methodincludes providing an aqueous formulation of an anti-VLA-1 antibodycomposition, for example, one made by a process described herein, andproviding an evaluation of the formulation by assessing a solutionparameter, such as color (for example, colorless to slightly yellow, orcolorless to yellow), clarity (for example, clear to slightly opalescentor clear to opalescent), or viscosity (for example, about 5 cP to about30 cP (for example, about 10 cP or about 20 cP) when measured at ambienttemperature, such as at about 20° C. to about 30° C., for example, about25° C.). The evaluation can include an assessment of one or moresolution parameters. Optionally, a determination of whether the solutionparameter meets a preselected criteria is determined, for example,whether the preselected criteria is present, or is present in apreselected range, is determined, thereby analyzing the process. In oneembodiment, the invention includes a measure of the stability of theanti-VLA-1 antibody formulation. Stability of the antibody formulationcan be measured, for example, by aggregate formation, which is assayed,for example, by size exclusion high pressure liquid chromatography(HPLC), by color, clarity, or viscosity as described herein. Aformulation can be determined to be stable, and therefore acceptable forfurther processing or distribution, if the change in an assay parameteris less than about 10%, less than about 5%, less than about 3%, lessthan about 2%, less than about 1%, less than about 0.5%, less than about0.05%, or less than about 0.005% or less, over a pre-set period of time,and optionally at a given temperature. In one embodiment, a liquidanti-VLA-1 antibody formulation is stable for 1 day, 2 days, 3 days, 4days, or 5 days or more at room temperature, such as at about 18° C.,about 19° C., about 20° C., about 21° C., about 22° C., about 23° C.,about 24° C., or about 25° C.

In one embodiment, the method further includes comparing the valuedetermined with a reference value, to thereby analyze the manufacturingprocess.

In one embodiment, the method further includes maintaining themanufacturing process based, at least in part, upon the analysis. In oneembodiment, the method further includes altering the manufacturingprocess based upon the analysis.

In another embodiment the method includes evaluating a process, such asa manufacturing process, of an aqueous formulation of an anti-VLA-1antibody made by a selected process, that includes making adetermination about the process based upon a method or analysisdescribed herein. In one embodiment, the method further includesmaintaining or altering the manufacturing process based, at least inpart, upon the method or analysis. Thus, in another embodiment the partymaking the evaluation does not practice the method or analysis describedherein but merely relies on results which are obtained by a method oranalysis described herein.

In another embodiment the method includes comparing two or morepreparations in a method of monitoring or controlling batch-to-batchvariation or to compare a preparation to a reference standard.

In yet another embodiment, the method can further include making adecision, such as a decision to classify, select, accept or discard,release or withhold, process into a drug product, ship, move to adifferent location, formulate, label, package, release into commerce,sell or offer for sale the preparation, based, at least in part, uponthe determination.

In another aspect, the invention features a method of storing,distributing, or using an anti-VLA-1 antibody formulation, such as aSAN-300 formulation, described herein. The method includes:

storing the formulation at a suitable temperature, such as at 2° C. to8° C.;

providing the formulation to a recipient, for example, an end-user, suchas for example, a patient or healthcare provider;

instructing the recipient to store the formulation at a suitabletemperature, such as at 2° C. to 8° C.; and

after receipt by the recipient, storing the formulation for up to 24months, 36 months, or 48 months at the suitable temperature, such as at2° to 8° C.

In another aspect, the invention features a method of complying with aregulatory requirement, such as a post approval requirement of aregulatory agency, such as the FDA. The method includes providing anevaluation of an antibody formulation for a solution parameter, such ascolor (for example, colorless to slightly yellow, or colorless toyellow), clarity (for example, clear to slightly opalescent or clear toopalescent), or viscosity (for example, about 5 cP to about 30 cP whenmeasured at ambient temperature, such as at 20° C. to 30° C.). The postapproval requirement can include a measure of one more of the aboveparameters. The method also includes, optionally, determining whetherthe observed solution parameter meets a preselected criteria or if theparameter is in a preselected range; optionally, memorializing the valueor result of the analysis, or communicating with the agency, such as bytransmitting the value or result to the regulatory agency.

In another aspect, the invention features a method of making a batch ofan aqueous formulation of anti-VLA-1 antibody having a preselectedproperty, for example, meeting a release specification, labelrequirement, or compendial requirement, for example, a propertydescribed herein. The method includes providing a test antibodypreparation; analyzing the test antibody preparation according to amethod described herein; determining if the test antibody preparationsatisfies a preselected criteria, such as by having a preselectedrelationship with a reference value, such as one or more referencevalues disclosed herein, and selecting the test antibody preparation tomake a batch of product.

In another aspect, the invention features multiple batches of an aqueousformulation of anti-VLA-1 antibody, wherein one or more solutionparameters (for example, a value or solution parameter determined by amethod described herein), for each batch varies less than a preselectedrange from a pre-selected desired reference value or criteria, forexample, a range or criteria described herein. In some embodiments, oneor more parameters for one or more batches of an antibody formulation,is determined and a batch or batches selected as a result of thedetermination. Some embodiments include comparing the results of thedetermination to a preselected value or criteria, such as a referencestandard. Other embodiments include adjusting the dose of the batch tobe administered, such as based on the result of the determination of thevalue or parameter.

In another aspect, the invention features a method of one or more of:providing a report to a report-receiving entity, evaluating a sample ofan aqueous formulation of anti-VLA-1 antibody for compliance with areference standard, such as an FDA requirement, seeking indication fromanother party that a preparation of the anti-VLA-1 antibody meets somepredefined requirement, or submitting information about a preparation ofan anti-VLA-1 antibody to another party. Exemplary receiving entities orother parties include a government, such as the U.S. federal government,of a government agency, such as the FDA. The method includes one or more(or all) of the following steps for making and/or testing an aqueousformulation of anti-VLA-1 antibody in a first country, such as the US;sending at least an aliquot of the sample outside the first country, forexample, sending it outside the United States, to a second country;preparing, or receiving, a report which includes data about thestructure of the preparation of the anti-VLA-1 antibody, for example,data related to a structure and/or chain described herein, such as datagenerated by one or more of the methods described herein; and providingsaid report to a report recipient entity.

In one embodiment, the report-receiving entity can determine if apredetermined requirement or reference value is met by the data and,optionally, a response from the report-receiving entity is received,such as by a manufacturer, distributor or seller of an aqueousformulation of an anti-VLA-1 antibody. In one embodiment, upon receiptof approval from the report recipient entity, the preparation ofanti-VLA-1 antibody is selected, packaged, or placed into commerce.

In one aspect, the invention features a method of evaluating the qualityof a composition described herein, where the method includes evaluatingthe composition for a preselected parameter, and determining whether thevalue meets a preselected criteria. Responsive to the evaluation, thecomposition can be classified, selected, accepted or discarded, releasedor withheld, processed into a drug product, shipped, moved to adifferent location, formulated, labeled, packaged, released intocommerce, or sold or offered for sale. In another embodiment, thecomposition evaluated is provided as a unit dosage form.

In one embodiment, the preselected parameter is selected fromaggregation, stability, color, clarity, viscosity, or plunger force.

In one embodiment, the method includes providing a comparison of thevalue determined for a parameter with a reference value, or values, tothereby evaluate the sample. The comparison can include, for example,determining if the test value has a preselected relationship with thereference value, for example, determining if it meets the referencevalue. The value need not be a numerical value but can be merely anindication of whether the subject entity is present.

In one embodiment, the method includes determining if a test value isequal to or greater than a reference value, if it is less than or equalto a reference value, or if it falls within a range (either inclusive orexclusive of one or both endpoints).

In some embodiments, the test value, or an indication of whether thepreselected relationship is met, can be memorialized, such as in acomputer readable record.

In some embodiments, a decision or step is taken, for example, thesample is classified, selected, accepted or discarded, released orwithheld, processed into a drug product, shipped, moved to a differentlocation, formulated, labeled, packaged, released into commerce, or soldor offered for sale, depending on whether the preselected relationshipis met. For example, based on the result of the determination, or uponcomparison to a reference standard, the batch from which the sample istaken can be processed, such as just described.

In one aspect, the invention features a method of evaluating an aqueousformulation of anti-VLA-1 antibody. The method includes receiving datawith regard to the presence or level of anti-VLA-1 antibody; providing arecord which includes said data and optionally includes an identifierfor a batch of anti-VLA-1 antibody; submitting said record to adecision-maker, for example, a government agency, such as the FDA;optionally, receiving a communication from the decision maker;optionally, deciding whether to release or market the batch ofanti-VLA-1 antibody based on the communication from the decision maker.In one embodiment, the method further includes releasing the sample.

Exemplary formulations include the following:

1. SAN-300 at a concentration of ≥100 mg/mL to about 210 mg/mL, or about180 mg/mL to about 200 mg/mL, for example, about 180 mg/mL;

histidine buffer at a concentration of about 1 mM to about 100 mM, about5 mM to about 50 mM, or about 5 mM to about 40 mM, for example, about 30mM;

sorbitol at a concentration of about 50 mM to about 300 mM, about 100 mMto about 290 mM, or about 200 mM to about 280 mM, for example, about 250mM;

polysorbate 20 at a concentration of about 0.001% to about 0.1%, about0.005% to about 0.08%, or about 0.008% to about 0.04%, for example,about 0.01%, and

pH of about 6.0;

2. SAN-300 at a concentration of ≥100 mg/mL to about 210 mg/mL or about180 mg/mL to about 200 mg/mL, for example, about 190 mg/mL;

acetate buffer at a concentration of about 1 mM to about 100 mM, about 5mM to about 50 mM, or about 5 mM to about 40 mM, for example, about 30mM;

sorbitol at a concentration of about 50 mM to about 300 mM, about 100 mMto about 280 mM, or about 200 mM to about 250 mM, for example, about 220mM or about 250 mM;

polysorbate 80 at a concentration of about 0.001% to about 0.1%, about0.005% to about 0.08%, or about 0.008% to about 0.04%, for example,about 0.01%, and

pH of about 5.5;

3. about 180 mg/mL SAN-300;

histidine buffer at a concentration of about 1 mM to about 100 mM, about5 mM to about 50 mM, or about 5 mM to about 40 mM, for example, about 30mM;

250 mM sorbitol;

0.01% polysorbate 20, and

pH 6.0;

4. 190 mg/mL SAN-300;

acetate buffer at 1 mM to 100 mM, 5 mM to 50 mM, or 5 mM to 40 mM, forexample, 30 mM;

about 220 mM sorbitol;

about 0.01% polysorbate 80, and

pH 5.5;

5. about 180 mg/mL SAN-300;

about 30 mM histidine buffer;

sorbitol at a concentration of about 50 mM to about 300 mM, about 100 mMto about 290 mM, or about 200 mM to about 280 mM, for example, about 250mM;

about 0.01% polysorbate 20; and

pH 6.0;

6. about 190 mg/mL SAN-300;

about 30 mM acetate buffer;

sorbitol at a concentration of about 50 mM to about 300 mM, about 100 mMto about 280 mM, or about 200 mM to about 250 mM, for example, about 220mM;

about 0.01% polysorbate 80; and

pH 5.5;

7. about 180 mg/mL SAN-300;

about 30 mM histidine buffer;

about 250 mM sorbitol;

polysorbate 20 at a concentration of about 0.001% to about 0.1%, about0.005% to about 0.08%, or about 0.008% to about 0.04%, for example,about 0.01%, and

pH 6.0;

8. about 190 mg/mL SAN-300;

about 30 mM acetate buffer;

about 220 mM sorbitol;

polysorbate 80 at about 0.001% to about 0.1%, about 0.005% to about0.08%, or about 0.008% to about 0.04%, for example, about 0.01%, and

pH 5.5;

9. SAN-300 at a concentration of about 160 mg/mL to about 210 mg/mL, orabout 180 mg/mL to about 200 mg/mL, for example, about 180 mg/mL;

about 30 mM histidine buffer;

about 250 mM sorbitol;

about 0.01% polysorbate 20;

pH 6.0;

10. SAN-300 at a concentration of about 160 mg/mL to about 210 mg/mL orabout 180 mg/mL to about 200 mg/mL, for example, about 190 mg/mL;

about 30 mM acetate buffer;

about 220 mM sorbitol;

about 0.01% polysorbate 80; and

pH 5.5;

11. about 180 mg/mL SAN-300;

about 30 mM histidine buffer;

about 250 mM sorbitol;

about 0.01% polysorbate 20; and

pH 6.0;

12. about 190 mg/mL SAN-300;

about 30 mM acetate buffer;

about 220 mM sorbitol;

about 0.01% polysorbate 80 and

pH 5.5.

13. SAN-300 at a concentration of ≥100 mg/mL to about 210 mg/mL, orabout 180 mg/mL to about 200 mg/mL, for example, about 180 mg/mL;

histidine buffer at about 1 mM to about 100 mM, about 5 mM to about 50mM, or about 5 mM to about 40 mM, for example, about 30 mM;

NaCl at a concentration of about 50 mM to about 300 mM, about 100 mM toabout 200 mM, or about 140 mM to about 160 mM, for example, about 150mM;

polysorbate 20 at a concentration of about 0.001% to about 0.1%, about0.005% to about 0.08%, or about 0.008% to about 0.04%, for example,about 0.01%, and

pH 6.0;

14. SAN-300 at a concentration of ≥100 mg/mL to about 210 mg/mL or about180 mg/mL to about 200 mg/mL, for example, about 190 mg/mL;

acetate buffer at a concentration of about 1 mM to about 100 mM, about 5mM to about 50 mM, or about 5 mM to about 40 mM, for example, about 30mM;

NaCl at a concentration of about 50 mM to about 300 mM, about 100 mM toabout 200 mM, or about 140 mM to about 160 mM, for example, about 150mM;

polysorbate 80 at a concentration of about 0.001% to about 0.1%, about0.005% to about 0.08%, or about 0.008% to about 0.04%, for example,about 0.01%, and

pH 5.5;

15. about 180 mg/mL SAN-300;

histidine buffer at a concentration of about 1 mM to about 100 mM, about5 mM to about 50 mM, or about 5 mM to about 40 mM, for example, about 30mM;

about 150 mM NaCl;

about 0.01% polysorbate 20, and

pH 6.0;

16. about 190 mg/mL SAN-300;

acetate buffer at a concentration of about 1 mM to about 100 mM, about 5mM to

about 50 mM, or about 5 mM to about 40 mM, for example, about 30 mM;

about 150 mM NaCl;

about 0.01% polysorbate 80, and

pH 5.5;

17. about 180 mg/mL SAN-300;

about 30 mM histidine buffer;

NaCl at a concentration of about 50 mM to about 300 mM, about 100 mM toabout 200 mM, or about 140 mM to about 160 mM, for example, about 150mM;

about 0.01% polysorbate 20; and

pH 6.0;

18. about 190 mg/mL SAN-300;

about 30 mM acetate buffer;

NaCl at a concentration of about 50 mM to about 300 mM, about 100 mM toabout 200 mM, or about 140 mM to about 160 mM, for example, about 150mM;

about 0.01% polysorbate 80; and

pH 5.5;

19. about 180 mg/mL SAN-300;

about 30 mM histidine buffer;

about 150 mM NaCl;

polysorbate 20 at a concentration of about 0.001% to about 0.1%, about0.005% to about 0.08%, or about 0.008% to about 0.04%, for example,about 0.01%, and

pH 6.0;

20. about 190 mg/mL SAN-300;

about 30 mM acetate buffer;

about 150 mM NaCl;

polysorbate 80 at a concentration of about 0.001% to about 0.1%, about0.005% to about 0.08%, or about 0.008% to about 0.04%, for example,about 0.01%, and

pH 5.5;

21. SAN-300 at a concentration of about 160 mg/mL to about 210 mg/mL, orabout 180 mg/mL to about 200 mg/mL, for example, about 180 mg/mL;

about 30 mM histidine buffer;

about 150 mM NaCl;

about 0.01% polysorbate 20;

pH 6.0;

22. SAN-300 at a concentration about 160 mg/mL to about 210 mg/mL orabout 180 mg/mL to about 200 mg/mL, for example, about 190 mg/mL;

about 30 mM acetate buffer;

about 150 mM NaCl;

about 0.01% polysorbate 80; and

pH 5.5;

23. about 180 mg/mL SAN-300;

about 30 mM histidine buffer;

about 150 mM NaCl;

about 0.01% polysorbate 20; and

pH 6.0;

24. about 190 mg/mL SAN-300;

about 30 mM acetate buffer;

about 150 mM NaCl;

about 0.01% polysorbate 80 and

pH 5.5.

In some embodiments, any of the above formulations 1 to 24 can beessentially free of an amino acid, such as arginine.

Methods and compositions disclosed herein can be used where thepresence, distribution, or amount, of one or more structures in themixture may possess or impinge on the biological activity. The methodsare also useful from a structure-activity prospective, to evaluate orensure biological equivalence.

An “anti-VLA-1 antibody formulation” as used herein, refers to anaqueous formulation containing an anti-VLA-1 antibody, such as SAN-300,at a concentration of ≥100 mg/mL to about 225 mg/mL, for example, about110 mg/mL, about 120 mg/mL, about 130 mg/mL, about 140 mg/mL, about 150mg/mL, about 160 mg/mL, about 170 mg/mL, about 180 mg/mL, about 190mg/mL, about 200 mg/mL, about 205 mg/mL, about 210 mg/mL, about 215mg/mL, about 220 mg/mL.

“Suitable for subcutaneous administration” means that a composition,provided, e.g., as unit dosage, provides antibody at a concentrationsufficient to allow a therapeutic effect from an amount, typically fromabout 0.5 mL to about 3 mL, that can be delivered by subcutaneousinjection. It may be free of components, such as citrate, that causeunwanted injection site symptoms, such as burning or stinging.

The term “treating” refers to administering a therapy in an amount,manner, and/or mode effective to improve a condition, symptom, orparameter associated with a disorder or to prevent progression of adisorder, to either a statistically significant degree or to a degreedetectable to one skilled in the art. An effective amount, manner, ormode can vary depending on the subject and may be tailored to thesubject.

A “stable” formulation of anti-VLA-1 antibody exhibits little or nosigns of any one or more of aggregation, precipitation, fragmentation,deamidation, oxidation, denaturation, size modification, chemicalalteration, or change in biological activity, such as the ability tobind VLA-1, over a predetermined period of time. The predeterminedperiod of time can be, for example, equal to or more than 4 days, 10days, 14 days, 21 days, 30 days or longer, such as for 6 months, 12months, 24 months, 36 months, 1 year, 2 years, 3 years, for example,when stored under suitable conditions. Exemplary suitable conditionsinclude, for example, a temperature of about 2° C. to about 8° C., forexample, at about 4° C., in darkness, in a closed container. In oneembodiment, the container is the same type that the composition will beprovided to the end user. In another embodiment, a stable formulationwill meet manufacturer or regulatory (such as Food and DrugAdministration (FDA), or a foreign counterpart to the FDA) release orpackage label or insert requirements, such as for the times andconditions mentioned above. For example, in one embodiment, less thanabout 1%, less than about 2%, less than about 5%, less than about 10%,or less than about 15% of the composition is aggregated, fragmented, oroxidized at the end of the predetermined period or otherwise at the timeof evaluation for stability. Aggregation, precipitation, and/ordenaturation can be assessed by known methods, such as visualexamination of color and/or clarity, or by UV light scattering, sizeexclusion chromatography, dynamic light scattering (DLS), ordifferential scanning calorimetry (DSC). The ability of the protein toretain its biological activity can be assessed by detecting andquantifying chemically altered forms of the antibody. Size modification,such as clipping, can be evaluated using size exclusion chromatography,SDS-PAGE and/or matrix-assisted laser desorptionionization/time-of-flight mass spectrometry (MALDI/TOF MS), or peptidemapping of endoproteinase-treated antibody, for example. Other types ofchemical alteration include charge alteration, such as that may occur asa result of deamidation, can be evaluated by ion-exchangechromatography, for example. An antibody “retains its biologicalactivity” in a pharmaceutical formulation, if the biological activity ofthe antibody at a given time is within about 1%, about 2%, about 5%,about 10%, or about 15% of the biological activity exhibited at the timethe pharmaceutical formulation was prepared as determined, for example,in an antigen binding assay.

“Aggregation” as used herein, refers to the formation of insolublestructures from completely or partially unfolded polypeptides, such asanti-VLA-1 antibodies. “Fragmentation” as used herein, refers topartially degraded proteins, such as anti-VLA-1 antibodies.“Deamidation” refers to the removal of an amide group from apolypeptide, such as an anti-VLA-1 antibody. Deamidation typicallyoccurs at glutaminyl or asparaginyl amino acid residues, and can causestructural changes in the protein that affect protein function, such asbinding affinity for a VLA-1 ligand.

As used herein, “syringeability” refers to the suitability of acomposition for delivery with a syringe. One component of syringeabilityis the ability of a composition, such as an anti-VLA-1 antibodycomposition, to be expelled from a syringe, such as by a patient forself-administration, or by a health-care provider. Self-administrationby the patient can be, for example, by subcutaneous administration. Thepressure, or “plunger force” can be, for example, such that a patient,for example, an elderly or weak patient, can self administer thecomposition. In embodiments the plunger force is equal to or less than 4lbs.

In one embodiment, the plunger force will allow delivery of a unitdosage in 10 seconds or less. In another embodiment, about 1 mL of anaqueous pharmaceutical composition, disposed in a syringe having aneedle of a preselected gauge, can be expelled at a preselected ratewith a plunger force of no more than a preselected amount. In anotherembodiment, about 2 mL of aqueous pharmaceutical composition, disposedin a syringe having a needle of a preselected gauge, can be expelled ata preselected rate with a plunger force of no more than a preselectedamount. For example, about 1 mL aqueous pharmaceutical composition,disposed in a syringe having a 25 gauge needle, a 27 guage needle, or a30 guage needle can be expelled at 10 muJminute with a plunger force ofno more than 4 lbs.

In one embodiment, a suitable plunger force, such as a force equal to orless than 4 lbs, will allow delivery of a unit dosage within apreselected time period, such as in 10 seconds or less.

Syringeability also refers to the ability of the protein to survivepassage though a needle without fragmenting by more than about 1%, morethan about 2%, more than about 5%, more than about 10% or more thanabout 15%.

An “anti-VLA-1 antibody” refers to an antibody that binds to a VLA-1integrin, such as to the al subunit of the VLA-1 integrin, and at leastpartially inhibits an activity of VLA-1, particularly a binding activityof a VLA-1 integrin or a signaling activity, such as the ability totransduce a VLA-1 mediated signal. For example, an anti-VLA-1 antibodymay inhibit binding of VLA-1 to a cognate ligand of VLA-1, for example,an extracellular matrix component, such as collagen, for example,collagen I or collagen IV, or laminin. An anti-VLA-1 antibody may bindto either the α1 subunit or the β1 subunit, or to both. In oneembodiment, the antibody binds an epitope on the I domain of α1. Ananti-VLA-1 antibody may bind to VLA-1 with a K_(d) of less than about10⁻⁶, less than about 10⁻⁷, less than about 108, less than about 10⁻⁹,less than about 10⁻¹⁰, or less than about 10⁻¹¹ M. VLA-1 is also knownas α1/β1 and CD49a/CD29.

As used herein, the term “antibody” refers to a protein that includes atleast one immunoglobulin variable region, such as an amino acid sequencethat provides an immunoglobulin variable domain or immunoglobulinvariable domain sequence. For example, an antibody can include a heavy(H) chain variable region (abbreviated herein as VH), and a light (L)chain variable region (abbreviated herein as VL). In another example, anantibody includes two heavy (H) chain variable regions and two light (L)chain variable regions. The term “antibody” encompasses antigen-bindingfragments of antibodies (such as single chain antibodies, Fab fragments,F(ab′)₂ fragments, Fd fragments, Fv fragments, and dAb fragments) aswell as complete antibodies, for example, intact immunoglobulins oftypes IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof). The lightchains of the immunoglobulin may be of types kappa or lambda. In oneembodiment, the antibody is glycosylated. An antibody can be functionalfor antibody dependent cytotoxicity and/or complement-mediatedcytotoxicity, or may be non-functional for one or both of theseactivities.

An immunoglobulin variable domain sequence is an amino acid sequencethat can form the structure of an immunoglobulin variable domain. Forexample, the sequence may include all or part of the amino acid sequenceof a naturally-occurring variable domain. For example, the sequence mayomit one, two or more N- or C-terminal amino acids, internal aminoacids, may include one or more insertions or additional terminal aminoacids, or may include other alterations. In one embodiment, apolypeptide that includes an immunoglobulin variable domain sequence canassociate with another immunoglobulin variable domain sequence to form atarget binding structure (or “antigen binding site”), for example, astructure that interacts with VLA-1.

The VH and VL regions can be further subdivided into regions ofhypervariability, termed “complementarity determining regions” (“CDR”),interspersed with regions that are more conserved, termed “frameworkregions” (FR). The extent of the FRs and CDRs has been precisely defined(see, Kabat, E. A., et al. (1991) Sequences of Proteins of ImmunologicalInterest, Fifth Edition, U.S. Department of Health and Human Services,NIH Publication No. 91-3242; and Chothia, C. et al. (1987) J. Mol. Biol.196:901-917). Kabat definitions are used herein. Each VH and VL istypically composed of three CDRs and four FRs, arranged fromamino-terminus to carboxyl-terminus in the following order: FR1, CDR1,FR2, CDR2, FR3, CDR3, FR4.

The VH or VL chain of the antibody can further include all or part of aheavy or light chain constant region, to thereby form a heavy or lightimmunoglobulin chain, respectively. In one embodiment, the antibody is atetramer of two heavy immunoglobulin chains and two light immunoglobulinchains. The heavy and light immunoglobulin chains can be connected bydisulfide bonds. The heavy chain constant region typically includesthree constant domains, CH1, CH2 and CH3. The light chain constantregion typically includes a CL domain. The variable region of the heavyand light chains contains a binding domain that interacts with anantigen. The constant regions of the antibodies typically mediate thebinding of the antibody to host tissues or factors, including variouscells of the immune system (such as effector cells) and the firstcomponent (Clq) of the classical complement system.

One or more regions of an antibody can be human, effectively human, orhumanized. For example, one or more of the variable regions can be humanor effectively human. For example, one or more of the CDRs, such as HCCDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3, can be human (HC,heavy chain; LC, light chain). In one embodiment, each of the lightchain CDRs can be human. In one embodiment, HC CDR3 is human. One ormore of the framework regions can be human, such as FR1, FR2, FR3,and/or FR4 of the HC or LC. In one embodiment, all the framework regionsare human, for example, derived from a human somatic cell, such as ahematopoietic cell that produces immunoglobulins or a non-hematopoieticcell. In one embodiment, the human sequences are germline sequences, forexample, encoded by a germline nucleic acid. One or more of the constantregions can be human, effectively human, or humanized. In anotherembodiment, at least about 70%, at least about 75%, at least about 80%,at least about 85%, at least about 90%, at least about 92%, at leastabout 95%, or at least about 98% of the framework regions, such as FR1,FR2, and FR3, collectively, or FR1, FR2, FR3, and FR4, collectively, orthe entire antibody can be human, effectively human, or humanized. Forexample, FR1, FR2, and FR3 collectively can be at least about 70%, atleast about 75%, at least about 80%, at least about 85%, at least about90%, at least about 92%, at least about 95%, at least about 98%, or atleast about 99% identical to a human sequence encoded by a humangermline segment.

An effectively human immunoglobulin variable region is an immunoglobulinvariable region that includes a sufficient number of human frameworkamino acid positions such that the immunoglobulin variable region doesnot elicit an immunogenic response in a normal human. An “effectivelyhuman” antibody is an antibody that includes a sufficient number ofhuman amino acid positions such that the antibody does not elicit animmunogenic response in a normal human.

A humanized immunoglobulin variable region is an immunoglobulin variableregion that is modified such that the modified form elicits less of animmune response in a human than does the non-modified form. For example,a humanized immunoglobulin variable region can be modified to include asufficient number of human framework amino acid positions such that theimmunoglobulin variable region does not elicit an immunogenic responsein a normal human. Descriptions of humanized immunoglobulins include,for example, U.S. Pat. Nos. 6,407,213 and 5,693,762. In someembodiments, a humanized immunoglobulin includes a non-human amino acidat one or more framework amino acid positions.

All or part of an antibody can be encoded by an immunoglobulin gene or asegment thereof. Exemplary human immunoglobulin genes include the kappa,lambda, a (IgA1 and IgA2), gamma (IgG1, IgG2, IgG3, IgG4), delta,epsilon and mu constant region genes, as well as the myriadimmunoglobulin variable region genes. Full-length immunoglobulin “lightchains” (about 25 Kd or 214 amino acids) are encoded by a variableregion gene at the NH2-terminus (about 110 amino acids) and a kappa orlambda constant region gene at the COOH-terminus. Full-lengthimmunoglobulin “heavy chains” (about 50 Kd or 446 amino acids) aresimilarly encoded by a variable region gene (about 116 amino acids) andone of the other aforementioned constant region genes, such as gamma(encoding about 330 amino acids).

The term “antigen-binding fragment” of a full length antibody refers toone or more fragments of a full-length antibody that retain the abilityto specifically bind to a target of interest, such as VLA-1. Examples ofbinding fragments encompassed within the term antigen-binding fragmentof a full length antibody include (i) a Fab fragment, a monovalentfragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′)₂fragment, a bivalent fragment including two Fab fragments linked by adisulfide bridge at the hinge region; (iii) a Fd fragment consisting ofthe VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VHdomains of a single arm of an antibody, (v) a dAb fragment (Ward et al.,(1989) Nature 341:544-546), which consists of a VH domain; and (vi) anisolated complementarity determining region (CDR) that retainsfunctionality. Furthermore, although the two domains of the Fv fragment,VL and VH, are coded for by separate genes, they can be joined, usingrecombinant methods, by a synthetic linker that enables them to be madeas a single protein chain in which the VL and VH regions pair to formmonovalent molecules known as single chain Fv (scFv). See for example,Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc.Natl. Acad. Sci. USA 85:5879-5883.

Calculations of homology or sequence identity between two sequences (theterms are used interchangeably herein) are performed as follows. Thesequences are aligned for optimal comparison purposes (for example, gapscan be introduced in one or both of a first and a second amino acid ornucleic acid sequence for optimal alignment and non-homologous sequencescan be disregarded for comparison purposes). The optimal alignment isdetermined as the best score using the GAP program in the GCG softwarepackage with a Blossum 62 scoring matrix with a gap penalty of 12, a gapextend penalty of 4, and a frameshift gap penalty of 5. The amino acidresidues or nucleotides at corresponding amino acid positions ornucleotide positions are then compared. When a position in the firstsequence is occupied by the same amino acid residue or nucleotide as thecorresponding position in the second sequence, then the molecules areidentical at that position (as used herein amino acid or nucleic acid“identity” is equivalent to amino acid or nucleic acid “homology”). Thepercent identity between the two sequences is a function of the numberof identical positions shared by the sequences.

Guidance for performing hybridization reactions can be found in CurrentProtocols in Molecular Biology, John Wiley & Sons, N.Y. (1989),6.3.1-6.3.6, which is incorporated by reference. Aqueous and nonaqueousmethods are described in that reference and either can be used. Highstringency hybridization conditions include hybridization in 6×SSC atabout 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 65°C., or substantially similar conditions.

Certain advantages are provided by embodiments of the invention. In somecases, it is difficult to make high concentration formulations ofproteins, such as antibodies, for use in pharmaceutical compositions.Methods of preparing such formulations are presented herein.Pharmaceutical compositions containing high concentrations of protein,such as anti-VLA-1 antibody, can be useful for administration over ashorter time frame. A formulation of, for example, anti-VLA-1 antibody,can also be administered by simplified methods (for example,subcutaneously).

In one aspect, the disclosure provides an aqueous pharmaceuticalcomposition comprising

-   -   (a) 150 to 210 mg/mL, 155 to 205 mg/mL, 160 to 200 mg/mL, or 165        to 190 mg/mL of an anti-VLA-1 antibody having        -   a light chain sequence described herein, e.g., a sequence of            SEQ ID NO:1 or a sequence that differs from SEQ ID NO: 1 by            at least one but not more than 2, 3, 4, 5, 6, 7, 9, or 10            amino acid residues; and        -   a heavy chain sequence described herein, e.g., a sequence of            SEQ ID NO:2 or        -   a sequence that differs from SEQ ID NO:2 by at least one but            not more than 2, 3, 4, 5, 6, 7, 9, or 10 amino acid            residues;    -   (b) 25 to 35 mM acetate or 25 to 35 mM histidine;    -   (c) 170 to 288 mM sorbitol; and    -   (d) 0.008 to 0.012% polysorbate, e.g., polysorbate 20 or        polysorbate 80;    -   wherein the aqueous pharmaceutical composition has a pH of 5 to        7.

In one embodiment, the aqueous pharmaceutical composition comprises

-   -   (a) 150 to 210 mg/mL of an anti-VLA-1 antibody having a light        chain sequence of SEQ ID NO: 1 and a heavy chain sequence of SEQ        ID NO:2;    -   (b) 25 to 35 mM acetate or 25 to 35 mM histidine;    -   (c) 170 to 288 mM sorbitol; and    -   (d) 0.008 to 0.012% polysorbate, wherein the polysorbate is        polysorbate 20 or polysorbate 80;        wherein the aqueous pharmaceutical composition has a pH of 5        to 7. In embodiments, the composition comprises histidine and        the polysorbate is polysorbate 20. In embodiments, the        composition comprises acetate and the polysorbate is polysorbate        80.

In some embodiments, the aqueous pharmaceutical composition has anosmolality of 270 mOsm/kg to 380 mOsm/kg.

In embodiments, the aqueous pharmaceutical composition has a viscosityof less than 15 cP or less than 14 cP. In embodiments, the aqueouspharmaceutical composition described herein has a viscosity of 10 to 14cP, 11 to 14 cP, 13 to 14 cP, or 11 to 12 cP.

In one embodiment, the aqueous pharmaceutical composition comprises

-   -   (a) 165 to 190 mg/mL of an anti-VLA-1 antibody having        -   a light chain sequence described herein, e.g., a sequence of            SEQ ID NO:1 or a sequence that differs from SEQ ID NO:1 by            at least one but not more than 2, 3, 4, 5, 6, 7, 9, or 10            amino acid residues; and        -   a heavy chain sequence described herein, e.g., a sequence of            SEQ ID NO:2 or a sequence that differs from SEQ ID NO:2 by            at least one but not more than 2, 3, 4, 5, 6, 7, 9, or 10            amino acid residues;    -   (b) 25 to 35 mM histidine;    -   (c) 170 to 288 mM sorbitol; and    -   (d) 0.008 to 0.012% polysorbate, e.g., polysorbate 20;        wherein the aqueous pharmaceutical composition has a pH of 5 to        7.

In a certain embodiment, the aqueous pharmaceutical compositioncomprises

-   -   (a) 180 mg/mL of an anti-VLA-1 antibody having        -   a light chain sequence described herein, e.g., a sequence of            SEQ ID NO:1 or a sequence that differs from SEQ ID NO:1 by            at least one but not more than 2, 3, 4, 5, 6, 7, 9, or 10            amino acid residues; and        -   a heavy chain sequence described herein, e.g., a sequence of            SEQ ID NO:2 or a sequence that differs from SEQ ID NO:2 by            at least one but not more than 2, 3, 4, 5, 6, 7, 9, or 10            amino acid residues;    -   (b) 30 mM histidine;    -   (c) 250 mM sorbitol; and    -   (d) 0.01% polysorbate, e.g., polysorbate 20;        wherein the aqueous pharmaceutical composition has a pH of 5 to        7.

In embodiments, variability, e.g., a variability of 1 to 5%, 5 to 10%,10 to 15%, or 15 to 20%, is permitted in the amounts of one or morecomponents of the above embodiment. In some such embodiments, theaqueous pharmaceutical composition comprises

-   -   (a) 180 mg/mL±1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%,        13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% of the antibody;    -   (b) 30 mM±1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%,        13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% histidine;    -   (c) 250 mM±1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%,        13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% sorbitol; and    -   (d) 0.01%±1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%,        13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% polysorbate, e.g.,        polysorbate 20;        wherein the aqueous pharmaceutical composition has a pH of 5        to 7. The variability permitted in the individual components is        independently selected (e.g., the antibody can be present at a        concentration of 180 mg/mL±10%, the histidine at a concentration        of 30 mM±5%, the sorbitol at a concentration of 250 mM±7%, and        the polysorbate 20 at 0.01%±2%). In some embodiments, the        aqueous pharmaceutical composition has a pH of 5.5 to 6.5. In        some embodiments, the aqueous pharmaceutical composition has a        pH of 5.6 to 6.4, 5.7 to 6.3, 5.8 to 6.2, or 5.9 to 6.1. In some        embodiments, the aqueous pharmaceutical composition has a pH of        6.0.

In another embodiment, the aqueous pharmaceutical composition comprises

-   -   (a) 165 to 200 mg/mL of an anti-VLA-1 antibody having        -   a light chain sequence described herein, e.g., a sequence of            SEQ ID NO:1 or a sequence that differs from SEQ ID NO:1 by            at least one but not more than 2, 3, 4, 5, 6, 7, 9, or 10            amino acid residues; and        -   a heavy chain sequence described herein, e.g., a sequence of            SEQ ID NO:2 or a sequence that differs from SEQ ID NO:2 by            at least one but not more than 2, 3, 4, 5, 6, 7, 9, or 10            amino acid residues;    -   (b) 25 to 35 mM acetate;    -   (c) 170 to 253 mM sorbitol; and    -   (d) 0.008 to 0.012% polysorbate, e.g., polysorbate 80;        wherein the aqueous pharmaceutical composition has a pH of 4.5        to 6.5.

In a certain embodiment, the aqueous pharmaceutical compositioncomprises 190 mg/mL of an anti-VLA-1 antibody having

-   -   a light chain sequence described herein, e.g., a sequence of SEQ        ID NO:1 or a sequence that differs from SEQ ID NO:1 by at least        one but not more than 2, 3, 4, 5, 6, 7, 9, or 10 amino acid        residues; and    -   a heavy chain sequence described herein, e.g., a sequence of SEQ        ID NO:2 or a sequence that differs from SEQ ID NO:2 by at least        one but not more than 2, 3, 4, 5, 6, 7, 9, or 10 amino acid        residues;    -   (b) 30 mM acetate;    -   (c) 220 mM sorbitol; and    -   (d) 0.01% polysorbate, e.g., polysorbate 80;        wherein the aqueous pharmaceutical composition has a pH of 4.5        to 6.5.

In embodiments, variability, e.g., a variability of 1 to 5%, 5 to 10%,10 to 15%, or 15 to 20%, is permitted in the amounts of one or morecomponents of the above embodiment. In some such embodiments, theaqueous pharmaceutical composition comprises

-   -   (a) 190 mg/mL±1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%,        13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% of the antibody;    -   (b) 30 mM±1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%,        13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% acetate;    -   (c) 220 mM±1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%,        13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% sorbitol; and    -   (d) 0.01%±1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%,        13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% polysorbate, e.g.,        polysorbate 80;        wherein the aqueous pharmaceutical composition has a pH of 4.5        to 6.5. The variability permitted in the individual components        is independently selected (e.g., the antibody can be present at        a concentration of 180 mg/mL±10%, the acetate at a concentration        of 30 mM±5%, the sorbitol at a concentration of 220 mM±7%, and        the polysorbate 80 at 0.01%±2%). In some embodiments, the        aqueous pharmaceutical composition has a pH of 5.0 to 6.0. In        some embodiments, the aqueous pharmaceutical composition has a        pH of 5.1 to 5.9, 5.2 to 5.8, 5.3 to 5.7, or 5.4 to 5.6. In some        embodiments, the aqueous pharmaceutical composition has a pH of        5.5.

In embodiments, an aqueous pharmaceutical composition described hereinhas a viscosity of less than 15 cP or less than 14 cP. In embodiments, aaqueous pharmaceutical composition described herein has a viscosity of10 to 14 cP.

In embodiments, an aqueous pharmaceutical composition described herein(e.g., a aqueous pharmaceutical composition described herein thatcomprises histidine, sorbitol, and polysorbate, e.g., polysorbate 20)has a viscosity of 13 to 14 cP. In embodiments, such an aqueouspharmaceutical composition has a viscosity of less than 12 cP. Inembodiments, such an aqueous pharmaceutical composition has a viscosityof 11 to 12 cP.

In embodiments, 1 mL of an aqueous pharmaceutical composition describedherein has ≤6000 particles that are ≥10 μM and/or has ≤600 particlesthat are ≥25 μM.

In embodiments, the antibody that is included in an aqueouspharmaceutical composition described herein demonstrates binding to theintegrin α1 I domain as assessed using ELISA. In embodiments, theantibody that is included in an aqueous pharmaceutical compositiondescribed herein demonstrates a potency of 80%-125% of a referencestandard (e.g., an antibody that is from the same lot (e.g., productionbatch) but that is not formulated in the aqueous pharmaceuticalcomposition).

In embodiments, an aqueous pharmaceutical composition described hereinshows <15% impurities by reducing CE-SDS.

In embodiments, an aqueous pharmaceutical composition described hereinshows ≤10% total aggregation as assessed by size exclusionchromatography.

In embodiments, an aqueous pharmaceutical composition described hereinhas ≤90.0 EU/mL endotoxin.

In embodiments, 1 mL of an aqueous pharmaceutical composition describedherein has ≤6000 particles that are ≥10 μM. In embodiments, 1 mL anaqueous pharmaceutical composition described herein has ≤600 particlesthat are ≥25 μM. In embodiments, 1 mL of an aqueous pharmaceuticalcomposition described herein has ≤6000 particles that are ≥10 μM and≥600 particles that are ≥25 μM. In embodiments, an aqueouspharmaceutical composition described herein complies with USP<71>.

In some embodiments, an aqueous pharmaceutical composition describedherein (e.g., a histidine formulation) meets one or more of the criteriadescribed in Table 32.

In one embodiment, the aqueous pharmaceutical composition comprises

-   -   (a) 165 to 190 mg/mL an anti-VLA-1 antibody having        -   a light chain sequence described herein, e.g., a sequence of            SEQ ID NO:1 or a sequence that differs from SEQ ID NO:1 by            at least one but not more than 2, 3, 4, 5, 6, 7, 9, or 10            amino acid residues; and        -   a heavy chain sequence described herein, e.g., a sequence of            SEQ ID NO:2 or a sequence that differs from SEQ ID NO:2 by            at least one but not more than 2, 3, 4, 5, 6, 7, 9, or 10            amino acid residues;    -   (b) 25 to 35 mM histidine;    -   (c) 170 to 288 mM sorbitol; and    -   (d) 0.008 to 0.012% polysorbate, e.g., polysorbate 20;        wherein the aqueous pharmaceutical composition has pH 5 to 7.

In a certain embodiment, the aqueous pharmaceutical compositioncomprises

-   -   (a) 180 mg/mL an anti-VLA-1 antibody having        -   a light chain sequence described herein, e.g., a sequence of            SEQ ID NO:1 or a sequence that differs from SEQ ID NO:1 by            at least one but not more than 2, 3, 4, 5, 6, 7, 9, or 10            amino acid residues; and        -   a heavy chain sequence described herein, e.g., a sequence of            SEQ ID NO:2 or a sequence that differs from SEQ ID NO:2 by            at least one but not more than 2, 3, 4, 5, 6, 7, 9, or 10            amino acid residues;    -   (b) 30 mM histidine;    -   (c) 250 mM sorbitol; and    -   (d) 0.01% polysorbate, e.g., polysorbate 20;        wherein the aqueous pharmaceutical composition has pH 5 to 7.

In some embodiments, the aqueous pharmaceutical composition is disposedin a container with a final fill volume of 1 mL. In embodiments, thecontainer is a 2 mL USP Type 1 borosilicate glass vial with a 13 mmchlorobutyl based stopper with flourotech coating on plug and B2 coatingon the top and an aluminum over seal with flip top cap.

In some embodiments, the aqueous pharmaceutical composition meets thecriterion (see Table 32) for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,or 14 of attributes A to M, either immediately after production or afterstorage under conditions described herein (e.g., as described herein inthe Examples, e.g., after storage for up to 12 months (e.g., afterstorage for 1 month, 3 months, 6 months, 9 months, or 12 months), e.g.,storage at −75° C., at 2 to 8° C., at 30° C. and 65% RH, or at 40° C.and 75% RH). In some embodiments, the aqueous pharmaceutical compositionmeets the criterion for all attributes A to M. In some embodiments, theaqueous pharmaceutical composition meets the criterion for at least oneattribute in each of Groups 1 to 4. In some embodiments, the aqueouspharmaceutical composition meets the criterion for at least twoattributes in each of Groups 1 to 4.

In some embodiments, the aqueous pharmaceutical composition meets thecriterion for attributes G and/or H, K, and I and/or J. In embodiments,the aqueous pharmaceutical composition meets the criterion forattributes G, K, and I; for attributes H, K, and I; for attributes G, K,and J; or for attributes H, K, and J. In embodiments, the aqueouspharmaceutical composition meets the criterion for attributes G, H, K,and I; for attributes G, H, K, and J; for attributes G, K, I, and J; orfor attributes H, K, I, and J. In embodiments, the aqueouspharmaceutical composition meets the criterion for attributes G H, K, Iand J.

TABLE 32 Criteria for Liquid Formulations, e.g., Histidine FormulationsAttribute Criterion General A Appearance Clear to opalescent (Group 1)Slightly yellow to yellow Essentially free from visible particulatematter B PH 5-7 C Particulates ≥10 μm particles: ≤6000 particles percontainer ≥25 μm particles: ≤600 particles per container D Osmolality¹270-380 mOsm/Kg E Protein 165-190 mg/mL Concentration (A280) Identity FCharge Profile by pI of the main peak is ± (Group 2) Imaging Capillary0.1 from that of the Isoelectric reference standard Focusing (icIEF) GPotency (ELISA) Demonstrates Binding to Integrin α1 I domain BiologicalH Potency (ELISA) 80%-125% of Potency Reference Standard (Group 3)Purity and I Impurities by Total impurities <15.0% impurities ReducingCE- (Group 4) SDS J Impurities by Total impurities <15.0% Non-ReducingCE-SDS K Aggregation by ≤10.0% Total Size Exclusion AggregationChromatography (SEC) Safety L Endotoxin ≤90.0 EU/mL (Group 5) MSterility Complies with USP requirements

In some embodiments, an aqueous pharmaceutical composition describedherein (e.g., an acetate formulation) meets one or more of the criteriadescribed in Table 33.

In one embodiment, the aqueous pharmaceutical composition comprises

-   -   (a) 165 to 200 mg/mL of an anti-VLA-1 antibody having        -   a light chain sequence described herein, e.g., a sequence of            SEQ ID NO:1 or a sequence that differs from SEQ ID NO:1 by            at least one but not more than 2, 3, 4, 5, 6, 7, 9, or 10            amino acid residues; and        -   a heavy chain sequence described herein, e.g., a sequence of            SEQ ID NO:2 or a sequence that differs from SEQ ID NO:2 by            at least one but not more than 2, 3, 4, 5, 6, 7, 9, or 10            amino acid residues;    -   (b) 25 to 35 mM acetate;    -   (c) 170 to 253 mM sorbitol; and    -   (d) 0.008 to 0.012% polysorbate, e.g., polysorbate 80;        wherein the aqueous pharmaceutical composition has pH 4.5 to        6.5.

In a certain embodiment, the aqueous pharmaceutical compositioncomprises

-   -   (a) 190 mg/mL of an anti-VLA-1 antibody having        -   a light chain sequence described herein, e.g., a sequence of            SEQ ID NO:1 or a sequence that differs from SEQ ID NO:1 by            at least one but not more than 2, 3, 4, 5, 6, 7, 9, or 10            amino acid residues; and        -   a heavy chain sequence described herein, e.g., a sequence of            SEQ ID NO:2 or a sequence that differs from SEQ ID NO:2 by            at least one but not more than 2, 3, 4, 5, 6, 7, 9, or 10            amino acid residues;    -   (b) 30 mM acetate;    -   (c) 220 mM sorbitol; and    -   (d) 0.01% polysorbate, e.g., polysorbate 80;        wherein the aqueous pharmaceutical composition has a pH of 4.5        to 6.5.

In some embodiments, the aqueous pharmaceutical composition is disposedin a container with a final fill volume of 1 mL. In embodiments, thecontainer is a 2 mL USP Type 1 borosilicate glass vial with a 13 mmchlorobutyl based stopper with flourotech coating on plug and B2 coatingon the top and an aluminum over seal with flip top cap.

In some embodiments, the aqueous pharmaceutical composition meets thecriterion (see Table 33) for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,or 14 of attributes A to M. In some embodiments, the aqueouspharmaceutical composition meets the criterion for all attributes A toM. In some embodiments, the aqueous pharmaceutical composition meets thecriterion for at least one attribute in each of Groups 1 to 4. In someembodiments, the aqueous pharmaceutical composition meets the criterionfor at least two attributes in each of Groups 1 to 4.

In some embodiments, the aqueous pharmaceutical composition meets thecriterion for attributes G and/or H, K, and I and/or J. In embodiments,the aqueous pharmaceutical composition meets the criterion forattributes G, K, and I; for attributes H, K, and I; for attributes G, K,and J; or for attributes H, K, and J. In embodiments, the aqueouspharmaceutical composition meets the criterion for attributes G H, K,and I; for attributes G, H, K, and J; for attributes G, K, I, and J; orfor attributes H, K, I, and J. In embodiments, the aqueouspharmaceutical composition meets the criterion for attributes G, H, K, Iand J.

TABLE 33 Criteria for Liquid Formulations. e.g., Acetate FormulationsAttribute Criterion General A Appearance Clear to opalescent (Group 1)Slightly yellow to yellow Essentially free from visible particulatematter B PH 4.5-6.5 C Particulates ≥10 μm particles: ≤6000 particles percontainer ≥25 μm particles: ≤600 particles per container D Osmolality¹270-380 mOsm/Kg E Protein 165-200 mg/mL Concentration (A280) Identity FCharge Profile by pI of the main peak is ± (Group 2) Imaging Capillary0.1 from that of the Isoelectric Focusing (icIEF) reference standard GPotency (ELISA) Demonstrates Binding to Integrin α1 I domain BiologicalH Potency (ELISA) 80%-125% of Potency Reference Standard (Group 3)Purity and I Impurities by Total Impurities ≤15.0% impurities ReducingCE- (Group 4) SDS J Impurities by Total impurities ≤15.0% Non-ReducingCE-SDS K Aggregation by ≤10.0% Total Size Exclusion AggregationChromatography (SEC) Safety L Endotoxin ≤90.0 EU/mL (Group 5) MSterility Complies with USP requirements

In some embodiments, the aqueous pharmaceutical composition is stable.In some embodiments, stability is established based on testing theaqueous pharmaceutical composition after storage under controlledconditions for a preselected period of time, e.g., 1 month, 3 months, 6,months, 9 months or 12 months. Controlled conditions are describedherein in the Examples. For example, controlled conditions can includestorage at a fixed temperature or fixed temperature range, controlledhumidity conditions, controlled light levels (e.g., storage indarkness), and/or storage in sterile sealed vials, e.g., sterile,depyrogenated type I borosilicate glass vials (e.g., at a volume of 1mL), that are sealed with FluroTec® stoppers, e.g. 13 mm FluroTec®stoppers. In embodiments, the aqueous pharmaceutical composition isstored at −75° C., 2 to 8° C., 30° C. and 65% RH, or 40° C. and 75% RH,e.g., as described herein in the Examples.

In some embodiments, stability is established based on testing ofparameters such as, e.g., appearance, protein content, pH, particlecounts, % heavy chain, % light chain, % IgGC % intact IgG loss,

In some embodiments, stability is established based on appearance. Insome embodiments, the aqueous pharmaceutical composition is clear toopalescent. In some embodiments, the aqueous pharmaceutical compositionis slightly yellow to yellow. In some embodiments, the aqueouspharmaceutical composition is essentially free from visible particulatematter.

In some embodiments, stability is established based on particle counts,e.g., counts of particles ≥10 μM and/or particles ≥25 μM, as determinedusing a liquid particle counter, e.g., a particle counter as describedherein in the Examples.

In some embodiments, stability is established based on protein content.In some embodiments, there is no detectable loss in protein contentafter storage for a preselected period of time, e.g., 1 month, 3 months,6, months, 9 months or 12 months. In some embodiments, stability isassessed based on purity. In some embodiments, purity is determinedbased on the % heavy chain, % light chain, % IgG, and/or % intact IgGloss, as assessed using reduced SDS-PAGE, e.g., as described herein inthe examples. In some embodiments, purity is determined based on themonomer average % area, the % fragmentation (this is 100-monomer average% area), the aggregate 3 average % area, the aggregate 2 average % area,the aggregate 1 average % area, the LMWI 1 average % area, and/or theLMWI 2 average % area, as assessed using SEC, e.g., as described hereinin the examples.

In some embodiments, stability is assessed based on charge heterogeneityas assessed using CEX, e.g., as described herein in the examples. Inembodiments, an aqueous pharmaceutical composition described herein isstable if the particle counts meet particle limits for injection set byUSP<788>. In embodiments, an aqueous pharmaceutical compositiondescribed herein is stable if the particle counts for particles for ≥210μM particles are less than 6000 or the particle counts for ≥25 μMparticles are less than 600. In embodiments, an aqueous pharmaceuticalcomposition described herein is stable if the particle counts forparticles for ≥10 μM particles are less than 6000 and the particlecounts for ≥25 μM particles are less than 600.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at −75° C. for up to 12 months (e.g., for up to12 months (e.g., for 1 month, 3 months, 6 months, 9 months or 12months)), as indicated by the presence of less than 1600, 1700, 1800,1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, or3000 particles/mL as assessed by the cumulative counts/mL for ≥10 μMparticles using a liquid particle counter. In an embodiment, the aqueouspharmaceutical composition is stable after storage at −75° C. for 12months, as indicated by the presence of less than 1600 particles/mL asassessed by the cumulative counts/mL for ≥10 μM particles using a liquidparticle counter.

In embodiments, an aqueous pharmaceutical composition described herein(e.g., an aqueous pharmaceutical composition described herein thatcomprises histidine, sorbitol, and polysorbate, e.g., polysorbate 20) isstable after storage at −75° C. for up to 12 months (e.g., for up to 12months (e.g., for 1 month, 3 months, 6 months, 9 months or 12 months)),as indicated by the presence of less than 600, 700, 800, 900, 1000,1100, 1200, 1300, 1400, or 1500 particles/mL as assessed by thecumulative counts/mL for ≥10 μM particles using a liquid particlecounterIn an embodiment, the aqueous pharmaceutical composition isstable after storage at −75° C. for 12 months, as indicated by thepresence of less than 600 particles/mL as assessed by the cumulativecounts/mL for ≥10 μM particles using a liquid particle counter.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at −75° C. for up to 12 months (e.g., for up to12 months (e.g., for 1 month, 3 months, 6 months, 9 months or 12months)), as indicated by the presence of less than 210, 220, 230, 240,250, 300, 350, 400, 500, or 600, particles/mL as assessed by thecumulative counts/mL for ≥25 μM particles using a liquid particlecounter. In an embodiment, the aqueous pharmaceutical composition isstable after storage at −75° C. for 12 months, as indicated by thepresence of less than 250 particles/mL as assessed by the cumulativecounts/mL for ≥25 μM particles using a liquid particle counter.

In embodiments, an aqueous pharmaceutical composition described herein(e.g., an aqueous pharmaceutical composition described herein thatcomprises histidine, sorbitol, and polysorbate, e.g., polysorbate 20) isstable after storage at −75° C. for up to 12 months (e.g., for up to 12months (e.g., for 1 month, 3 months, 6 months, 9 months or 12 months)),as indicated by the presence of less than 100, 90, 80, 70, 50, 40, or 30particles/mL as assessed by the cumulative counts/mL for ≥25 μMparticles using a liquid particle counter. In an embodiment, the aqueouspharmaceutical composition is stable after storage at −75° C. for 12months, as indicated by the presence of less than 100 particles/mL asassessed by the cumulative counts/mL for ≥25 μM particles using a liquidparticle counter.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at 2 to 8° C. for up to 12 months (e.g., for upto 12 months (e.g., for 1 month, 3 months, 6 months, 9 months or 12months)), as indicated by the presence of less than 2600, 2700, 2800,2900, 3000, 3500, 4000, 4500, 5000, 5500, or 6000 particles/mL asassessed by the cumulative counts/mL for ≥10 μM particles using a liquidparticle counter. In an embodiment, the aqueous pharmaceuticalcomposition is stable after storage at 2- to 8° C. for 12 months, asindicated by the presence of less than 2600 particles/mL as assessed bythe cumulative counts/mL for ≥10 μM particles using a liquid particlecounter.

In embodiments, an aqueous pharmaceutical composition described herein(e.g., an aqueous pharmaceutical composition described herein thatcomprises histidine, sorbitol, and polysorbate, e.g., polysorbate 20) isstable after storage at 2 to 8° C. for up to 12 months (e.g., for up to12 months (e.g., for 1 month, 3 months, 6 months, 9 months or 12months)), as indicated by the presence of less than 1500, 1600, 1700,1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 particles/mL asassessed by the cumulative counts/mL for ≥10 μM particles using a liquidparticle counter. In an embodiment, the aqueous pharmaceuticalcomposition is stable after storage at 2 to 8° C. for 12 months, asindicated by the presence of less than 1500 particles/mL as assessed bythe cumulative counts/mL for ≥10 μM particles using a liquid particlecounter.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at 2 to 8° C. for up to 12 months (e.g., for upto 12 months (e.g., for 1 month, 3 months, 6 months, 9 months or 12months)), as indicated by the presence of less than 210, 220, 230, 240,250, 300, 350, 400, 500, or 600 particles/mL as assessed by thecumulative counts/mL for ≥25 μM particles using a liquid particlecounter. In an embodiment, the aqueous pharmaceutical composition isstable after storage at 2- to 8° C. for 12 months, as indicated by thepresence of less than 250 particles/mL as assessed by the cumulativecounts/mL for ≥25 μM particles using a liquid particle counter.

In embodiments, an aqueous pharmaceutical composition described herein(e.g., an aqueous pharmaceutical composition described herein thatcomprises histidine, sorbitol, and polysorbate, e.g., polysorbate 20) isstable after storage at 2 to 8° C. for up to 12 months (e.g., for up to12 months (e.g., for 1 month, 3 months, 6 months, 9 months or 12months)), as indicated by the presence of less than 50, 60, 70, 80, 90,100, 110, 120, 130, 140, 150, 160, 170, or 180 particles/mL as assessedby the cumulative counts/mL for ≥25 μM particles using a liquid particlecounter. In an embodiment, the aqueous pharmaceutical composition isstable after storage at 2 to 8° C. for 12 months, as indicated by thepresence of less than 50 particles/mL as assessed by the cumulativecounts/mL for ≥25 μM particles using a liquid particle counter.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at 30° C. for up to 12 months (e.g., for 1month, 3 months, 6 months, 9 months or 12 months), as indicated by thepresence of less than 2600, 2700, 2800, 2900, 3000, 3500, 4000, 4500,5000, 5500, or 6000 particles/mL as assessed by the cumulative counts/mLfor ≥10 μM particles using a liquid particle counter. In an embodiment,the aqueous pharmaceutical composition is stable after storage at 30° C.for 12 months, as indicated by the presence of less than 2600particles/mL as assessed by the cumulative counts/mL for ≥10 μMparticles using a liquid particle counter.

In embodiments, an aqueous pharmaceutical composition described herein(e.g., an aqueous pharmaceutical composition described herein thatcomprises histidine, sorbitol, and polysorbate, e.g., polysorbate 20) isstable after storage at 30° C. for up to 12 months (e.g., for 1 month, 3months, 6 months, 9 months or 12 months), as indicated by the presenceof less than 2500, 2400, or 2300 particles/mL as assessed by thecumulative counts/mL for ≥10 μM particles using a liquid particlecounter. In an embodiment, the aqueous pharmaceutical composition isstable after storage at 30° C. for 12 months, as indicated by thepresence of less than 2300 particles/mL as assessed by the cumulativecounts/mL for ≥10 μM particles using a liquid particle counter.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at 30° C. for up to 12 months (e.g., for 1month, 3 months, 6 months, 9 months or 12 months), as indicated by thepresence of less than 210, 220, 230, 240, 250, 300, 350, 400, 500, or600 particles/mL as assessed by the cumulative counts/mL for ≥25 μMparticles using a liquid particle counter. In an embodiment, the aqueouspharmaceutical composition is stable after storage at 30° C. for 12months, as indicated by the presence of less than 250 particles/mL asassessed by the cumulative counts/mL for ≥25 μM particles using a liquidparticle counter.

In embodiments, an aqueous pharmaceutical composition described herein(e.g., an aqueous pharmaceutical composition described herein thatcomprises histidine, sorbitol, and polysorbate, e.g., polysorbate 20) isstable after storage at 30° C. for up to 12 months (e.g., for 1 month, 3months, 6 months, 9 months or 12 months), as indicated by the presenceof less than 120, 130, 140, 150, 160, 170, 180, or 190 particles/mL asassessed by the cumulative counts/mL for ≥25 μM particles using a liquidparticle counter. In an embodiment, the aqueous pharmaceuticalcomposition is stable after storage at 30° C. for 12 months, asindicated by the presence of less than 120 particles/mL as assessed bythe cumulative counts/mL for ≥25 μM particles using a liquid particlecounter.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at 40° C. for up to 6 months (e.g., 1 month, 3months, or 6 months), as indicated by the presence of less than 2600,2700, 2800, 2900, 3000, 3500, 4000, 4500, 5000, 5500, or 6000particles/mL as assessed by the cumulative counts/mL for ≥10 μMparticles using a liquid particle counter. In an embodiment, the aqueouspharmaceutical composition is stable after storage at 40° C. for 6months, as indicated by the presence of less than 2600 particles/mL asassessed by the cumulative counts/mL for ≥10 μM particles using a liquidparticle counter.

In embodiments, an aqueous pharmaceutical composition described herein(e.g., an aqueous pharmaceutical composition described herein thatcomprises histidine, sorbitol, and polysorbate, e.g., polysorbate 20) isstable after storage at 40° C. for up to 6 months (e.g., for 1 month, 3months, or 6 months), as indicated by the presence of less than 120,130, 140, 150, 160, 170, 180, or 190 particles/mL as assessed by thecumulative counts/mL for ≥10 μM particles using a liquid particlecounter. In an embodiment, the aqueous pharmaceutical composition isstable after storage at 40° C. for 6 months, as indicated by thepresence of less than 120 particles/mL as assessed by the cumulativecounts/mL for ≥10 μM particles using a liquid particle counter.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at −75° C. for up to 12 months (e.g., for 1month, 3 months, 6 months, 9 months or 12 months), as indicated by lessthan 1%, 2%, or 3% relative loss of intact IgG as assessed using reducedSDS-PAGE. As used in this context, “relative loss” refers to losscompared with a reference standard, e.g., an antibody that is from thesame lot (e.g., production batch) but that is not formulated in theaqueous pharmaceutical composition. In an embodiment, the aqueouspharmaceutical composition is stable after storage at −75° C. for 12months, as indicated by less than 1% relative loss of intact IgG asassessed using reduced SDS-PAGE.

In embodiments, an aqueous pharmaceutical composition described herein(e.g., an aqueous pharmaceutical composition described herein thatcomprises histidine, sorbitol, and polysorbate, e.g., polysorbate 20) isstable after storage at −75° C. for up to 12 months (e.g., for 1 month,3 months, 6 months, 9 months or 12 months), as indicated by less than0.5%. 0.6%, 0.7%, or 0.8% relative loss of intact lgG as assessed usingreduced SDS-PAGE. In an embodiment, the aqueous pharmaceuticalcomposition is stable after storage at −75C for 12 months, as indicatedby less than 0.5% relative loss of intact IgG as assessed using reducedSDS-PAGE.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at 2 to 8° C. for up to 12 months (e.g., for 1month, 3 months, 6 months, 9 months or 12 months), as indicated by lessthan 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% relative loss of intactIgG as assessed using reduced SDS-PAGE. In an embodiment, aqueouspharmaceutical composition is stable after storage at 2- to 8° C. for 12months, as indicated by less than 10% relative loss of intact IgG asassessed using reduced SDS-PAGE.

In embodiments, an aqueous pharmaceutical composition described herein(e.g., an aqueous pharmaceutical composition described herein thatcomprises histidine, sorbitol, and polysorbate, e.g., polysorbate 20) isstable after storage at 2 to 8° C. for up to 12 months (e.g., for 1month, 3 months, 6 months, 9 months, or 12 months), as indicated by lessthan 3%, 4%, 5%, or 6% relative loss of intact IgG as assessed usingreduced SDS-PAGE. In an embodiment, the aqueous pharmaceuticalcomposition is stable after storage at 2- to 8° C. for 12 months, asindicated by less than 3% relative loss of intact IgG as assessed usingreduced SDS-PAGE.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at 30° C. for up to 12 months (e.g., for 1month, 3 months, 6 months, 9 months or 12 months), as indicated by lessthan 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% relative loss of intactIgG as assessed using reduced SDS-PAGE. In an embodiment, the aqueouspharmaceutical composition is stable after storage at 30° C. for 12months, as indicated by less than 25% relative loss of intact IgG asassessed using reduced SDS-PAGE.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at 40° C. for up to 6 months (e.g., for 1 month,3 months, or 6 months), as indicated by less than 30% relative loss ofintact IgG as assessed using reduced SDS-PAGE. In an embodiment, theaqueous pharmaceutical composition is stable after storage at 40° C. for6 months, as indicated by less than 30% relative loss of intact IgG asassessed using reduced SDS-PAGE.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at 40° C. for up to 6 months (e.g., for 1 month,3 months, or 6 months), as indicated by less than 25% relative loss ofintact IgG as assessed using reduced SDS-PAGE. In an embodiment, theaqueous pharmaceutical composition is stable after storage at 40° C. for6 months, as indicated by less than 25% relative loss of intact IgG asassessed using reduced SDS-PAGE.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at −75° C. for up to 12 months (e.g., for 1month, 3 months, 6 months, 9 months or 12 months), as indicated by lessthan 4%, 5%, 6%, 7%, 8%, 9%, or 10% fragmentation as assessed using sizeexclusion chromatography. In an embodiment, the aqueous pharmaceuticalcomposition is stable after storage at −75° C. 12 months, as indicatedby less than 4% fragmentation as assessed using size exclusionchromatography.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at 2 to 8° C. for up to 12 months (e.g., for 1month, 3 months, 6 months, 9 months or 12 months), as indicated by lessthan 5%, 6%, 7%, 8%, 9%, or 10% fragmentation as assessed using sizeexclusion chromatography. In an embodiment, the aqueous pharmaceuticalcomposition is stable after storage at 2- to 8° C. for 12 months, asindicated by less than 5% fragmentation as assessed using size exclusionchromatography.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at 30° C. for up to 12 months (e.g., for 1month, 3 months, 6 months, 9 months or 12 months), as indicated by lessthan 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% fragmentation as assessedusing size exclusion chromatography.

In embodiments, an aqueous pharmaceutical composition described herein(e.g., an aqueous pharmaceutical composition described herein thatcomprises histidine, sorbitol, and polysorbate, e.g., polysorbate 20) isstable after storage at 30° C. for up to 12 months (e.g., for 1 month, 3months, 6 months, 9 months or 12 months), as indicated by less than 12%fragmentation as assessed using size exclusion chromatography.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at 40° C. for up to 6 months (e.g., for 1 month,3 months, or 6 months), as indicated by less than 16, 17, 18, 19, 20,21, 22, 23, 24, or 25% fragmentation as assessed using size exclusionchromatography.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at 40° C. for up to 6 months (e.g., for 1 month,3 months, or 6 months), as indicated by less than 20, 21, 22, 23, 24,25, 26, 27, 28, 29, or 30% fragmentation as assessed using sizeexclusion chromatography

In embodiments, an aqueous pharmaceutical composition described herein(e.g., an aqueous pharmaceutical composition described herein thatcomprises histidine, sorbitol, and polysorbate, e.g., polysorbate 20) isstable after storage at 40° C. for up to 6 months (e.g., for 1 month, 3months, or 6 months), as indicated by less than 17, 18, 19, or 20%fragmentation as assessed using size exclusion chromatography.

In embodiments, an aqueous pharmaceutical composition described hereinis stable after storage at 30° C. for up to 12 months (e.g., for 1month, 3 months, 6 months, 9 months or 12 months), as indicated by lessthan 5, 6, 7, 8, 9 or 10 LMWI 1 average % area as assessed using sizeexclusion chromatography.

In embodiments, an aqueous pharmaceutical composition described herein(e.g., an aqueous pharmaceutical composition described herein thatcomprises histidine, sorbitol, and polysorbate, e.g., polysorbate 20) isstable after storage at 30° C. for up to 12 months (e.g., for 1 month, 3months, 6 months, 9 months or 12 months), as indicated by less than 3,4, or 5 LMWI 1 average % area as assessed using size exclusionchromatography.

In embodiments, an aqueous pharmaceutical composition described hereinis suitable for subcutaneous administration.

Also provided herein is a unit dosage form of an aqueous pharmaceuticalcomposition, e.g., an aqueous pharmaceutical composition describedherein. In embodiments, the unit dosage form will, when administered toa human, deliver antibody at about 2.0 mg per kg of body weight to about4.0 mg per kg of body weight to the human.

In embodiments, a plurality of unit dosage forms of an aqueouspharmaceutical composition (e.g., an aqueous pharmaceutical compositiondescribed herein) is provided.

In embodiments, a kit comprising the unit dosage form, or the pluralityof unit dosage forms, is provided.

In embodiments, an aqueous pharmaceutical composition described hereinis disposed in a container. In embodiments, the container has disposedtherein a unit dosage form of the pharmaceutical composition. Inembodiments, the container is a delivery device. In embodiments, thecontainer is suitable for administering the pharmaceutical compositionsubcutaneously. In embodiments, the container is a syringe, e.g., aprefilled syringe. In embodiments, the container is a sealed vial.

In one aspect, the disclosure provides a method of treating a patient inneed of anti-VLA-1 therapy, comprising administering to the patient aneffective amount of an aqueous pharmaceutical composition describedherein. In some embodiments, the patient has an inflammatory disorder.In some embodiments, the patient has a disorder selected from the groupconsisting of arthritis, inflammatory bowel disease, lupus, transplantrejection, psoriasis, and sarcoidosis. In some embodiments, the patienthas sarcoidosis. In some embodiments, the patient has arthritis. In someembodiments, the patient has rheumatoid arthritis. In some embodiments,the patient has moderately to severely active rheumatoid arthritis. Insome embodiments, the patient has an inflammatory bowel disease. In someembodiments, the patient has Crohn's disease. In some embodiments, thepatient has ulcerative colitis. In some embodiments, the patient haslupus nephritis. In some embodiments, the method is effective to treatthe disorder from which the patient in need of anti-VLA-1 therapy issuffering (e.g., the inflammatory disorder or the disorder selected fromthe group consisting of arthritis, inflammatory bowel disease, lupus,transplant rejection, psoriasis, and sarcoidosis).

In some embodiments, the patient has moderately to severely activerheumatoid arthritis.

In some embodiments, the patient is an adult. In some embodiments, thepatient is an adult with moderately to severely active rheumatoidarthritis.

In some embodiments, the aqueous pharmaceutical composition isadministered subcutaneously. In some embodiments, the composition isadministered weekly. In some embodiments, the composition isadministered every 4, 5, 6, 7, 8, 9, or 10 days. In some embodiments,the composition is administered every two weeks. In some embodiments,the composition is administered every three weeks or every four weeks.

In some embodiments, the composition is administered for at least 2, 3,4, 5, 6, 7, 8, 9, 10, 11, or 12 weeks. In some embodiments, thecomposition is administered weekly for at least 6 weeks.

In some embodiments, the composition is administered at a dose of 0.5mg/kg to 6 mg/kg. In some embodiments, the composition is administeredat a dose of 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 4.0 mg/kg, or 6.0 mg/kg.In some embodiments, the composition is administered at a dose of 2.0mg/kg to 6.0 mg/kg. In some embodiments, the composition is administeredat a dose of 2.0 mg/kg, 4.0 mg/kg, or 6.0 mg/kg.

In some embodiments, the method reduces a sign or symptom (e.g., a signor symptom of the disorder from which the patient is suffering, e.g., asign or symptom of rheumatoid arthritis), slows progression ofstructural damage (e.g., structural damage associated with the disorderfrom which the patient is suffering, e.g., structural damage associatedwith rheumatoid arthritis), or improves physical function. In someembodiments, treating the patient according to the method for at least 2weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, or 8 weeks reduces asign or symptom, slows progression of structural damage, or improvesphysical function.

The efficacy of the method (e.g., efficacy in reducing a sign orsymptom, slowing progression of structural damage, or improving physicalfunction) can be assessed using measures known in the art. Inembodiments, efficacy is assessed using ACR20, ACR50, ACR70, DAS28 CRP,HAQ-DI, and/or MRI results.

In some embodiments, the method is not associated with any adverseevents in the patient or in a clinical study of patients who have thesame disease as the patient to be treated. In some events, the method isnot associated with any severe or moderate adverse events in the patientor in a clinical study of patients who have the same disease as thepatient to be treated.

In some embodiments, the subject has rheumatoid arthritis. In someembodiments, the patient is an adult. In some embodiments, the patienthas undergone a prior alternate treatment (e.g., a prior alternatetreatment for the disorder from which the patient is suffering). A“prior alternate treatment,” as used herein, refers to any treatmentother than a treatment comprising an anti-VLA-1 antibody as describedherein. In some embodiments, the patient has had an inadequate responseto the prior alternate treatment.

In some embodiments, the patient has rheumatoid arthritis and hasundergone a prior alternate treatment for rheumatoid arthritis. In someembodiments, the patient has had an inadequate response to the prioralternate treatment.

In an aspect, the disclosure provides a method of treating a patient(e.g., an adult patient) with rheumatoid arthritis (e.g., moderately toseverely active rhematoid arthritis) who has had a prior alternatetreatment (e.g., a prior alternate treatment for rhematoid arthritis),said method comprising subcutaneously administering to said patient aliquid formulation (e.g., an aqueous pharmaceutical composition)comprising

-   -   (a) 150 to 210 mg/mL of an anti-VLA-1 antibody having a light        chain sequence of SEQ ID NO:1 and a heavy chain sequence of SEQ        ID NO:2;    -   (b) 25 to 35 mM acetate or 25 to 35 mM histidine;    -   (c) 170 to 288 mM sorbitol; and    -   (d) 0.008 to 0.012% polysorbate, wherein the polysorbate is        polysorbate 20 or polysorbate 80;        wherein the composition has a pH of 5 to 7.

In embodiments, the method reduces a sign or symptom of rheumatoidarthritis, slows progression of structural damage associated withrheumatoid arthritis, or improves physical function.

In embodiments, the liquid formulation (e.g., the aqueous pharmaceuticalcomposition) comprises

-   -   (a) 180 mg/mL an anti-VLA-1 antibody having a light chain        sequence of SEQ ID NO: 1 and a heavy chain sequence of SEQ ID        NO:2;    -   (b) 30 mM histidine;    -   (c) 250 mM sorbitol; and    -   (d) 0.01% polysorbate 20; and        wherein the composition has a pH of 6.0.

In embodiments, the liquid formulation is administered to the patient ata dose of 0.5 to 6.0 mg/kg. In embodiments, the liquid formulation isadministered to the patient at a dose of 2 to 6 mg/kg. In embodiments,the liquid formulation is administered to the patient at a dose of 2mg/kg, 4 mg/kg, or 6 mg/kg.

In embodiments, the liquid formulation or aqueous pharmaceuticalcomposition is administered repeatedly, e.g., weekly. In embodiments,the liquid formulation or aqueous pharmaceutical composition isadministered every 4, 5, 6, 7, 8, 9, or 10 days. In embodiments, thecomposition is administered every two weeks. In embodiments, thecomposition is administered every three weeks or every four weeks.

In embodiments, the liquid formulation or aqueous pharmaceuticalcomposition is administered repeatedly (e.g., weekly) for at least 2, 4,6, 8, 10, 12, 14, 16 or more weeks. In embodiments, the liquidformulation or aqueous pharmaceutical composition is administered for 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more weeks.

In embodiments, the liquid formulation is administered weekly. Inembodiments, the liquid formulation is administered for at least 6weeks. In embodiments, the liquid formulation is administered weekly forat least 6 weeks.

In embodiments, the prior alternate treatment comprises a DMARD (DiseaseModifying Antirheumatic Drug) or a TNF-α (Tumor Necrosis Factor-α)inhibitor.

In embodiments, the DMARD is methotrexate, leflunomide, sulfasalazine,or hydroxychloroquine.

In embodiments, the prior alternate treatment comprises a biologicagent, e.g., a TNF-α inhibitor. In embodiments, the TNF-α inhibitor isinfliximab, adalimumab, certolizumab pegol, golimumab or etanercept.

In embodiments, the prior alternate treatment comprises an agentselected from infliximab, adalimumab, certolizumab pegol, golimumab,etanercept abatacept, rituximab, tocilizumab, tofacitinib, methotrexate,leflunomide, sulfasalazine, and hydroxychloroquine

In embodiments, the prior alternate treatment comprises an agentselected from abatacept, rituximab, tocilizumab, golimumab, andtofacitinib.

In some embodiments, the subject has had an inadequate response to theprior alternate treatment. In embodiments, the response is inadequate ifassessed based on ACR criteria. In embodiments, the patient does notachieve ACR20 after the prior alternate treatment. In embodiments, thepatient does not achieve ACR50 after the prior alternate treatment. Inembodiements, the patient does not achieve ACR70 after the prioralternate treatment. In embodiments, the prior alternate treatment isdetermined to be inadequate after 6 months of treatment, or after 6 ormore months of treatment. In embodiments, the prior alternate treatmentis determined to be inadequate after 1 or more, 2 or more, 3 or more, 4or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 ormore, 11 or more, or 12 or more months of treatment.

In embodiments, the method further comprises administering to thepatient a second therapeutic agent, e.g., a corticosteroid or ananti-inflammatory.

In embodiments, the method is associated with ≤10% infection risk.

In embodiments, the method is associated with greater than mildinjection site reactions in ≤10% of patients, e.g., ≤10% of patients ina clinical study.

In one embodiment, the method comprises treating an adult patient withmoderately to severely active rheumatoid arthritis who has had aninadequate response to a prior alternate treatment, e.g., a prioralternate treatment comprising a biologic agent, said method comprisingsubcutaneously administering once weekly to said patient a liquidformulation (e.g., an aqueous pharmaceutical composition) comprising

-   -   (a) 165 to 190 mg/mL of an anti-VLA-1 antibody having a light        chain sequence of SEQ ID NO: 1 and a heavy chain sequence of SEQ        ID NO:2;    -   (b) 25 to 35 mM histidine;    -   (c) 170 to 288 mM sorbitol; and    -   (d) 0.008 to 0.012% polysorbate 20; and        wherein the liquid formulation (e.g., the aqueous pharmaceutical        composition) has a pH of 5 to 7. In embodiments, the method        reduces a sign or symptom of rheumatoid arthritis, slows        progression of structural damage associated with rheumatoid        arthritis, or improves physical function. In embodiments, the        liquid formulation is administered at a dose of 2 to 6 mg/kg.

In an aspect provided herein is a method of making an aqueouspharmaceutical composition comprising 150 to 210 mg/mL of an anti-VLA-1antibody having a light chain sequence of SEQ ID NO: 1 and a heavy chainsequence of SEQ ID NO:2; the method comprising combining said antibodywith a buffer selected from histidine and acetate, a surfactant selectedfrom polysorbate 20 and polysorbate 80, and sorbitol to obtain anaqueous pharmaceutical composition comprising

-   -   (a) 150 to 210 mg/mL of an anti-VLA-1 antibody having a light        chain sequence of SEQ ID NO: 1 and a heavy chain sequence of SEQ        ID NO:2;    -   (b) 25 to 35 mM acetate or 25 to 35 mM histidine;    -   (c) 170 to 288 mM sorbitol; and    -   (d) 0.008 to 0.012% polysorbate, wherein the polysorbate is        polysorbate 20 or polysorbate 80;        wherein the aqueous pharmaceutical composition has a pH of 4.5        to 7.

In some embodiments, the buffer is histidine. In some embodiments, thepolysorbate is polysorbate 20. In some embodiments, the buffer ishistidine and the polysorbate is polysorbate 20.

In some embodiments, the buffer is acetate. In some embodiments, thepolysorbate is polysorbate 80. In some embodiments, the buffer isacetate and the polysorbate is polysorbate 80.

In embodiments, the aqueous pharmaceutical composition comprises

-   -   (a) 165 to 190 mg/mL of an anti-VLA-1 antibody having a light        chain sequence of SEQ ID NO: 1 and a heavy chain sequence of SEQ        ID NO:2;    -   (b) 25 to 35 mM histidine;    -   (c) 170 to 288 mM sorbitol; and    -   (d) 0.008 to 0.012% polysorbate 20; and

the aqueous pharmaceutical composition has a pH of 5 to 7.

In an embodiment, the aqueous pharmaceutical composition comprises

-   -   (a) 180 mg/mL of an anti-VLA-1 antibody having a light chain        sequence of SEQ ID NO:1 and a heavy chain sequence of SEQ ID        NO:2;    -   (b) 30 mM histidine;    -   (c) 250 mM sorbitol; and    -   (d) 0.01% polysorbate 20; and

the aqueous pharmaceutical composition has a pH of 6.0.

In embodiments, the aqueous pharmaceutical composition comprises

-   -   (a) 165 to 200 mg/mL of an anti-VLA-1 antibody having a light        chain sequence of SEQ ID NO:1 and a heavy chain sequence of SEQ        ID NO:2;    -   (b) 25 to 35 mM acetate;    -   (c) 170 to 253 mM sorbitol; and    -   (d) 0.008 to 0.012% polysorbate 80; and        the aqueous pharmaceutical composition has a pH of 4.5 to 6.5.

In an embodiment, the aqueous pharmaceutical composition comprises

-   -   (a) 190 mg/mL of an anti-VLA-1 antibody having a light chain        sequence of SEQ ID NO:1 and a heavy chain sequence of SEQ ID        NO:2;    -   (b) 30 mM acetate;    -   (c) 220 mM sorbitol; and    -   (d) 0.01% polysorbate 80; and        wherein the aqueous pharmaceutical composition has a pH of 5.5.

Further specific aspects of the invention are disclosed below.

Aspect 1: An aqueous pharmaceutical composition comprising an anti-VLA-1(Very Late Antigen-1) antibody at a concentration of greater than about100 mg/mL.

Aspect 2: The aqueous pharmaceutical composition of Aspect 1, whereinsaid anti-VLA-1 antibody is a monoclonal antibody.

Aspect 3: The aqueous pharmaceutical composition of Aspect 1, whereinsaid anti-VLA-1 antibody is a CDR-grafted antibody.

Aspect 4: The aqueous pharmaceutical composition of Aspect 1, whereinsaid anti-VLA-1 antibody is a humanized antibody.

Aspect 5: The aqueous pharmaceutical composition of Aspect 1, whereinsaid anti-VLA-1 antibody comprises a light chain that is at least 80%identical with the light chain of SEQ ID NO: 1 and a heavy chain that isat least 80% identical with the heavy chain of SEQ ID NO:2.

Aspect 6: The aqueous pharmaceutical composition of Aspect 1, whereinsaid anti-VLA-1 antibody comprises a light chain having no more than 5amino acid differences from the light chain of SEQ ID NO:1 and a heavychain having no more than 5 amino acid differences from the heavy chainof SEQ ID NO:2.

Aspect 7: The aqueous pharmaceutical composition of Aspect 1, whereinsaid anti-VLA-1 antibody comprises a light chain having the sequence ofSEQ ID NO:1 and a heavy chain having the sequence of SEQ ID NO:2.

Aspect 8: The aqueous pharmaceutical composition of Aspect 1, wherein,said antibody concentration is at least about 160 mg/mL, at least about170 mg/mL, at least about 180 mg/mL, at least about 190 mg/mL, or atleast about 200 mg/mL.

Aspect 9: The aqueous pharmaceutical composition of Aspect 1, wherein,said antibody concentration is less than about 200 mg/mL, less thanabout 205 mg/mL, less than about 210 mg/mL, less than about 215 mg/mL,less than about 220 mg/mL, or less than about 225 mg/mL.

Aspect 10: The aqueous pharmaceutical composition of Aspect 1, wherein,said antibody is at a concentration of about 155 mg/mL to about 165mg/mL, about 165 mg/mL to about 175 mg/mL, about 175 mg/mL to about 185mg/mL, about 185 mg/mL to about 195 mg/mL, about 195 mg/mL to about 205mg/mL, about 205 mg/mL to about 215 mg/mL, or about 215 mg/mL to about225 mg/mL.

Aspect 11: The aqueous pharmaceutical composition of Aspect 1, wherein,said antibody is at a concentration of about 160 mg/mL to about 210mg/mL.

Aspect 12: The aqueous pharmaceutical composition of Aspect 1, whereinthe formulation is stable for at least 6 months, at least one year, atleast two years, or at least three years.

Aspect 13: The aqueous pharmaceutical composition of Aspect 1, whereinafter 6 months, one year, two years, or three years, less than about 1%,less than about 2%, less than about 5%, less than about 10%, or lessthan about 15% of the antibody in the formulation has undergoneaggregation.

Aspect 14: The aqueous pharmaceutical composition of Aspect 13, whereinaggregation is determined by dynamic light scattering.

Aspect 15: The aqueous pharmaceutical composition of Aspect 1, whereinafter 6 months, one year, two years, or three years, less than about 1%,less than about 2%, less than about 5%, less than about 10%, or lessthan about 15% of the antibody in the formulation has undergonefragmentation.

Aspect 16: The aqueous pharmaceutical composition of Aspect 15, whereinfragmentation is determined by dynamic light scattering.

Aspect 17: The aqueous pharmaceutical composition of Aspect 1, whereinafter 6 months, one year, two years, or three years, less than about 1%,less than about 2%, less than about 5%, less than about 10%, or lessthan about 15% of the antibody in the formulation has undergonedeamidation.

Aspect 18: The aqueous pharmaceutical composition of Aspect 17, whereindeamidation is determined by protein loss as measured by spectroscopy.

Aspect 19: The aqueous pharmaceutical composition of Aspect 1, wherein,when stored in a closed container, at 4° C., for a preselected period oftime, said anti-VLA-1 antibody exhibits less than a preselected level ofaggregation.

Aspect 20: The aqueous pharmaceutical composition of Aspect 19, wherein,said preselected level is less than a preselected reference value forlevel of aggregation.

Aspect 21: The aqueous pharmaceutical composition of Aspect 19, wherein,said preselected level is less than 35%.

Aspect 22: The aqueous pharmaceutical composition of Aspect 19, whereinsaid preselected period is 30 days, 60 days, 90 days, 180 days, 1 year,1.5 years, 2 years, 2.5 years, or 3 years.

Aspect 23: The aqueous pharmaceutical composition of Aspect 19, whereinaggregation is determined by DLS.

Aspect 24: The aqueous pharmaceutical composition of Aspect 1, wherein,when subjected to a preselected number of freeze/thaw cycles, saidanti-VLA-1 antibody exhibits less than a preselected level of proteinloss.

Aspect 25: The aqueous pharmaceutical composition of Aspect 24, wherein,said preselected level is less than a preselected reference value of35%.

Aspect 26: The aqueous pharmaceutical composition of Aspect 25, wherein,said preselected level is less than 10% protein loss.

Aspect 27: The aqueous pharmaceutical composition of Aspect 24, whereinsaid preselected number of freeze/thaw cycles is 3, 4, 5, 6, 7, or 8.

Aspect 28: The aqueous pharmaceutical composition of Aspect 24, whereinsaid preselected number of freeze/thaw cycles is 5.

Aspect 29: The aqueous pharmaceutical composition of Aspect 24, whereina freeze/thaw cycle comprises incubation at −80° C. for 2 hours followedby thawing at 20° C. until melted.

Aspect 30: The aqueous pharmaceutical composition of Aspect 24, whereinprotein loss is determined by spectroscopy.

Aspect 31: The aqueous pharmaceutical composition of Aspect 1, wherein,when stored in a closed container at 4° C., and exposed to 1.2 lux hourswhite light and 200 W/m² UV energy, said anti-VLA-1 antibody exhibitsless than a preselected level of protein loss.

Aspect 32: The aqueous pharmaceutical composition of Aspect 1, wherein,when subjected to shaking at 650 rpm, for a preselected period of time,at room temperature said composition exhibits less than a preselectedlevel of protein loss.

Aspect 33: The aqueous pharmaceutical composition of Aspect 32, wherein,said preselected level is less than 5%.

Aspect 34: The aqueous pharmaceutical composition of Aspect 32, whereinsaid preselected period of time is 24 hours, 48 hours, 72 hours or 96hours.

Aspect 35: The aqueous pharmaceutical composition of Aspect 32, whereinsaid preselected period of time is 72 hours.

Aspect 36: The aqueous pharmaceutical composition of Aspect 32, whereinprotein loss is determined by spectroscopy.

Aspect 37: The aqueous pharmaceutical composition of Aspect 1, wherein,when subjected to a preselected level of oxidation stress, saidcomposition exhibits a preselected level of protein loss.

Aspect 38: The aqueous pharmaceutical composition of Aspect 37, wherein,said preselected level is less than 35%.

Aspect 39: The aqueous pharmaceutical composition of Aspect 37, whereinsaid preselected level of oxidation stress is provided by the presenceof hydrogen peroxide at a final concentration of 0.04% (VN) withincubation at 37° C., for a preselected period of time.

Aspect 40: The aqueous pharmaceutical composition of Aspect 39, whereinsaid preselected period of time is 2 hours, 3 hours, 4 hours, 5 hours or6 hours.

Aspect 41: The aqueous pharmaceutical composition of Aspect 39, whereinsaid preselected period of time is 4 hours.

Aspect 42: The aqueous pharmaceutical composition of Aspect 39, whereinprotein loss is determined by spectroscopy.

Aspect 43: The aqueous pharmaceutical composition of Aspect 1, having asyringeability suitable for patient self administration to asubcutaneous site.

Aspect 44: The aqueous pharmaceutical composition of Aspect 1, whendisposed in a syringe suitable for subcutaneous delivery to a patient,can be expelled and thereby injected into a subcutaneous site of thepatient, with a plunger force equal to or less than 4 lbs.

Aspect 45: The aqueous pharmaceutical composition of Aspect 1, in a formsuitable for patient self-administration.

Aspect 46: The aqueous pharmaceutical composition of Aspect 44, whereinsaid pressure will allow delivery of a unit dosage in 10 seconds orless.

Aspect 47: The aqueous pharmaceutical composition of Aspect 1, wherein,when disposed in a 1 mL syringe having a needle of preselected gauge,can be expelled at a preselected rate with a plunger force of no morethan a preselected amount.

Aspect 48: The aqueous pharmaceutical composition of Aspect 1, furthercomprising a Aspect 49: The aqueous pharmaceutical composition of Aspect1, further comprising one or more of histidine, acetate, succinate orphosphate.

Aspect 50: The aqueous pharmaceutical composition of Aspect 1, furthercomprising one or more of histidine or acetate.

Aspect 51: The aqueous pharmaceutical composition of Aspect 1, furthercomprising histidine.

Aspect 52: The aqueous pharmaceutical composition of Aspect 51, whereinsaid histidine is at a concentration of about 10 mM to about 50 mM.

Aspect 53: The aqueous pharmaceutical composition of Aspect 51, whereinsaid histidine is at a concentration of about 20 mM to about 40 mM.

Aspect 54: The aqueous pharmaceutical composition of Aspect 51, whereinsaid histidine is at a concentration of about 30 mM.

Aspect 55: The aqueous pharmaceutical composition of Aspect 1, furthercomprising acetate.

Aspect 56: The aqueous pharmaceutical composition of Aspect 55, whereinsaid acetate is at a concentration of about 10 mM to about 50 mM.

Aspect 57: The aqueous pharmaceutical composition of Aspect 55, whereinsaid acetate is at a concentration of about 20 mM to about 40 mM.

Aspect 58: The aqueous pharmaceutical composition of Aspect 55, whereinsaid acetate is at a concentration of about 30 mM.

Aspect 59: The aqueous pharmaceutical composition of Aspect 1, furthercomprising an excipient.

Aspect 60: The aqueous pharmaceutical composition of Aspect 59, whereinsaid excipient is selected from sorbitol, sodium chloride, sucrose,trehelose, and mannitol.

Aspect 61: The aqueous pharmaceutical composition of Aspect 60, whereinsaid sorbitol is at a concentration of about 180 mM to about 300 mM.

Aspect 62: The aqueous pharmaceutical composition of Aspect 60, hereinsaid sorbitol is at a concentration of about 200 mM to about 270 mM.

Aspect 63: The aqueous pharmaceutical composition of Aspect 60, whereinsaid sorbitol is at a concentration of about 200 mM to about 240 mM.

Aspect 64: The aqueous pharmaceutical composition of Aspect 60, whereinsaid sorbitol is at a concentration of about 230 mM to about 270 mM.

Aspect 65: The aqueous pharmaceutical composition of Aspect 60, whereinsaid sorbitol is at a concentration of about 230 mM to about 270 mM.

Aspect 66: The aqueous pharmaceutical composition of Aspect 60, whereinsaid sorbitol is at a concentration of about 240 mM to about 260 mM.

Aspect 67: The aqueous pharmaceutical composition of Aspect 60, whereinsaid sodium chloride is at a concentration of about 100 mM to about 200mM.

Aspect 68: The aqueous pharmaceutical composition of Aspect 60, whereinsaid sucrose is at a concentration of about 230 mM to about 270 mM.

Aspect 69: The aqueous pharmaceutical composition of Aspect 60, whereinsaid trehalose is at a concentration of about 230 mM to about 270 mM.

Aspect 70: The aqueous pharmaceutical composition of Aspect 60, whereinsaid mannitol is at a concentration of about 230 mM to about 270 mM.

Aspect 71: The aqueous pharmaceutical composition of Aspect 1, whereinthe osmolality is about 280 mOsm/kg to about 350 mOsm/kg.

Aspect 72: The aqueous pharmaceutical composition of Aspect 1, whereinthe osmolality is less than about 455 mOsm/kg.

Aspect 73: The aqueous pharmaceutical composition of any of Aspects 1 to72, further comprising a surfactant.

Aspect 74: The aqueous pharmaceutical composition of Aspect 1, furthercomprising a buffer and a surfactant.

Aspect 75: The aqueous pharmaceutical composition of Aspect 74, whereinthe surfactant is polysorbate 20 or polysorbate 80.

Aspect 76: The aqueous pharmaceutical composition of Aspect 1, furthercomprising polysorbate 80.

Aspect 77: The aqueous pharmaceutical composition of Aspect 1, furthercomprising polysorbate 20.

Aspect 78: The aqueous pharmaceutical composition of Aspect 74, 75, 76,or 77, wherein the concentration of surfactant is about 0.001% to about0.1%.

Aspect 79: The aqueous pharmaceutical composition of Aspect 74, 75, 76,or 77, wherein the concentration of surfactant is about 0.005% to about0.05%.

Aspect 80: The aqueous pharmaceutical composition of Aspect 74, 75, 76,or 77, wherein the concentration of surfactant is about 0.01%.

Aspect 81: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition has a pH of 5 to 7.

Aspect 82: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition has a pH of 5 to 6.

Aspect 83: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition has a pH of 5.5 to 6.5

Aspect 84: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition has a pH of 5.5.

Aspect 85: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition has a pH of 6.

Aspect 86: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition has a pH of 6.5.

Aspect 87: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition has a pH of 7.0.

Aspect 88: The aqueous pharmaceutical composition of Aspect 1, having aviscosity suitable for subcutaneous delivery with a syringe.

Aspect 89: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition has a viscosity of less than 21 cP.

Aspect 90: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition has a viscosity of less than 18 cP.

Aspect 91: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition has a viscosity of less than 15 cP.

Aspect 92: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition has a viscosity of less than 14 cP.

Aspect 93: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition has a viscosity of 10 cP to 14 cP.

Aspect 94: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition has a viscosity of 10 cP to 13 cP.

Aspect 95: The aqueous pharmaceutical composition of Aspect 1,comprising a buffer, an excipient and a surfactant.

Aspect 96: The aqueous pharmaceutical composition of Aspect 1, furthercomprising a buffer, wherein the buffer is histidine, acetate, succinateor phosphate.

Aspect 97: The aqueous pharmaceutical composition of Aspect 1, furthercomprising an excipient, wherein the excipient is sorbitol, sodiumchloride, sucrose, trehalose or mannitol.

Aspect 98: The aqueous pharmaceutical composition of Aspect 1, furthercomprising a surfactant, wherein the surfactant is polysorbate 20 orpolysorbate 80.

Aspect 99: The aqueous pharmaceutical composition of Aspect 1,comprising acetate, sorbitol, and polysorbate 80.

Aspect 100: The aqueous pharmaceutical composition of Aspect 1, whereinsaid acetate is a concentration of about 20 mM to about 40 mM, saidsorbitol is at a concentration of about 200 mM to about 300 mM, saidpolysorbate 80 is at a concentration of about 0.0055% to about 0.05%,and has pH 4.5 to 5.5.

Aspect 101: The aqueous pharmaceutical composition of Aspect 100,wherein the pH is 4.5.

Aspect 102: The aqueous pharmaceutical composition of Aspect 100,wherein the pH is 5.

Aspect 103: The aqueous pharmaceutical composition of Aspect 100,wherein the pH is 5.5

Aspect 104: The aqueous pharmaceutical composition of Aspect 1, whereinsaid acetate is at a concentration of about 30 mM, said sorbitol is at aconcentration of about 250 mM, and said polysorbate 80 is at aconcentration of about 0.01% and having pH 5.5.

Aspect 105: The aqueous pharmaceutical composition of Aspect 1,comprising histidine, sorbitol, and polysorbate 80 or polysorbate 20.

Aspect 106: The aqueous pharmaceutical composition of Aspect 1,comprising acetate, sodium chloride, and polysorbate 80 or polysorbate20.

Aspect 107: The aqueous pharmaceutical composition of Aspect 1,comprising histidine, sodium chloride, and polysorbate 80 or polysorbate20.

Aspect 108: The aqueous pharmaceutical composition of Aspect 1, whereinsaid histidine is at a concentration of about 20 mM to about 40 mM, saidsorbitol is at a concentration of about 230 mM to about 270 mM, and saidpolysorbate 20 is at a concentration of about 0.005% to about 0.05% andhaving pH 6 to pH 7.

Aspect 109: The aqueous pharmaceutical composition of Aspect 108,wherein the pH is 6.

Aspect 110: The aqueous pharmaceutical composition of Aspect 108,wherein the pH is 6.5.

Aspect 111: The aqueous pharmaceutical composition of Aspect 108,wherein the pH is 7.

Aspect 112: The aqueous pharmaceutical composition of Aspect 1, whereinsaid histidine is at a concentration of about 30 mM, said sorbitol is ata concentration of about 250 mM, said polysorbate 20 is at aconcentration of about 0.01% and having pH 6.0.

Aspect 113: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition is suitable for subcutaneous administration.

Aspect 114: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition is suitable for treatment of arthritis, inflammatorybowel disease, lupus, transplant rejection or psoriasis.

Aspect 115: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition is suitable for treatment of arthritis.

Aspect 116: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition is suitable for treatment of rheumatoid arthritis.

Aspect 117: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition is suitable for an inflammatory bowel disease.

Aspect 118: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition is disposed in a syringe.

Aspect 119: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition is suitable for administration by a healthcareprofessional.

Aspect 120: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition is suitable for self-administered by the patient.

Aspect 121: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition does not comprise arginine, or citrate.

Aspect 122: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition is substantially free of arginine.

Aspect 123: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition does not comprise arginine.

Aspect 124: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition comprises less than 20 mM citrate.

Aspect 125: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition is substantially free of citrate.

Aspect 126: The aqueous pharmaceutical composition of Aspect 1, whereinthe composition does not comprise citrate.

Aspect 127: An aqueous pharmaceutical composition comprising:

an anti-VLA-1 antibody comprising a light chain having the sequence ofSEQ ID NO:1 and a heavy chain having the sequence of SEQ ID NO:2;

acetate at a concentration of 10 mM to 50 mM;

sorbitol at a concentration of 180 mM to 300 mM;

polysorbate 80 at 0.005% to 0.05%; and having a pH of 4.5 to 6.0.

Aspect 128: The aqueous pharmaceutical composition of Aspect 127,wherein, said antibody concentration is at least about 160 mg/mL, atleast about 165 mg/mL, at least about 175 mg/mL, at least about 180mg/mL, at least about 190 mg/mL, or at least about 200 mg/mL.

Aspect 129: The aqueous pharmaceutical composition of Aspect 127,wherein, said antibody at a concentration of about 155 mg/mL to about200 mg/mL, about 160 mg/mL to about 200 mg/mL, or about 170 mg/mL toabout 200 mg/mL.

Aspect 130: The aqueous pharmaceutical composition of Aspect 127,wherein, said antibody concentration is about 180 mg/mL.

Aspect 131: The aqueous pharmaceutical composition of Aspect 127,wherein said acetate is at a concentration of 20 mM to 40 mM.

Aspect 132: The aqueous pharmaceutical composition of Aspect 127,wherein said acetate is at a concentration of about 30 mM.

Aspect 133: The aqueous pharmaceutical composition of Aspect 127,wherein said sorbitol is at a concentration of 200 mM to 300 mM.

Aspect 134: The aqueous pharmaceutical composition of Aspect 127,wherein said sorbitol is at a concentration of 200 mM to 275 mM.

Aspect 135: The aqueous pharmaceutical composition of Aspect 127,wherein said sorbitol is at a concentration of 225 mM to 275 mM.

Aspect 136: The aqueous pharmaceutical composition of Aspect 127,wherein said sorbitol is at a concentration of about 250 mM.

Aspect 137: The aqueous pharmaceutical composition of Aspect 127,wherein said polysorbate 80 is at a concentration of about 0.005% toabout 0.05%.

Aspect 138: The aqueous pharmaceutical composition of Aspect 127,wherein said polysorbate 80 is at a concentration of about 0.001% toabout 0.05%.

Aspect 139: The aqueous pharmaceutical composition of Aspect 127,wherein said polysorbate 80 is at a concentration of about 0.01%.

Aspect 140: The aqueous pharmaceutical composition of Aspect 127, havingpH 5.5.

Aspect 141: The aqueous pharmaceutical composition of Aspect 127,wherein the osmolality is about 280 mOsm/kg to about 350 mOsm/kg.

Aspect 142: The aqueous pharmaceutical composition of Aspect 127,comprising an anti-VLA-1 antibody comprising a light chain having thesequence of SEQ ID NO: 1 and a heavy chain having the sequence of SEQ IDNO:2 at a concentration of about 170 mg/mL to about 210 mg/mL,

acetate at a concentration of about 25 mM to about 35 mM,

sorbitol at a concentration of about 210 mM to 250 mM, and

polysorbate 80 at about 0.005% to about 0.02%, at pH 5.5.

Aspect 143: The aqueous pharmaceutical composition of Aspect 127,comprising:

an anti-VLA-1 antibody comprising a light chain having the sequence ofSEQ ID NO:1 and a heavy chain having the sequence of SEQ ID NO:2 at 185to 195 mg/mL;

acetate at a concentration of about 30 mM;

sorbitol at a concentration of about 250 mM;

polysorbate 80 at about 0.01%; and having a pH of about 5.5.

Aspect 144: The aqueous pharmaceutical composition of Aspect 127,wherein said antibody is at about 190 mg/mL.

Aspect 145: An aqueous pharmaceutical composition comprising:

an anti-VLA-1 antibody comprising a light chain having the sequence ofSEQ ID NO:1 and a heavy chain having the sequence of SEQ ID NO:2;

histidine at a concentration of 10 mM to 50 mM;

sorbitol at a concentration of 180 mM to 300 mM;

polysorbate 20 or polysorbate 80 at from about 0.005% to 0.05%; andhaving a pH from 5.5 to 7.0.

Aspect 146: The aqueous pharmaceutical composition of Aspect 145,comprising:

an anti-VLA-1 antibody comprising a light chain having the sequence ofSEQ ID NO:1 and a heavy chain having the sequence of SEQ ID NO:2 at 185to 195 mg/mL;

histidine at a concentration of about 30 mM;

sorbitol at a concentration of about 250 mM;

polysorbate 80 or polysorbate 20 at about 0.01%; and having a pH ofabout 5.5.

Aspect 147: The aqueous pharmaceutical composition of Aspect 145,comprising polysorbate 20 from about 0.005% to about 0.05%.

Aspect 148: The aqueous pharmaceutical composition of Aspect 145,comprising polysorbate 80 from about 0.005% to about 0.05%.

Aspect 149: The aqueous pharmaceutical composition of Aspect 145,wherein, said antibody concentration is at least about 160 mg/mL, atleast about 165 mg/mL, at least about 175 mg/mL, at least about 180mg/mL, at least about 190 mg/mL or at least about 200 mg/mL.

Aspect 150: The aqueous pharmaceutical composition of Aspect 145,wherein, said antibody at a concentration of about 155 mg/mL to about200 mg/mL, about 160 mg/mL to about 200 mg/mL, or about 170 mg/mL toabout 200 mg/mL.

Aspect 151: The aqueous pharmaceutical composition of Aspect 145,wherein, said antibody concentration is about 180 mg/mL.

Aspect 152: The aqueous pharmaceutical composition of Aspect 127,comprising:

an anti-VLA-1 antibody comprising a light chain having the sequence ofSEQ ID NO:1 and a heavy chain having the sequence of SEQ ID NO:2 at 185to 195 mg/mL;

acetate at a concentration of about 30 mM;

sodium chloride at a concentration of about 150 mM;

polysorbate 80 or polysorbate 20 at about 0.01%; and having a pH ofabout 5 to 7.

Aspect 153: The aqueous pharmaceutical composition of Aspect 127,wherein, said antibody concentration is at least about 160 mg/mL, atleast about 165 mg/mL, at least about 175 mg/mL, at least about 180mg/mL, at least about 190 mg/mL or at least about 200 mg/mL.

Aspect 154: An aqueous pharmaceutical composition comprising:

an anti-VLA-1 antibody comprising a light chain having the sequence ofSEQ ID NO:1 and a heavy chain having the sequence of SEQ ID NO:2;

histidine at a concentration of about 30 mM;

sodium chloride at a concentration of about 150 mM;

polysorbate 20 or polysorbate 80 at from about 0.01%; and having a pHabout 5 to 7.

Aspect 155: The aqueous pharmaceutical composition of Aspect 154,wherein, said antibody concentration is at least about 160 mg/mL, atleast about 165 mg/mL, at least about 175 mg/mL, at least about 180mg/mL, at least about 190 mg/mL or at least about 200 mg/mL.

Aspect 156: The aqueous pharmaceutical composition of Aspect 145,wherein said histidine is at a concentration of about 20 mM to about 40mM.

Aspect 157: The aqueous pharmaceutical composition of Aspect 145,wherein said histidine is at a concentration of about 30 mM.

Aspect 158: The aqueous pharmaceutical composition of Aspect 145,wherein said sorbitol is at a concentration of about 220 mM to about 280mM.

Aspect 159: The aqueous pharmaceutical composition of Aspect 145,wherein said sorbitol is at a concentration of about 240 mM to about 260mM.

Aspect 160: The aqueous pharmaceutical composition of Aspect 145,wherein said sorbitol is at a concentration of about 250 mM.

Aspect 161: The aqueous pharmaceutical composition of Aspect 145,wherein said polysorbate 20 is at a concentration of about 0.005% toabout 0.05%.

Aspect 162: The aqueous pharmaceutical composition of Aspect 145,wherein said polysorbate 20 is at a concentration of about 0.01%.

Aspect 163: The aqueous pharmaceutical composition of Aspect 145, havingpH 6.0.

Aspect 164: The aqueous pharmaceutical composition of Aspect 145,wherein the osmolality is about 280 mOsm/kg to about 350 mOsm/kg.

Aspect 165: The aqueous pharmaceutical composition of Aspect 145,comprising anti-VLA-1 antibody comprising a light chain having thesequence of SEQ ID NO:1 and a heavy chain having the sequence of SEQ IDNO:2 at a concentration of about 160 mg/mL to about 200 mg/mL,

histidine at a concentration of about 25 mM to about 35 mM,

sorbitol at a concentration of about 240 mM to about 260 mM, and

polysorbate 20 at a concentration of about 0.005% to about 0.02%, at pH6.

Aspect 166: The aqueous pharmaceutical composition of Aspect 145,comprising:

an anti-VLA-1 antibody comprising a light chain having the sequence ofSEQ ID NO:1 and a heavy chain having the sequence of SEQ ID NO:2 at 170to 180 mg/mL;

histidine at a concentration of about 30 mM;

sorbitol at a concentration of about 250 mM;

polysorbate 20 at a concentration of about 0.01%; and having a pH ofabout 6.

Aspect 167: The aqueous pharmaceutical composition of Aspect 145,wherein said antibody is at a concentration of about 180 mg/mL.

Aspect 168: A unit dosage form of an aqueous pharmaceutical compositionof any of Aspects 1, 127, 142, 143, 145, 166 or 167.

Aspect 169: The unit dosage form of Aspect 168, comprising at leastabout 160 mg of said antibody, at least about 170 mg of said antibody,at least about 180 mg of said antibody, at least about 190 mg of saidantibody, or at least about 200 mg of said antibody.

Aspect 170: The unit dosage form of Aspect 168, comprising said antibodyat about 155 mg to about 165 mg, about 165 mg to about 175 mg, about 175mg to about 185 mg, about 185 mg to about 195 mg, about 195 mg to about205 mg, about 205 mg to about 215 mg, about 215 mg to about 225 mg.

Aspect 171: The unit dosage form of Aspect 168, comprising said antibodyat about 160 mg to about 210 mg.

Aspect 172: The unit dosage form of Aspect 168, comprising about 180 mgof said antibody.

Aspect 173: The unit dosage form of Aspect 168, comprising about 190 mgof said antibody.

Aspect 174: The unit dosage form of Aspect 168, which, when administeredto a human will deliver antibody at about 2.0 mg per kg of body weightto about 4.0 mg per kg of body weight to the human.

Aspect 175: The unit dosage form of Aspect 168, having a volume of about0.25 mL to about 1.5 mL.

Aspect 176: The unit dosage form of Aspect 168, having a volume of about1 mL.

Aspect 177: A kit comprising the unit dosage form of Aspect 168.

Aspect 178: A plurality of unit dosage forms of an aqueouspharmaceutical composition of any of Aspects 1, 127, 142, 143, 145, 166or 167.

Aspect 179: The plurality of unit dosage forms of Aspect 178, whereinsaid plurality is two.

Aspect 180: The plurality of unit dosage forms of Aspect 179, whereinsaid dosage forms, taken together, comprise at least about 160 mg ofsaid antibody, at least about 170 mg of said antibody, at least about180 mg of said antibody, at least about 190 mg of said antibody, or atleast about 200 mg of said antibody.

Aspect 181: The plurality of unit dosage forms of Aspect 178, whereineach dosage form contains an equal amount of antibody.

Aspect 182: The plurality of unit dosage forms of Aspect 179, whereinsaid dosage forms, taken together, comprise said antibody at about 155mg to about 165 mg, about 165 mg to about 175 mg, about 175 mg to about185 mg, about 185 mg to about 195 mg, about 195 mg to about 205 mg,about 205 mg to about 215 mg, or about 215 mg to about 225 mg.

Aspect 183: The plurality of unit dosage forms of Aspect 182, whereineach dosage form contains an equal amount of antibody.

Aspect 184: The plurality of unit dosage forms of Aspect 179, whereinsaid dosage forms, taken together, comprise said antibody at about 160mg to about 210 mg.

Aspect 185: The plurality of unit dosage forms of Aspect 184, whereineach dosage form contains an equal amount of antibody.

Aspect 186: The plurality of unit dosage forms of Aspect 179, whereinsaid dosage forms, taken together, comprise about 180 mg of saidantibody.

Aspect 187: The plurality of unit dosage forms of Aspect 186, whereineach dosage form contains an equal amount of antibody.

Aspect 188: The plurality of unit dosage forms of Aspect 179, whereinsaid dosage forms, taken together, comprise about 190 mg of saidantibody.

Aspect 189: The plurality of unit dosage forms of Aspect 188, whereineach dosage form contains an equal amount of antibody.

Aspect 190: The plurality of unit dosage forms of Aspect 179, whereinsaid dosage forms, taken together, when administered to a human willdeliver about 2 mg and about 4 mg antibody per kg of body weight to thehuman.

Aspect 191: The plurality of unit dosage forms of Aspect 190, whereineach dosage form contains an equal amount of antibody.

Aspect 192: The plurality of unit dosage forms of Aspect 179, whereinsaid dosage forms each have a volume of about 0.25 mL to about 1.5 mL.

Aspect 193: The plurality of unit dosage forms of Aspect 178, whereinsaid dosage forms each have a volume of about 1 mL.

Aspect 194: A kit comprising the plurality of unit dosage forms ofAspect 178.

Aspect 195: A container, having disposed therein, an aqueouspharmaceutical composition of any of Aspects 1, 127, 142, 143, 145, 166or 167.

Aspect 196: The container of Aspect 195, having disposed therein, a unitdosage formulation of any of Aspects 127 or 145.

Aspect 197: The container of Aspect 195, wherein said container is adelivery device.

Aspect 198: The container of Aspect 195, wherein said container issuitable for subcutaneous administration.

Aspect 199: The container of Aspect 195, wherein said container is asyringe.

Aspect 200: A method of administering an aqueous pharmaceuticalcomposition of Aspects 1, 127, or 145 to a patient, comprising one orboth of:

i) activating a delivery device; and

ii) administering said antibody disposed in said delivery device to saidpatient, to thereby administer said composition.

Aspect 201: The method of Aspect 200, wherein activating comprises oneof more of removing said device from packaging, removing a cover fromthe needle or orifice of said device, or shaking said device.

Aspect 202: The method of Aspect 200, further comprising inspecting saiddevice for the presence of precipitate, colored material, or turbidity,or opalescence.

Aspect 203: The method of Aspect 200, wherein said patient performs oneor both of steps i and ii.

Aspect 204: The method of Aspects 200, wherein the patient has aninflammatory disorder.

Aspect 205: The method of Aspect 200, wherein the patient has a disorderselected from the group consisting of arthritis, inflammatory boweldisease, lupus, transplant rejection, and psoriasis.

Aspect 206: A method of treating a patient in need of anti-VLA-1therapy, comprising administering to said patient an effective amount ofthe composition of Aspect 1.

Aspect 207: The method of Aspect 206, wherein the patient has aninflammatory disorder.

Aspect 208: The method of Aspect 206, wherein the patient has a disorderselected from the group consisting of arthritis, inflammatory boweldisease, lupus, transplant rejection, and psoriasis.

Aspect 209: The method of Aspect 206, wherein the composition isadministered as a regimen.

Aspect 210: The method of Aspect 206, further comprising selecting saidpatient for said treatment.

Aspect 211: The method of Aspect 210, wherein the patient has rheumatoidarthritis, and has demonstrated an inadequate response to a prioralternate treatment for rheumatoid arthritis.

Aspect 212: The method of Aspect 210, wherein the patient has rheumatoidarthritis, and is selected on the basis of having demonstrated aninadequate response to a prior alternate treatment for rheumatoidarthritis.

Aspect 213: The method of Aspect 211, wherein the prior alternatetreatment for rheumatoid arthritis is a DMARD (Disease ModifyingAntirheumatic Drug) or a TNF-α (Tumor Necrosis Factor-α) inhibitor.

Aspect 214: The method of Aspect 213, wherein the DMARD is methotrexate,leflunomide, sulfasalazine, or hydroxychloroquine.

Aspect 215: The method of Aspect 213, wherein the TNF-α inhibitor isinfliximab, adalimumab, certolizumab pegol, golimumab or etanercept.

Aspect 216: The method of Aspect 206, further comprising administeringto the patient a second therapeutic agent, wherein the secondtherapeutic agent is a corticosteroid or an anti-inflammatory.

Aspect 217: A method of treating a patient in need of anti-VLA-1therapy, comprising administering to said patient an effective amount ofa composition comprising

180 mg/mL anti-VLA-1 antibody,

30 mM histidine,

250 mM sorbitol,

0.1% polysorbate 20, and

having pH 6.

Aspect 218: A method of treating a patient in need of anti-VLA-1therapy, comprising administering to said patient an effective amount ofa composition comprising

180 mg/mL anti-VLA-1 antibody,

30 mM histidine,

150 mM sodium chloride,

0.1% polysorbate 20, and

having pH 6.

Aspect 219: A method of treating a patient in need of anti-VLA-1therapy, comprising administering to said patient an effective amount ofa composition comprising

190 mg/mL anti-VLA-1 antibody,

30 mM acetate,

250 mM sorbitol,

0.1% polysorbate 80, and

having pH 5.5.

Aspect 220: A method of treating a patient in need of anti-VLA-1therapy, comprising administering to said patient an effective amount ofa composition comprising

190 mg/mL anti-VLA-1 antibody,

30 mM acetate,

250 mM sodium chloride,

0.1% polysorbate 80, and

having pH 5.5.

Aspect 221: A method of evaluating a patient comprising (i) determiningif the patient meets a preselected criterion, and (ii) if the patientmeets said preselected criterion approving, providing, prescribing, oradministering a composition of Aspect 1.

Aspect 222: The method of Aspect 221, wherein the patient has rheumatoidarthritis, and the patient has had an inadequate response to a prioralternate treatment for rheumatoid arthritis.

Aspect 223: A method of evaluating a patient comprising (i) determiningif the patient meets a preselected criterion, and (ii) if the patientmeets said preselected criterion approving, providing, prescribing, oradministering a composition comprising

180 mg/mL anti-VLA-1 antibody,

30 mM histidine,

250 mM sorbitol,

0.1% polysorbate 20, and

having pH 6.

Aspect 224: A method of evaluating a patient comprising (i) determiningif the patient meets a preselected criterion, and (ii) if the patientmeets said preselected criterion approving, providing, prescribing, oradministering a composition comprising

180 mg/mL anti-VLA-1 antibody,

30 mM histidine,

150 mM sodium chloride,

0.1% polysorbate 20, and

having pH 6.

Aspect 225: A method of evaluating a patient comprising (i) determiningif the patient meets a preselected criterion, and (ii) if the patientmeets said preselected criterion approving, providing, prescribing, oradministering a composition comprising

190 mg/mL anti-VLA-1 antibody,

30 mM acetate,

250 mM sorbitol,

0.1% polysorbate 80, and

having pH 5.5.

Aspect 226: A method of evaluating a patient comprising (i) determiningif the patient meets a preselected criterion, and (ii) if the patientmeets said preselected criterion approving, providing, prescribing, oradministering a composition comprising

190 mg/mL anti-VLA-1 antibody,

30 mM acetate,

250 mM sodium chloride,

0.1% polysorbate 80, and

having pH 5.5.

Aspect 227: A method of making an aqueous composition comprising 160mg/mL to 210 mg/mL of an anti-VLA-1 antibody comprising, combining saidantibody, a buffer, an excipient, and a surfactant in proportion toobtain a stable aqueous composition comprising 160 mg/mL to 210 mg/mL ofsaid anti-VLA-1 antibody.

Aspect 228: The method of Aspect 227, wherein said buffer is histidine.

Aspect 229: The method of Aspect 227, wherein said buffer is acetate.

Aspect 230: The method of Aspect 227, wherein said surfactant ispolysorbate 80.

Aspect 231: The method of Aspect 227, wherein said surfactant ispolysorbate 20.

Aspect 232: The method of Aspect 227, wherein said anti-VLA-1 antibodycomprises a light chain having the sequence of SEQ ID NO:1 and a heavychain having the sequence of SEQ ID NO:2.

Aspect 233: The method of Aspect 227, wherein the composition comprisesa viscosity of about 10 cP to about 20 cP.

Aspect 234: The method of Aspect 227, wherein the composition comprisesa viscosity of about 10 cP to about 15 cP.

Aspect 235: The method of Aspect 227, wherein the composition comprisesa viscosity of about 10 cP to about 14 cP.

Aspect 236: The method of Aspect 227, wherein said composition is thecomposition of Aspect 1.

Aspect 237: The method of Aspect 227, wherein said composition comprises

180 mg/mL anti-VLA-1 antibody,

30 mM histidine,

250 mM sorbitol,

0.1% polysorbate 20, and

having pH 6.

Aspect 238: The method of Aspect 227, wherein said composition comprises

180 mg/mL anti-VLA-1 antibody,

30 mM histidine,

150 mM sodium chloride,

0.1% polysorbate 20, and

having pH 6.

Aspect 239: The method of Aspect 227, wherein said composition comprises

190 mg/mL anti-VLA-1 antibody,

30 mM acetate,

250 mM sorbitol,

0.1% polysorbate 80, and

having pH 5.5.

Aspect 240: The method of Aspect 227, wherein said composition comprises

190 mg/mL anti-VLA-1 antibody,

30 mM acetate,

250 mM sodium chloride,

0.1% polysorbate 80, and

having pH 5.5.

Aspect 241: A method of evaluating the quality of a composition ofAspect 1, comprising:

evaluating the composition for a preselected parameter, and

determining whether said value meets a preselected criteria, therebyevaluating the quality of a composition.

Aspect 242: The method of Aspect 241, further comprising, responsive tosaid evaluation, said composition is: is classified, selected, acceptedor discarded, released or withheld, processed into a drug product,shipped, moved to a different location, formulated, labeled, packaged,released into commerce, or sold or offered for sale,

Aspect 243: The method of Aspect 241, wherein said preselected parameteris selected from aggregation, stability, color, clarity, viscosity, orplunger force.

Aspect 244: The method of Aspect 241, wherein the composition evaluatedis provided as a unit dosage form.

Aspect 245: An aqueous pharmaceutical composition comprising:

-   -   (i) an anti-VLA-1 antibody in an amount effective for treatment        of inflammatory disease; and    -   (ii) means for delivering said effective amount of said        anti-VLA-1 antibody in a subcutaneous formulation.

The details of one or more embodiments of the invention are set forth inthe accompanying drawings and the description below. Other features,objects, and advantages of the invention will be apparent from thedescription and drawings, and from the claims.

DESCRIPTION OF DRAWINGS

FIGS. 1A to 1D is the cDNA (SEQ ID NO: 6) and amino acid sequence ofhuman VLA-1 (Ref Seq No. NP_852478; SEQ ID NO:3). The I domain isunderlined (see FIGS. 1A and 1B).

FIGS. 2A and 2B are sequence fragments of a light chain polypeptide (SEQID NO:4) and a heavy chain polypeptide (SEQ ID NO:5), respectively, foran anti-VLA-1 antibody. These sequence fragments include the light chainand heavy chain CDRs, respectively.

FIG. 3 is the sequence of the light chain polypeptide (SEQ ID NO:1) ofSAN-300.

FIG. 4 is the sequence of the heavy chain polypeptide (SEQ ID NO:2) ofSAN-300.

FIG. 5 shows representative chromatogram overlays for high-concentrationSAN-300 formulations. The top panel shows NB1206p86A (solid line) andNB1206p86B (dashed line) at the initial time point. The bottom panelshows NB1206p86A (solid line) and NB1206p86B (dashed line) after 12months at 2-8° C.

FIG. 6 shows representative SEC chromatogram overlays for highconcentration NB1206p86B samples. The top panel shows NB1206p86B samplesat the 6 month time point. Samples were held at −75° C., 2-8° C.,inverted at 2-8° C., 30° C., and 40° C. The bottom panel showsNB1206p86B samples at the 12 month time point. Samples were held at −75°C., 2-8° C., inverted at 2-8° C., and 30° C.

DETAILED DESCRIPTION

Provided herein are stable formulations of an anti-VLA-1 antibodyparticularly well suited for subcutaneous (SC) administration. Theformulations featured in the invention contain from about ≥100 to about225 mg/mL humanized anti-VLA-1 antibody, such as SAN-300.

Pharmaceutical Compositions

The compositions described herein are formulated as pharmaceuticalcompositions. An anti-VLA-1 antibody, such as SAN-300, can be provided,for example, in a buffered solution at a concentration of about 160mg/mL to about 210 mg/mL, for example, about 160 mg/mL to about 200mg/mL, about 170 mg/mL to about 190 mg/mL; for example, about 165 mg/mL,about 170 mg/mL, about 175 mg/mL, about 180 mg/mL, about 185 mg/mL,about 190 mg/mL, about 195 mg/mL, about 200 mg/mL, about 205 mg/mL. Inone embodiment, the anti-VLA-1 antibody, such as SAN-300, is provided ina buffered solution at a concentration greater than about 100 mg/mL andless than about 225 mg/mL. In another embodiment, the formulation isprepared at a higher concentration, for example, about 200 mg/mL toabout 210 mg/mL, and then diluted back to the desired concentration,such as to about 180 mg/mL to about 190 mg/mL. In one embodiment, theformulation is administered at the stock concentration (for example, atabout 110 mg/mL, about 120 mg/mL, about 130 mg/mL, about 140 mg/mL,about 150 mg/mL, about 160 mg/mL, about 165 mg/mL, about 170 mg/mL,about 175 mg/mL, about 180 mg/mL, about 185 mg/mL, about 190 mg/mL,about 195 mg/mL, about 200 mg/mL, about 205 mg/mL, about 210 mg/mL).

The composition can be stored at a suitable temperature, such as atabout 2° C. to about 8° C., for example, at about 4° C., about 5° C.,about 6° C., or about 7° C.

In one embodiment, the anti-VLA-1 antibody can be formulated with anexcipient, such as sorbitol or NaCl, a histidine buffer, and asurfactant, such as polysorbate 20 or polysorbate 80.

Acetate buffers are known in the art and include, for example, aqueoussolutions of sodium acetate, triethylammonium acetate buffer, andTris-acetate-EDTA buffer, brought to the proper pH.

Histidine buffers are also known in the art and include, for example,aqueous solutions of D-histidine, D-histidine monochloride monohydrate,DL-histidine, DL-histidine monochloride monohydrate, L-histidine, orL-histidine monochloride monohydrate, brought to the proper pH witheither hydrochloric acid or sodium hydroxide, or other acid or baseknown in the art.

In one embodiment, the anti-VLA-1 antibody formulation can besubstantially free of citrate. In another embodiment, the anti-VLAantibody formulation is substantially free of arginine.

A pharmaceutical composition may also include solvents, dispersionmedia, coatings, antibacterial and antifungal agents, isotonic andabsorption delaying agents, and the like that are physiologicallycompatible. An “isotonic” formulation has equal osmotic pressure, suchas caused by equal solute concentration inside and outside a cell.

A “pharmaceutically acceptable salt” refers to a salt that retains thedesired biological activity of the antibody and does not impart anyundesired toxicological effects (see, for example, Berge, S. M., et al.(1977) J. Pharm. Sci. 66:1-19). Examples of such salts include acidaddition salts and base addition salts. Acid addition salts includethose derived from nontoxic inorganic acids, such as hydrochloric,nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, and the like, aswell as from nontoxic organic acids such as aliphatic mono- anddicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoicacids, aromatic acids, aliphatic and aromatic sulfonic acids, free aminoacids, and the like. Base addition salts include those derived fromalkaline earth metals, such as sodium, potassium, magnesium, calcium andthe like, as well as from nontoxic organic amines, such asN,N′-dibenzylethylenediamine, N-methylglucamine, chloroprocaine,choline, diethanolamine, ethylenediamine, procaine and the like.

The formulations featured herein can include a pharmaceuticallyacceptable excipient, such as a surfactant, such as polysorbate 80, orpolysorbate 20. In one embodiment, the formulations featured hereininclude a surfactant at a concentration of about 0.001% to about 0.8%,for example, about 0.005% to about 0.05%; for example, about 0.01% toabout 0.01%. As used herein, the concentration of surfactant is providedas a percentage of weight to volume (w/v)

The pharmaceutical compositions containing anti-VLA-1 antibodies are inthe form of a liquid solution, such as an injectable and infusiblesolution. Such compositions can be administered by a parenteral mode,such as by subcutaneous administration. The formulations are alsosuitable for intravenous (IV) administration, for example, when dilutedinto an acceptable infusion matrix, such as normal saline. The phrases“parenteral administration” and “administered parenterally” as usedherein mean modes of administration other than enteral and topicaladministration, usually by injection, and include subcutaneousadministration, as well as intramuscular, intravenous, intracapsular,intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal,subcuticular, subcapsular, subarachnoid, intraspinal, epidural andintrasternal injection and infusion. In one embodiment, the formulationsdescribed herein are administered subcutaneously.

Pharmaceutical compositions are sterile and stable under the conditionsof manufacture and storage. A pharmaceutical composition can also betested to insure it meets regulatory and industry standards foradministration.

Sterile injectable solutions can be prepared by incorporating ananti-VLA-1 antibody described herein in the required amount in anappropriate formulation as described above, followed by filteredsterilization.

In one embodiment, the final anti-VLA-1 antibody formulation is packagedas a liquid in a 3.0 mL fill vial with an extractable minimum volume of1 mL. For example, the fill vial can include about 1.1 mL to about 1.5mL (for example, about 1.1 mL, about 1.2 mL, about 1.3 mL, about 1.4 mL)of antibody formulation. In another embodiment, that antibodyformulation is packaged in a pre-filled syringe, in an amount such that1 mL of solution is injected into a patient upon use, and the 1 mLsolution delivers the desired amount of antibody, for example, ≥100 mgSAN-300 to 225 mg SAN-300, for example, 180 mg SAN-300 or 190 mgSAN-300.

In some embodiments, parameters that describe the formulations, forexample, parameters that may appear on the product label, arecharacterized. Such parameters include, for example, color (typicallycolorless to slightly yellow, or colorless to yellow), clarity(typically clear to slightly opalescent, or clear to opalescent), andviscosity (typically about 5 cP to about 30 cP when measured at ambienttemperature, such as at about 20° C. to about 30° C.). Such parameterscan be measured by methods known in the art. For example, clarity can bemeasured using commercially available opalescence standards (availablefrom, for example, HunterLab Associates, Inc., Reston, Va.).

In some embodiments, the stability of the antibody formulations isassayed. Exemplary methods include, for example, aggregation studies,oxidation studies, fragmentation studies, sialylation studies,isoelectric point studies, half-antibody studies, heavy and light chainparity studies, and analysis of secondary structure, such as by circulardichroism; thermal denaturation, such as by circular dichroism ofdifferential scanning calorimetry; tryptophan environment, such as byfluorescence; IgG fold, such as by far UV circular dichroism; andaromatic residue environment, such as by UV-Visible (“UV-Vis”)spectroscopy.

SAN-300 and Other Anti-VLA-1 Antibodies

Antibodies suitable for an anti-VLA-1 antibody formulation describedherein include SAN-300, a humanized al integrin binding antibody. Theamino acid sequence of the light chain and heavy chain of SAN-300 priorto any in vivo modifications (such as clipping of amino acids) is shownin FIG. 3 and FIG. 4, respectively. The amino acid sequence of the lightchain and heavy chain variable domains is shown in FIGS. 2A and 2B,respectively.

VLA-1 is a major collagen L collagen IV and laminin receptor. It isexpressed in many different cell types including those of hematopoietic,neuronal and mesenchymal origin. The VLA-1 integrin plays an importantrole in chronic inflammation and fibrosis processes. The a chain ofVLA-1 contains an inserted I domain (also known as an A domain) thatplays a central role in ligand binding. The I-domain of human VLA-1 islocated at about from amino acids Thr145-Glu336 of VLA-1 (Ref Seq No.NP_852478; FIGS. 1A-1D). The I-domain has a dinucleotide-binding foldcharacterized by a β-sheet surrounded by α-helices. The I domaincontains a conserved metal ion-dependent-adhesion site (MIDAS) that hasbeen identified to constitute part of the ligand binding site. Theacidic residue side-chains of a bound integrin ligand, such as acollagen, coordinates the metal ion of the I domain MIDAS site. Crystalstructure studies have indicated that SAN-300 uses an aspartic acid tocoordinate the VLA-1 I domain metal ion. SAN-300 inhibits VLA-1 at leastby sterically preventing binding of the I-domain to collagen (Karpuseset al., J. Mol. Biol. 322:1031-1041, 2003).

Anti-VLA-1 antibodies can block the interaction of pro-inflammatoryleukocytes with components of the extracellular matrix including, butnot limited to collagens, e.g., collagen I and IV, laminin andfibronectin. The VLA-1 is expressed, for example, on lymphocytes, andthe 1-domain of VLA-1 is important for binding of lymphocytes toextracellular matrix proteins, such as fibronectin (Fabbri et al.,Tissue Antigens 48:47-51, 1996).

SAN-300 binds the α1 I domain of VLA-1 (see, e.g., U.S. Pat. No.7,358,054). Further SAN-300 binds human but not rat α1-I domain (Id.).

SAN-300 and related anti-VLA-1 antibodies are described, for example, inU.S. Pat. Nos. 6,955,810, 7,462,353, 7,358,054, 7,723,073, and7,910,099. The contents of these patents are incorporated herein byreference in their entirety. SAN-300 is a humanized version of murinemonoclonal AQC2 antibody (see, for example, U.S. Pat. Nos. 6,955,810,and 7,358,054). Several additional anti-VLA-1 monoclonal antibodiesinclude 1B3.1 (Chess et al. U.S. Pat. No. 5,788,966), TS2/7 and FBl2(Fabbri et al., Tissue Antigens 48:47-51, 1996), 5E8D9 (Luque et al.,FEBS Letters 346:278-284, 1994), and SR-84 (Rikkonen et al., Biochem.Biophys. Res. Commun. 209:205-212, 1995).

Some anti-VLA-1 antibodies recognize epitopes of the al subunit that areinvolved in binding to a cognate ligand, such as collagen and laminin.Many such antibodies inhibit binding of VLA-1 to the cognate ligands.

An exemplary anti-VLA-1 antibody has one or more CDRs, for example, allthree HC CDRs and/or all three LC CDRs of a particular antibodydisclosed herein, or CDRs that are, in sum, at least 80%, at least 85%,at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, or at least 99% identical to such an antibody,for example a SAN-300 antibody. In one embodiment, the H1 and H2hypervariable loops have the same canonical structure as those of anantibody described herein. In one embodiment, the L1 and L2hypervariable loops have the same canonical structure as those of anantibody described herein.

In one embodiment, the amino acid sequence of the HC and/or LC variabledomain sequence is at least 70%, at least 80%, at least 85%, at least90%, at least 92%, at least 95%, at least 97%, at least 98%, at least99%, or at least 100% identical to the amino acid sequence of the HCand/or LC variable domain of an antibody described herein, such as aSAN-300 antibody. The amino acid sequence of the HC and/or LC variabledomain sequence can differ by at least one amino acid, but no more thanten, eight, six, five, four, three, or two amino acids from thecorresponding sequence of an antibody described herein, such as aSAN-300 antibody. For example, the differences may be primarily orentirely in the framework regions.

The amino acid sequences of the HC and LC variable domain sequences canbe encoded by a nucleic acid sequence that hybridizes under highstringency conditions to a nucleic acid sequence described herein or onethat encodes a variable domain or an amino acid sequence describedherein. In one embodiment, the amino acid sequences of one or moreframework regions (for example, FR1, FR2, FR3, and/or FR4) of the HCand/or LC variable domain are at least 70%, at least 80%, at least 85%,at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, atleast 99%, or at least 100% identical to corresponding framework regionsof the HC and LC variable domains of an antibody described herein. Inone embodiment, one or more heavy or light chain framework regions (forexample, HC FR1, FR2, and FR3) are at least 70%, at least 80%, at least85%, at least 90%, at least 95%, at least 96%, at least 97%, at least98%, or at least 100% identical to the sequence of correspondingframework regions from a human germline antibody.

Suitable antibodies for use in the methods described herein include:antibodies having one, two, or three light chain (LC) CDRs and one, twoor three heavy chain (HC) CDRs, and in an embodiment all six CDRs,having the sequence of an antibody disclosed in U.S. Pat. No. 7,358,054;antibodies wherein each of the CDRs differs by no more than 1 or 2 aminoacids from the CDRs of an antibody disclosed in U.S. Pat. No. 7,358,054(variant amino acids, when used in this context, can be independently,or as a group, conservative on non-conservative changes).

In one embodiment, an anti-VLA-1 antibody useful for the methodsdescribed herein includes a LC variable region, a HC variable region, orboth, from an antibody disclosed in U.S. Pat. No. 7,358,054; an antibodythat binds an overlapping epitope with, or competes for binding with anantibody disclosed in U.S. Pat. No. 7,358,054; an antibody having a LCvariable region, a HC variable region, or both, having at least 90%, atleast 95%, or at least 99% amino acid homology with the correspondingportions of an antibody disclosed in U.S. Pat. No. 7,358,054; anantibody having a LC variable region which differs by no more than 10amino acid residues, 5 amino acid residues, or 1 amino acid residue, aHC variable region which differs by no more than 10 amino acid residues,5 amino acid residues, or 1 amino acid residue, or both, from thecorresponding portions of an antibody disclosed in U.S. Pat. No.7,358,054.

In one embodiment, an anti-VLA-1 antibody useful for the methodsdescribed herein includes a light chain variable region that is the sameas or differs by no more than 10 amino acids, 5 amino acids, 3 aminoacids, or 1 amino acid from the sequence of SEQ ID NO:4 (FIG. 2A), and aheavy chain variable region that is the same as or differs by no morethan 10 amino acids, 5 amino acids, 3 amino acids, or 1 amino acid fromthe sequence of SEQ ID NO:5 (FIG. 2B).

In one embodiment, an anti-VLA-1 antibody has a light chain sequencethat is the same as or differs by no more than 10 amino acids, 5 aminoacids, 3 amino acids, or 1 amino acid from the sequence of SEQ ID NO: 1(FIG. 3) and a heavy chain sequence that is the same as or differs by nomore than 10 amino acids, 5 amino acids, 3 amino acids, or 1 amino acidfrom the sequence of SEQ ID NO:2 (FIG. 4).

As discussed herein, exemplary anti-VLA-1 antibodies useful in themethods described herein include the antibodies described in U.S. Pat.No. 7,358,054, which is incorporated herein by reference in itsentirety. Antibodies described in U.S. Pat. No. 7,358,054, include, forexample, monoclonal antibody AJH10 (ATCC PTA-3580; deposited on Aug. 2,2001, with the American Type Culture Collection, 10801 UniversityBoulevard, Manassas, Va. 20110-2209), hAQC2 (ATCC PTA-3275; deposited onApr. 18, 2001), haAQC2 (ATCC PTA-3274; deposited on Apr. 18, 2001),hsAQC2 (ATCC PTA-3356; deposited on May 4, 2001) and mAQC2 (ATCCPTA-3273). All of these antibodies were deposited under the BudapestTreaty.

In one embodiment, an anti-VLA-1 antibody useful for the methodsdescribed herein includes a light chain polypeptide comprising thesequence of SEQ ID NO:4 (FIG. 2A), and a heavy chain polypeptidecomprising the sequence of SEQ ID NO:5 (FIG. 2B).

In one embodiment, an anti-VLA-1 antibody has a light chain sequencecomprising the sequence of SEQ ID NO:1 (FIG. 3) and a heavy chainsequence comprising the sequence of SEQ ID NO:2 (FIG. 4). Otheranti-VLA-1 antibodies include, e.g., monoclonal antibody 1B3 (ATCCHB-10536) described in U.S. Pat. Nos. 5,391,481 and 5,788,966, andHa31/8.

In one embodiment, an anti-VLA-1 antibody inhibits the interactionbetween VLA-1 and a VLA-1 ligand (e.g., collagen), such as by physicallyblocking the interaction, decreasing the affinity of VLA-1 for itscounterpart, disrupting or destabilizing VLA-1 complexes, sequesteringVLA-1, or targeting VLA-1 for degradation. In one embodiment, theantibody can bind to VLA-1 at one or more amino acid residues thatparticipate in the VLA-1/ligand binding interface. Such amino acidresidues can be identified, e.g., by alanine scanning. In anotherembodiment, the antibody can bind to residues that do not participate inthe VLA-1/ligand binding. For example, the antibody can alter aconformation of VLA-1 and thereby reduce binding affinity, or theantibody may sterically hinder VLA-1/ligand binding. In one embodiment,the antibody can reduce activation of a VLA-1-mediated event oractivity.

Administration

The anti-VLA-1 antibody formulations described herein can beadministered to a subject, such as a human subject, by a variety ofmethods. Typically, administration is by subcutaneous injection.

The formulation can be administered as a fixed dose, or in a mg/kg dose.Typically the administration is in a fixed dose. For example, theformulation is administered at a fixed unit dose of anti-VLA-1 antibodyof about 80 mg to about 315 mg (for example, about 100 mg, about 110 mg,about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg,about 180 mg, about 190 mg, about 210 mg, about 250 mg, or about 300 mg)of anti-VLA-1 antibody daily, twice per week, weekly, every two weeks,every 4 weeks (for example, monthly).

The formulation can also be administered to a subject, such as a human,in a bolus at a dose of anti-VLA-1 antibody of about 2.0 mg per kg ofbody weight to about 4.0 mg per kg of body weight (for example, about2.1 mg per kg of body weight, about 2.2 mg per kg of body weight, about2.3 mg per kg of body weight, about 2.5 mg per kg of body weight, about2.8 mg per kg of body weight, about 3.0 mg per kg of body weight, about3.1 mg per kg of body weight, about 3.2 mg per kg of body weight, about3.3 mg per kg of body weight, about 3.4 mg per kg of body weight, orabout 3.6 mg per kg of body weight).

Modified dose ranges include a dose of anti-VLA-1 antibody that is lessthan about 400 mg/subject, less than about 300 mg/subject, less thanabout 250 mg/subject, less than about 200 mg/subject, less than about150 mg/subject or less than about 100 mg/subject, typically foradministration every fourth week or once a month. The anti VLA-1antibody can be administered, for example, every three to five weeks,for example, every fourth week, or monthly.

Dosage regimens can be adjusted to provide the desired response, such asa therapeutic response. As used herein, a “regimen” is a course oftherapy regulated by a set course of drug administration. For example,the course of therapy can include administration of a specific amount ofdrug on specific days at defined intervals. The dosages can beconsistent or varied, and the period of administration can be at regularintervals (such as daily or every two or three days), or the period ofadministration can vary (for example, every day for one week, then nodrug for a week, then drug every other day as needed for pain).

A “therapeutic response” is an improvement in a condition, symptom, orparameter associated with a disorder, to either a statisticallysignificant degree or to a degree detectable to one skilled in the art.

The dose of anti-VLA-1 antibody can be chosen to reduce or avoidproduction of antibodies against the anti-VLA-1 antibody, to achievegreater than 40%, greater than 50%, greater than 70%, greater than 75%,or greater than 80% saturation of the al subunit, to achieve to lessthan 80%, less than 70%, less than 60%, less than 50%, or less than 40%saturation of the axl subunit, or to prevent an increase the level ofcirculating white blood cells.

Dosage unit form or “fixed dose” as used herein refers to physicallydiscrete units suited as unitary dosages for the subjects to be treated;each unit contains a predetermined quantity of active antibodycalculated to produce the desired therapeutic effect in association withthe required pharmaceutical carrier and optionally in association withthe other agent.

A pharmaceutical composition may include a “therapeutically effectiveamount” of an anti-VLA-1 antibody described herein, such as SAN-300.Such effective amounts can be determined based on the effect of theadministered agent, or the combinatorial effect of an agent andsecondary agent if more than one agent is used. A therapeuticallyeffective amount of an agent may also vary according to factors such asthe disease state, age, sex, and weight of the individual, and theability of the antibody to elicit a desired response in the individual,such as amelioration of at least one disorder parameter, for example, aparameter of rheumatoid arthritis, or amelioration of at least onesymptom of the disorder, for example, rheumatoid arthritis. Atherapeutically effective amount is also one in which any toxic ordetrimental effects of the composition are outweighed by thetherapeutically beneficial effects.

Devices and Kits

Formulations having a high concentration of an anti-VLA-1 antibody (forexample, SAN-300) can be administered with a medical device. The devicecan be designed with or have features such as portability, roomtemperature storage, and ease of use so that it can be used in emergencysituations, such as by an untrained subject or by emergency personnel inthe field, removed to medical facilities and other medical equipment.The device can be a container that includes, for example, one or morehousings for storing pharmaceutical preparations that include ananti-VLA-1 antibody (e.g., SAN-300), and can be configured to deliverone or more unit doses of the agent.

A container, such as a delivery device, can contain a unit dosageformulation of anti-VLA-1 antibody. The container can be suitable forsubcutaneous administration. For example, the container can be asyringe.

A pharmaceutical composition comprising an anti-VLA-1 antibody can beadministered with a delivery device, such as a syringe, for example, ahypodermic or multichamber syringe. In one embodiment, the device is aprefilled syringe with an attached or integral needle. In otherembodiments, the device is a prefilled syringe not having a needleattached. The needle can be packaged with the prefilled syringe. In oneembodiment, the device is an auto-injection device, such as anauto-injector syringe. In another embodiment the injection device is apen-injector. In yet another embodiment, the syringe is a staked needlesyringe, luer lock syringe, or luer slip syringe. Other suitabledelivery devices include stents, catheters, microneedles, andimplantable controlled release devices. The composition can beadministered intravenously with standard IV equipment, including, forexample, IV tubings, with or without in-line filters. In certainembodiments, the device will be a syringe for use in SC or IMadministration.

An anti-VLA-1 antibody, such as SAN-300, can be provided in a kit. Inone embodiment, the kit includes one or more of: a container, such as inan injection device, such as a syringe that contains an antibodycomposition described herein; packaging material that encloses thecontainer, and optionally, other elements of the kit; a container thatcontains a composition including a second agent; and informationalmaterial. The informational material can be descriptive, instructional,marketing or other material that relates to the methods described hereinand/or the use of the agents for therapeutic benefit. In one embodiment,the kit also includes a second agent. For example, the kit includes afirst container that contains a composition that includes the anti-VLA-1antibody, and a second container that includes the second agent. In oneembodiment, the kit includes one or more single-use syringes pre-filledwith a high concentration liquid antibody formulation described herein.

The informational material of the kits is not limited in its form. Inone embodiment, the informational material can include information aboutproduction of the antibody, concentration, date of expiration, batch orproduction site information, and so forth. In one embodiment, theinformational material relates to methods of administering theanti-VLA-1 antibody, such as SAN-300, such as in a suitable dose, dosageform, or mode of administration, for example, a dose, dosage form, ormode of administration described herein, to treat a subject who has aninflammatory disease such as RA, or who is at risk for experiencing anepisode associated with an inflammatory disease. The information can beprovided in a variety of formats, including printed text, computerreadable material, video recording, or audio recording, or informationthat provides a link or address to substantive material.

The kit can include one or more containers for the composition orcompositions containing the agents. In some embodiments, the kitcontains separate containers, dividers or compartments for thecomposition and informational material. For example, the composition canbe contained in a bottle, vial, or syringe, and the informationalmaterial can be contained in a plastic sleeve or packet. In otherembodiments, the separate elements of the kit are contained within asingle, undivided container. For example, the composition is containedin a bottle, vial or syringe that has attached thereto the informationalmaterial in the form of a label. In some embodiments, the kit includes aplurality, for example, a pack, of individual containers, eachcontaining one or more unit dosage forms, such as a unit dosage formdescribed herein, of the agents. The containers can include acombination unit dosage, for example, a unit that includes both theanti-VLA-1 antibody, such as SAN-300, and the second agent, such as in adesired ratio. For example, the kit includes a plurality of syringes,ampoules, foil packets, blister packs, or medical devices, for example,each containing a single combination unit dose. The containers of thekits can be air tight, waterproof, for example, impermeable to changesin moisture or evaporation, and/or light-tight.

The kit optionally includes a device suitable for administration of thecomposition, for example, a syringe or other suitable delivery device.The device can be provided pre-loaded with one or both of the agents orcan be empty, but suitable for loading.

Rheumatoid Arthritis

Formulations having anti-VLA-1 antibody suitable for subcutaneousadministration are useful for the treatment of inflammatory diseases,such as autoimmune arthritis, for example, rheumatoid arthritis orpsoriatic arthritis; or other forms of inflammatory arthritis, such asarthritis associated with inflammatory bowel disease. Autoimmunearthritis is caused by abnormalities in the immune system that cause thebody to start attacking its own joints and connective tissue. Examplesof autoimmune arthritis include rheumatoid arthritis, juvenilearthritis, psoriatic arthritis, and ankylosing spondylitis. Rheumatoidarthritis is a chronic syndrome characterized by non-specific, usuallysymmetric inflammation of the peripheral joints, potentially resultingin progressive destruction of articular and periarticular structures,with or without generalized manifestations. Juvenile arthritis(arthritis beginning at or before age 16) is similar to adult rheumatoidarthritis, and tends to affect large and small joints, and may affectgrowth and development. Psoriatic arthritis, which occurs in about 7% ofpsoriasis patients, is an inflammatory arthritis associated withpsoriasis of the skin or nails; and a negative test for RF (Rheumatoidfactor). Ankylosing spondylitis is a systemic rheumatic disordercharacterized by inflammation of the axial skeleton and large peripheraljoints.

Other types of arthritis, particularly inflammatory arthritis, aresuited for treatment by the methods featured in the invention. Forexample, arthritis associated with inflammatory bowel disease can betreated with an anti-VLA-1 antibody, such as when a first-line therapyfails or ceases to relieve arthritic symptoms.

Efficacy of an agent for treatment of arthritis may be measured by anumber of available diagnostic tools, including but not limited to, forexample, physical examination, including assaying the number of tenderjoint counts or swollen joint counts, joint X-rays, blood tests, orexamination of fluid collected from affected joints. X-rays can revealerosions, cysts and joint space narrowing that can occur in chronicrheumatoid arthritis. Blood tests that indicate elevated ESR(Erythrocyte Sedimentation Rate) levels or the presence of antibodies toaltered γ-globulin (i.e., rheumatic factors, “RFs”) are indicative ofrheumatoid arthritis. Synovial fluid from joints of patients withrheumatoid arthritis is typically cloudy but sterile with reducedviscosity and usually 3,000 to 50,000 white blood cells (WBCs)/μL.

Symptoms of arthritis, including rheumatoid arthritis, include jointpain, joint swelling, joint deformities, reduced ability to move ajoint, redness of the skin around a joint, stiffness, warmth around ajoint, morning stiffness, and effusion (collection of liquid in thejoints). Criteria for the diagnosis of rheumatoid arthritis is set forthin, for example, Aletaha et al., “2010 Rheumatoid ArthritisClassification Criteria,” Arthritis and Rheumatism 62:2569-2581, 2010,and involves the assessment of the number of large and small jointsaffected in a subject, the levels of RF (rheumatoid factor) and ACPA(anti-citrullinated protein antibody) in serum, CRP (C-reactive protein)and ESR (erythrocyte sedimentation rate) levels, and whether thesubject's symptoms have persisted for at least six weeks, or for lessthan six weeks. The duration of symptoms is determined by the patient'sself-report of the duration of signs and symptoms of synovitis (pain,swelling, and tenderness) of any joint that is clinically involved atthe time of assessment. Each of these factors provides a score, and atotal score ≥6 (on a scale of 0-10), is indicative of rheumatoidarthritis.

“Large joints” include shoulders, elbows, hips, knees and ankles, and“small joints” include metacarpophalangeal, proximal interphalangeal(PIP), second through fifth metatarsophalangeal (MTP), and thumbinterphalangeal (IP) joints, and the wrists.

RF and ACPA levels are usually reported in IU (International Units).Based on the upper limit of normal (ULN) for the respective laboratorytest and assay the following definitions can be made: negative=less thanor equal to the ULN for the laboratory test and assay; low-levelpositive=higher than the ULN but ≤3 times the ULN for the laboratorytest and assay; high-level positive=>3 times the ULN for the laboratorytest and assay.

CRP and ESR levels are scored as normal or abnormal based on the locallaboratory standards. If results of at least one of these two tests areabnormal, the patient is scored as having an abnormal acute response.

Patients having arthritis, such as rheumatoid arthritis, also often havean increased level of VLA-1⁺ cells, such as VLA-1⁺ T cells or monocytes.

An “effective amount” of a therapy, such as a first line or secondtherapy, is an amount sufficient to cause beneficial or desired clinicalresults. An effective amount can be delivered in one or moreadministrations. An “effective amount” of a first line therapeutic willproduce an “adequate response.” An “adequate response” is manifested asan improvement in symptoms, such as a decrease in swollen joint countand/or tender joint count, or a decrease in joint pain. An “effectiveamount” of an anti-VLA-1 antibody is an amount sufficient to palliate,ameliorate, stabilize, reverse, slow or delay progression of arthritis,or a symptom of arthritis, in accordance with clinically acceptablestandards.

A subject can be monitored for improvements in arthritic symptomsfollowing treatment with an anti-VLA-1 antibody as a first line therapyor as a second line therapy. In one embodiment, a patient isadministered a high concentration anti-VLA-1 antibody formulation, afterfailing to respond, or after having an inadequate response to a firstline therapy. An “inadequate response” is manifested as failure toachieve an improvement in symptoms, such as failure to experience adecrease in swollen joint count and/or tender joint count, or a decreasein joint pain.

A subject can be monitored for improvements in arthritic symptoms upontreatment with a first or second-line therapy. For example, a subjectcan be monitored by assaying an ACR (American College of Rheumatology)score. For example, a score of ACR20 indicates that there is at least a20% reduction in the total number of tender and swollen joints and areduction of 20% in three of the following five parameters: physicianglobal assessment of disease, patient global assessment of disease,patient assessment of pain, C-reactive protein or erythrocytesedimentation rate, and degree of disability in Health AssessmentQuestionnaire (HAQ) score. Typically, a score of ACR20 indicates that apatient has significant improvement of arthritic symptoms followingadministration of a therapeutic agent, such as an anti-VLA-1 antibody ora first line therapy that is a drug other than an anti-VLA-1 antibody. Apatient can exhibit more significant improvements with scores of ACR50or ACR70, for example.

If a patient does not demonstrate a score of at least ACR20, forexample, ACR20, ACR50 or ACR70, following administration of a therapy,then the patient can receive a negative assessment, or be determined tohave an inadequate response to the therapy. In some embodiments, thepatient's ACR score is monitored over the course of one or two weeks, orone or two months, or longer. In some embodiments, a patient will notmeet a predetermined criterion that requires an ACR score of ACR20,ARC50, or ACR70 after treatment with a first line therapy, and thepatient will be selected for treatment with an anti-VLA-1 antibody.

The HAQ is a validated questionnaire, self-administered by the patient,that includes twenty items relating to function and four items relatingto aids and devices. The questions include eight subscales: dressing andgrooming, arising, hygiene, reach, eating, walking, grip, andactivities. Items are scored from 0 (able to function withoutdifficulty) to 3 (unable to function). The HAQ disease index is aweighted sum of the scale scores, with a higher score indicating poorerfunction. Decreases in the HAQ disease index exceeding −0.19 to −0.22(e.g., −0.2 or −0.21) are considered to be clinically important.

If a patient does not exhibit an improvement (an increase) in HAQ scoreby at least 0.19, for example, by at least 0.22 or more, followingadministration of a therapy, then the patient can receive a negativeassessment, or be determined to have an inadequate response to thetherapy. In some embodiments, the patient is monitored for animprovement in HAQ over the course of one or two weeks, or one or twomonths, or longer. In some embodiments, a patient will not meet apredetermined criterion that requires an improvement in HAQ score of atleast 0.19 or at least 0.22 or more, and the patient will be selectedfor treatment with an anti-VLA-1 antibody.

A patient can also be monitored for improvements in arthritic symptomsupon treatment with a first or second-line therapy by assaying for animprovement in DAS (Disease Activity Score). DAS is a measure of theactivity of rheumatoid arthritis that incorporates the followingparameters: the total number of tender and swollen joints, ESR, andpatient assessment of disease activity (Van der Heijde et al.,“Development of disease activity score based on judgment in clinicalpractice by rheumatologists” J. Rheumatol. 20:579-81, 1993). If apatient does not exhibit an improvement in DAS, for example, a decreasein DAS by at least 1.6, at least 1.8, at least 2.0, at least 2.5, atleast 3.0, at least 3.2, at least 3.6, or more, following administrationof a therapy, then the patient can receive a negative assessment, or bedetermined to have an inadequate response to the therapy. In someembodiments, the patient is monitored for an improvement in DAS over thecourse of one or two weeks, or one or two months, or longer. In someembodiments, a patient will not meet a predetermined criterion thatrequires an improvement in DAS (a decrease in DAS) by at least 1.6, atleast 2.0, at least 2.2, at least 2.8, at least 3.2, at least 3.6, ormore, and the patient will be selected for treatment with ananti-VLA-antibody. Typically, a DAS score of 2.6 or less indicatesremission of RA, and a DAS score of 3.2 or less indicates low diseaseactivity. In one embodiment, patient will not meet a predeterminedcriterion that is a DAS of 2.6 or less, or a patient will not meet apredetermined criterion that is a DAS of 3.2 or less.

The DAS for 28-joint counts (DAS28-CRP measure) includes a composite of4 variables: number of tender joints out of 28 joints, number of swollenjoints out of 28 joints, CRP (in mg/L), and subject assessment ofdisease activity measure on a Visual Analogue Scale (VAS) of 100millimeters (mm). DAS28-CRP values range from 0 to 9.31, with higherscores indicating more disease activity. Typically, a DAS28-CRP score of2.6 or less indicates remission of RA, and a DAS28-CRP score or 3.2 orless indicates low disease activity. In one embodiment, patient will notmeet a predetermined criterion that is a DAS of 2.6 or less, or apatient will not meet a predetermined criterion that is a DAS28 of 3.2or less.

A patient can also be monitored for improvements in arthritic symptomsby a count of the total number of tender and swollen joints. If thetotal number of tender and swollen joints does not decrease by, forexample, more than 1, 2, 3 or more following administration of atherapy, then the patient can receive a negative assessment, or bedetermined to have an inadequate response to the therapy. In someembodiments, the patient is monitored for a decrease in swollen ortender joint counts over the course of one or two weeks, or one or twomonths, or longer. In some embodiments, a patient will not meet apredetermined criterion that requires a decrease in swollen or tenderjoint count of 1, 2, 3 or more, and the patient will be selected fortreatment with an anti-VLA-1 antibody. In some embodiments, a patientwill not meet a predetermined criterion that requires a decrease inswollen or tender joint count of 15%, 20%, or 30% or more, and thepatient will be selected for treatment with an anti-VLA-1 antibody.

A patient can also be monitored for improvements in arthritic symptomsby radiographic methods, such as MRI, ultrasound or X-ray. These methodsprovide images that can reveal the extent of synovitis, erosive changes,and edema. Failure to see a decrease in the extent of synovitis, adecrease in the rate of erosion in the joint, or a decrease in edema,such as over the course of one or two weeks or one or two months, orlonger, for example, can indicate that the patient has an inadequateresponse to a therapy. In some embodiments, a patient will not meet apredetermined criterion that requires a decrease in the extent ofsynovitis, a decrease in the rate of erosion in the joint, or a decreasein “bone edema” or “osteitis” by 15%, 20%, 30% or more, and the patientwill be selected for treatment with an anti-VLA-1 antibody.

A patient can also be monitored for improvements in arthritic symptomsupon treatment with a first or second-line therapy by assaying for thenumber of VLA-1⁺ cells, for example, VLA-1⁺ T cells or monocytes, inblood or synovial fluid. If the number of VLA-1⁺ cells does not decreaseby, for example, more than 15%, more than 20% or more than 30% or morefollowing administration of a therapy, then the patient can receive anegative assessment, or be determined to have an inadequate response tothe therapy. In some embodiments, the patient is monitored for adecrease in VLA-1⁺ cells over the course of one or two weeks, or one ortwo months, or longer. In some embodiments, a patient will not meet apredetermined criterion that requires a decrease in VLA-1⁺ cells of 15%,20%, 30% or more, and the patient will be selected for treatment with ananti-VLA-1 antibody.

In some embodiments, a patient will not meet a predetermined criterionthat requires an improvement in both tender and swollen joint counts ofat least 15%, at least 20%, at least 30% or more, and an improvement ofat least 15%, at least 20%, or at least 30% or more in three of theremaining five core measures: patient's assessment of pain (on the basisof a visual-analogue scale ranging from 1 to 100, with higher scoresindicating more pain); levels of acute-phase reactants, such as CRPlevel: HAQ score; and patient and physician global assessment (eachassessed on a scale of 0 to 100, with higher numbers indicating moresevere disease).

Information regarding a patient's response to a first-line therapy canbe acquired directly or indirectly. For example, information regardingthe patient's response can be assessed by a clinician or caregiver whodirectly examines the patient for symptom improvements followingadministration of a first-line therapy. Alternatively, the informationcan be acquired indirectly, such as from patient records obtained fromthe records of a hospital or clinic, or clinician or caregiver, or froma database, such as an on-line database.

“Acquire” or “acquiring” as the terms are used herein, refer toobtaining possession of a physical entity, or a value, such as anumerical value, by “directly acquiring” or “indirectly acquiring” thephysical entity or value. “Directly acquiring” means performing aprocess (for example, examining the patient or a patient sample) toobtain the physical entity or value. “Indirectly acquiring” refers toreceiving the physical entity or value from another party or source (forexample, a third party laboratory that directly acquired the physicalentity or value).

Directly acquiring a physical entity includes performing a process thatincludes a physical change in a physical substance, such as a startingmaterial. Exemplary changes include making a physical entity from two ormore starting materials, shearing or fragmenting a substance, separatingor purifying a substance, combining two or more separate entities into amixture, performing a chemical reaction that includes breaking orforming a covalent or non-covalent bond.

Directly acquiring a value includes performing a process that includes aphysical change in a sample or another substance, for example,performing an analytical process which includes a physical change in asubstance, such as a sample, an analyte, or a reagent (sometimesreferred to herein as “physical analysis”), performing an analyticalmethod, such as a method that includes one or more of the following:separating or purifying a substance, such as an analyte, or a fragmentor other derivative thereof, from another substance; combining ananalyte, or fragment or other derivative thereof, with anothersubstance, such as a buffer, a solvent, or a reactant; or changing thestructure of an analyte, or a fragment or other derivative thereof, suchas by breaking or forming a covalent or non-covalent bond, between afirst and a second atom of the analyte; or by changing the structure ofa reagent, or a fragment or other derivative thereof, such as bybreaking or forming a covalent or non-covalent bond, between a first anda second atom of the reagent.

“Analyzing” a sample includes performing a process that involves aphysical change in a sample or another substance, such as a startingmaterial. Exemplary changes include making a physical entity from two ormore starting materials, shearing or fragmenting a substance, separatingor purifying a substance, combining two or more separate entities into amixture, performing a chemical reaction that includes breaking orforming a covalent or non-covalent bond. Analyzing a sample can includeperforming an analytical process which includes a physical change in asubstance, such as a sample, an analyte, or a reagent (sometimesreferred to herein as “physical analysis”), performing an analyticalmethod, such as a method which includes one or more of the following:separating or purifying a substance, such as an analyte, or a fragmentor other derivative thereof, from another substance; combining ananalyte, or fragment or other derivative thereof, with anothersubstance, such as a buffer, a solvent, or a reactant; or changing thestructure of an analyte, or a fragment or other derivative thereof, suchas by breaking or forming a covalent or non-covalent bond, between afirst and a second atom of the analyte; or by changing the structure ofa reagent, or a fragment or other derivative thereof, such as bybreaking or forming a covalent or non-covalent bond, between a first anda second atom of the reagent.

In one embodiment, determining whether a patient has improvements inarthritic symptoms, includes one or more of evaluating the patient, oranalyzing a sample from the patient, requesting evaluation of thepatient or analysis of the sample, requesting results from evaluation ofthe patient or analysis of the sample, or receiving the results fromevaluation of the patient or analysis of the sample. Generally, analysiscan include one or both of performing the underlying method, forexample, assaying for the number of VLA-1⁺ cells or monocytes in apatient sample, or receiving data from another who has performed theunderlying method.

In addition to or prior to human studies, an animal model can be used toevaluate the efficacy of using the two agents. An exemplary animal modelfor RA is described in U.S. Pat. No. 7,358,054. For example, in anarthritis model in mice, anti-collagen type II antibodies areadministered by i.p. injection, followed by i.p. injection of LPS(lipopolysaccharide). Mice develop symptoms such as swollen wrists,ankles and digits.

Other Disorders

The formulations and methods described herein can also be used to treatother inflammatory, immune, or autoimmune disorders, such as tissue ororgan graft rejection or graft-versus-host disease; acute CNS injury,such as stroke or spinal cord injury; chronic renal disease; an allergy,such as allergic asthma; type 1 diabetes; inflammatory bowel disorders,such as Crohn's disease and ulcerative colitis; myasthenia gravis;fibromyalgia; an arthritic disorder, such as psoriatic arthritis; aninflammatory/immune skin disorders, such as psoriasis, vitiligo,dermatitis, and lichen planus; systemic lupus erythematosus; Sjogren'sSyndrome; a hematological cancer, such as multiple myeloma, leukemia,and lymphoma; a solid cancer, such as a sarcoma or carcinoma, such as ofthe lung, breast, prostate, or brain; and a fibrotic disorder, such aspulmonary fibrosis, myelofibrosis, liver cirrhosis, mesangialproliferative glomerulonephritis, crescentic glomerulonephritis,diabetic nephropathy, and renal interstitial fibrosis.

For example, a formulation containing a high concentration of anti-VLA-1antibody, such as SAN-300, can be administered subcutaneously to treatthese and other inflammatory, immune, or autoimmune disorders.

Exemplary Second Agents

In some cases, the formulations described herein, for example,formulations containing an anti-VLA-1 antibody suitable for SCadministration, are administered in combination with a formulationcontaining a second agent. Typically, the anti-VLA-1 antibodyformulation, and the formulation containing the second agent areseparate formulations.

In one implementation, the antibody and the second agent are provided asseparate formulations, and the step of administering includessequentially administering the antibody and the second agent. Thesequential administrations can be provided on the same day, for example,within one hour of one another or at least 3 hours, at least 6 hours, orat least 12 hours apart, or on different days. The second agent can beadministered before administration of an anti-VLA-1 antibody orantigen-binding fragment thereof, after administration of an anti-VLA-1antibody or antigen-binding fragment thereof, or at the same time asadministration of an anti-VLA-1 antibody or antigen-binding fragmentthereof.

Generally, the antibody and the second agent are each administered as aplurality of doses separated in time. The antibody and the second agentare generally each administered according to a regimen. The regimen forone or both may have a regular periodicity. The regimen for the antibodycan have a different periodicity from the regimen for the second agent,for example, one can be administered more frequently than the other. Inone implementation, one of the antibody and the second agent isadministered once weekly and the other is administered once monthly. Theantibody and the second agent can be administered by any appropriatemethod, for example, subcutaneously.

In some embodiments, each of the antibody and the second agent isadministered at the same dose as each is prescribed for monotherapy. Inother embodiments, the antibody is administered at a dosage that isequal to or less than an amount required for efficacy if administeredalone. Likewise, the second agent can be administered at a dosage thatis equal to or less than an amount required for efficacy if administeredalone.

The second agent can be, for example, an anti-inflammatory, anantihistamine, an analgesic, such as acetaminophen, or a corticosteroid.

Non-limiting examples of second agents for treating rheumatoid arthritisin combination with an anti-VLA-1 antibody include a DMARD, such as goldsalts; hydroxychloroquine; an antifolate, such as methotrexate; apyrimidine synthesis inhibitor, such as leflunomide; or a sulfa drug,such as sulfasalazine. In another embodiment, the second agent fortreating rheumatoid arthritis is a TNF-α inhibitor, such as ananti-TNF-α antibody, for example, infliximab, adalimumab, certolizumabpegol, or golimumab; or etanercept.

Other exemplary second agents include a JAK (Janus Kinase) inhibitor(e.g., a JAK1, JAK2, JAK3 or TYK2 inhibitor), a SYK (Spleen TyrosineKinase) inhibitor) (for example, an inhibitor of SYK or ZAP-70), a VLA-2inhibitor, an IL-6 inhibitor, an IL-17 inhibitor, an IL-12/IL-23inhibitor, a MAdCAM-1 inhibitor, a CD20 inhibitor or another biologicagent. For example, the second therapeutic agent can be methotrexate,leflunomide, sulfasalazine, or hydroxychloroquine, infliximab,adalimumab, certolizumab pegol, golimumab, etanercept, rituximab,tocilizumab or abatacept.

The second agent can be, for example, an inhibitor of JAK3, such as thesmall molecule inhibitor CP-690,550 (tofacitinib), or the second agentcan be the SYK inhibitor R406, or its prodrug R788.

The second agent can alternatively be a B cell-depleting agent, such asan anti-CD20 antibody, for example rituximab (Rituxan, Genentech, Inc.,South San Francisco, Calif.; and IDEC Pharmaceutical, San Diego,Calif.), an anti-VLA-2 antibody, such as GBR 500; or an anti-MAdCAM-1antibody, such as vedolizumab.

Non-limiting examples of second agents for treating IBD in combinationwith an anti-VLA-1 antibody include, for example, an anti-MAdCAM-1antibody, such as vedolizumab.

In one embodiment, the second therapeutic agent is methotrexate,administered at a dose of about 35 mg/week, about 30 mg/week, about 25mg/week, about 20 mg/week, or about 15 mg/week, or less. In anotherembodiment, the second therapeutic agent is leflunomide, administered ata dose of about 30 mg/day, about 25 mg/day, about 20 mg/day, about 15mg/day, about 10 mg/day or less. In another embodiment the secondtherapeutic agent is sulfasalazine, administered at a dose of about 4000mg/day, about 3500 mg/day, about 3000 mg/day, about 2500 mg/day, about2000 mg/day, or less. In another embodiment, the second therapeucticagent is hydroxychloroquine, administered at a dose of about 500 mg/day,about 450 mg/day, about 400 mg/day, about 350 mg/day, about 300 mg/dayor less.

In one embodiment, the patient is administered a third therapeuticagent, which can be, for example, methotrexate, leflunomide,sulfasalazine, hydroxychloroquine, infliximab, adalimumab, certolizumabpegol, golimumab, etanercept, rituximab, tocilizumab or abatacept.

In one embodiment, administration of the first and second, andoptionally the third, therapeutic agents results in a greaterimprovement of symptoms than is observed following administration ofeither the first or the second (or third) therapeutic agents alone.

In some embodiments, a subject is treated with one or more therapeuticagents prior to receiving an anti-VLA-1 antibody therapy, such as aninfusion of an anti-VLA-1 therapy, such as to prevent or ameliorateadverse reactions to the anti-VLA-1 administration, for example, toprevent or ameliorate adverse events associated with infusion of ananti-VLA-1 antibody. Exemplary pre-treatment regimens include, forexample treatment with one or more of an analgesic, such asacetaminophen, an antihistamine, or a steroid, such as a corticosteroid,such as methylprednisolone. In one embodiment, a subject, such as an RApatient is administered acetaminophen and an antihistamine prior toadministration of an anti-VLA-1 antibody, such as prior to infusion withan anti-VLA-1 antibody. In one embodiment, an RA patient is administereda corticosteroid (also called a glucocorticoid), such asmethylprednisolone, prior to treatment with an anti-VLA-1 antibody.

In one embodiment, the pretreatment, such as the corticosteroid, such asmethylprednisolone, is administered at a dose of about 50 mg/75 kghuman, about 75 mg/75 mg human, about 100 mg/75 kg human, about 125mg/75 kg human, or about 150 mg/75 kg human.

In another embodiment, the pretreatment is administered for about 15minutes to about one hour or more, for example, about 15 minutes, about30 minutes, about 45 minutes, or about one hour or more prior toadministration of the anti-VLA-1 antibody, such as prior to infusion ofthe anti-VLA-1 antibody.

The pretreatment can be administered, for example, by intravenousdelivery, such as by infusion.

In some embodiments, a second agent may be used to treat one or moresymptoms or side effects of RA.

In addition to a second agent, it is also possible to deliver stillother agents to the subject. However, in some embodiments, no protein orbiologic agent, other than the anti-VLA-1 antibody and second agent, areadministered to the subject as a pharmaceutical composition. Theanti-VLA-1 antibody and the second agent may be the only agents that aredelivered by injection. In embodiments in which the anti-VLA-1 antibodyand the second agent are recombinant proteins, the anti-VLA-1 antibodyand second agent may be the only recombinant agents administered to thesubject, or at least the only recombinant agents that modulate immune orinflammatory responses. In still other embodiments, the anti-VLA-1antibody alone is the only recombinant agent or the only biologicadministered to the subject.

All references and publications included herein are incorporated byreference. The following examples are not intended to be limiting.

EXAMPLES Example 1. Biophvsical Characteristics of the Anti-VLA-1Antibody were Evaluated in Various Antibody Formulations

Biophysical characteristics of the anti-VLA-1 antibody were examined to,inter alia, determine the thermal and conformational stability of theantibody in the presence of various buffers and excipients.

The buffers listed in Table 1 were evaluated to assess theconformational stability of SAN-300.

TABLE 1 Buffers Buffer pH 30 mM Glutamate 4.5 5.0 30 mM Acetate 4.5 5.530 mM Citrate 5.0 6.0 30 mM Succinate 5.5 6.5 30 mM Histidine 6.0 7.0 30mM Phosphate 6.5 7.5

The target protein concentration for the biophysical studies was 2mg/mL. The protein samples were buffer exchanged using Amicon Ultra-4(30 k MWCO, RC Membrane) concentrators into the buffers listed inTable 1. The protein concentration in the samples was measured by UV-Visspectroscopy using an extinction coefficient of 1.53 mL/mg*cm. For theinitial biophysical screening, thermal and conformational stability ofthe protein in various buffers was determined using differentialscanning calorimetry (DSC) and dynamic light scattering (DLS). DSCmeasures denaturation, melting temperature and enthalpy. DLS provides ameasure of aggregation. The samples were analyzed at 2 mg/mL in thevarious formulation buffers. The final volume for each formulation was˜1.0 mL (˜24 mg of protein for the entire study).

The DSC data is summarized in Table 2. The formulations A-L in Table 2are provided in order of increasing pH. Glutamate did not provide clearpeaks, see Formulation A, indicating that it is less desirable.

TABLE 2 DSC Results For- Temperature T_(m)1 T_(m)2 T_(m)3 mulationBuffer of Onset (° C.) (° C.) (° C.) (° C.) A 30 mM Glutamate, NA_(a)76.99 NA NA pH 4.5 B 30 mM Glutamate, 58 66.96 78.63 81.13_(b) pH 5.0 C30 mM Acetate, 53 62.28 76.11 80.90_(b) pH 4.5 D 30 mM Acetate, 60 70.0179.01 83.38_(b) pH 5.5 E 30 mM Citrate, 54 64.20 76.02 81.26_(b) pH 5.0F 30 mM Citrate, 60 69.78 77.62 83.29 pH 6.0 G 30 mM Succinate, 58 68.7178.05 83.22 pH 5.5 H 30 mM Succinate, 61 71.43_(b) 77.81 83.65 pH 6.5 I30 mM Histidine, 58 68.82 78.49 83.16 pH 6.0 J 30 mM Histidine, 6071.80_(b) 77.89 84.06 pH 7.0 K 30 mM Phosphate, 61 71.45_(b) 77.56 83.73pH 6.5 L 30 mM Phosphate, 58 71.29_(b) 76.94 82.94 pH 7.5 T_(m)1 meansthe temperature for onset of melting. _(a)Data was insufficient forTemperature of Onset determination. _(b)Peak presented as a shoulder onthe DSC curve, and was unable to be identified by peak picking software.The value shown was picked manually.

The DLS data is summarized in the Table 3. Z-avg is the average diameterof all species. Pdi, the polydispersity index, is a measure ofpolydispersability and is correlated positively with aggregation. Avalue of less than 0.2 for Pdi is desired. Values approaching 0.2 areless desirable, for example, the 0.185 value for Formulation B is lessdesirable. See Table 3.

TABLE 3 DLS results Pk1 Pk2 Pk3 Pk1 Pk2 Pk3 Mean Mean Mean Width WidthWidth Z- Int Int Int Int Int Int Buffer pH Avg Pdi (d · nm) (d · nm) (d· nm) (d · nm) (d · nm) (d · nm) 30 mM 4.5 11.28 0.106 11.48 N/A N/A1.438 N/A N/A Glutamate 30 mM 5.0 12.45 0.185 12.05 1608 5017 1.77 856.6524.2 Glutamate 30 mM 4.5 11.15 0.065 11.53 N/A N/A 1.398 N/A N/AAcetate 30 mM 5.5 10.96 0.026 11.21 N/A N/A 1.078 N/A N/A Acetate 30 mM5.0 11.41 0.075 11.84 N/A N/A 1.61 N/A N/A Citrate 30 mM 6.0 11.23 0.01911.44 N/A N/A 1.109 N/A N/A Citrate 30 mM 5.5 11.82 0.12 11.95 N/A N/A1.55 N/A N/A Succinate 30 mM 6.5 11.24 0.079 11.69 N/A N/A 2.589 N/A N/ASuccinate 30 mM 6.0 10.84 0.067 11.22 N/A N/A 2.025 N/A N/A Histidine 30mM 7.0 10.32 0.077 10.62 N/A N/A 1.88 N/A N/A Histidine 30 mM 6.5 10.890.032 11.18 N/A N/A 1.674 N/A N/A Phosphate 30 mM 7.5 11.93 0.016 11.11N/A N/A 1.229 N/A N/A Phosphate

Generally, stability of the formulations increased with increased pH. ApH of 4.5 or less was determined not to be optimal. No aggregation wasobserved in any of the buffer conditions, and the melting temperaturewas found to be >50° C. (T_(M1)>50° C.). Glutamate was determined to bethe least favorable buffer, and citrate did not have clearly preferredproperties.

Excipients Screening.

The conformational and thermal stability of formulations comprisingSAN-300 and various excipients were assessed after exchange into theformulations listed below. For the excipient screening, buffer effectson the protein (˜2 mg/mL) were characterized using DSC and DLS.

TABLE 4 Results of excipient screening by DSC Temper- ature of Formu-Onset Tm1 Tm2 Tm3 lation Buffer Excipient (° C.) (° C.) (° C.) (° C.) A30 mM 150 mM NaCl 57 65.06 76.25 82.26 B Acetate, 250 mM Sorbitol 5967.82 78.49 83.66 C pH 5.0 250 mM Sucrose 59 68.12 78.65 83.84 D 250 mMTrehalose 58 67.06 77.76 83.45^(a) E 250 mM Mannitol 59 67.82 78.4883.68^(a) F 30 mM 150 mM NaCl 60 70.31 77.50 83.68 G Succinate, 250 mMSorbitol 60 71.35^(a) 77.98 84.32 H pH 6.0 250 mM Sucrose 62 71.60^(a)78.19 84.71 I 250 mM Trehalose 62 71.89^(a) 78.43 84.77 J 250 mMMannitol 60 71.45^(a) 77.90 84.39 K 30 mM 150 mM NaCl 62 69.30 77.3283.34 L Histidine, 250 mM Sorbitol 63 72.04^(a) 78.44 84.77 M pH 6.5 250mM Sucrose 62 72.27^(a) 78.58 84.93 N 250 mM Trehalose 63 72.33^(a)78.83 85.01 O 250 mM Mannitol 62 71.84^(a) 78.29 84.62 P 30 mM 150 mMNaCl 60 71.28^(a) 77.06 83.41 Q Phosphate, 250 mM Sorbitol 61 72.27^(a)76.14 83.48 R pH 7.0 250 mM Sucrose 61 72.11^(a) 76.48 83.51 S 250 mMTrehalose 61 73.15^(a) 76.79 83.81 T 250 mM Mannitol 60 71.94^(a) 75.9283.26 ^(a)Peak presented as a shoulder on the DSC curve, and was unableto be identified by peak picking software. The value shown was pickedmanually.

TABLE 5 Results of excipient screening by DLS Pk1 Pk2 Pk3 Mean Mean MeanPk1 Pk2 Pk3 Z-Avg Int Int Int Width Width Width Formulation^(a) (d · nm)PdI (d · nm) (d · nm) (d · nm) (d · nm) (d · nm) (d · nm) A 11.71 0.09512 0 0 1.754 0 0 B 11.74 0.052 12.46 0 0 2.521 0 0 C 17.72 0.387 14.26183.1 0 2.478 49.72 0 D 14.43 0.276 15.82 1380 1.591 3.475 640 0.111 E12.52 0.159 13.25 1688 0 3.529 863.6 0 F 11.22 0.016 11.41 0 0 1.097 0 0G 11.98 0.048 12.64 0 0 2.187 0 0 H 18.01 0.435 14.99 245.6 0 2.72577.19 0 I 14.51 0.287 15.95 2038 1.631 3.347 1025 0.1261 J 12.47 0.11313.71 0 0 3.79 0 0 K 11.56 0.122 12.71 0 0 4.188 0 0 L 11.43 0.093 12.430 0 2.162 0 0 M 21.57 0.582 13.93 128.8 767.1 2.303 38.08 317.6 N 12.060.226 14.53 1.417 0 3.035 0.1048 0 O 12.07 0.167 12.81 0 0 2.415 0 0 P11.46 0.09 11.93 0 0 2.74 0 0 Q 13.19 0.171 14.29 101.7 338.7 4.07442.57 112.8 R 17.23 0.383 14.79 150.7 0 2.88 40.26 0 S 13.37 0.226 15.741.473 4842 3.386 0.1095 686.7 T 12.27 0.116 13.7 0 0 3.284 0 0 Pk1 =peak corresponding to anti-VLA-1 antibody PK2 and Pk3 = peakscorresponding to aggregates ^(a)Formulations are as described in Table4.

Temperature of onset and Tm as determined by DSC is shown in Table 4.DLS data are shown in Table 5.

DSC data indicated that none of the excipients tested had a dramaticeffect on melting temperature (Tm1). For all excipients, the meltingtemperature was >50° C. The freezing temperature in NaCl was lower, asexpected, and the melting temperature in sugar and in the polyols wassimilar. Trehalose, mannitol and sucrose were less preferred. The polyolsorbitol and NaCl were more preferred.

Example 2. Solubility Characteristics of the Anti-VLA-1 Antibody

Solubility studies were conducted to, inter alia, maximize theconcentration of the SAN-300 antibody. The solubility of SAN-300 wasevaluated using various formulations. The formulations and results areprovided in Table 6.

TABLE 6 Solubility Data Approx. Approx. Protein Total Approx. SpinVolume Content Protein Content Time for after after after FirstAccounting Final Final Final Concen- for Sample Concen- Concen- Concen-tration Withdrawn tration tration tration Buffer Excipient Arginine (mg)(mg) (min) (mL) (mg/mL) 30 mM 150 mM  0 mM 76.2 72.4 15.0 0.300 223.3Acetate, NaCl 20 mM 88.9 84.5 15.0 0.325 215.8 pH 5.0 250 mM  0 mM 80.376.6 15.0 0.275 225.1 Sorbitol 20 mM 77.4 73.5 15.0 0.250 220.6 30 mM150 mM  0 mM 91.2 86.7 15.0 0.350 218.7 Succinate, NaCl 20 mM 88.2 83.515.0 0.325 219.0 pH 6.0 250 mM  0 mM 90.1 85.6 15.0 0.300 212.8 Sorbitol20 mM 83.0 78.5 15.0 0.300 212.9 30 mM 150 mM  0 mM 81.1 76.7 15.0 0.325209.1 Histidine, NaCl 20 mM 87.5 82.8 15.0 0.325 215.5 pH 6.5 250 mM  0mM 81.4 77.3 15.0 0.325 196.5 Sorbitol 20 mM 77.6 73.7 15.0 0.350 219.430 mM 150 mM  0 mM 92.8 88.2 25.0 0.300 255.7 Phosphate, NaCl 20 mM 86.081.7 25.0 0.275 259.7 pH 7.0 250 mM  0 mM 92.4 88.0 25.0 0.300 256.6Sorbitol 20 mM 99.7 95.1 25.0 0.300 219.1

Sample Preparation.

The protein samples were exchanged into the indicated buffers usingAmicon Ultra-4 (30K MWCO) concentrators. The concentrators werepre-rinsed with 3 mL of buffer followed by centrifugation at ˜3000×g for5 minutes. For each formulation, 1.7 mL SAN-300 (69 mg/mL) were dilutedwith 2.3 mL of the appropriate buffer in a rinsed concentrator, and thevolume reduced to ˜2 mL by centrifugation at −3000×g, resulting in aprotein concentration of ˜60 mg/mL. This process was repeated for atotal of four rounds of buffer exchange. Protein concentration was thenmeasured in duplicate by UV-Vis spectroscopy using disposable EppendorfUVettes (1.0 cm pathlength) and an extinction coefficient of 1.53mL/mg*cm. A 10 μL volume of the concentrated samples was diluted in 990μL of the appropriate buffer to a concentration ˜0.5 mg/mL.

Samples were next concentrated at 3000×g (or lower) until precipitationwas observed or the sample volume was reduced by half, at which pointthe protein concentration was measured as described above with anappropriate increase in the dilution volume. Each sample was furtherconcentrated and measured according to the table, or until precipitationwas observed. Protein concentrations and percent recoveries werereported for each formulation. Approximately 1900 mg of protein wereused for the entire study.

Example 3. Surfactant Studies

The role of surfactant in reducing protein loss and minimizingaggregation was evaluated. Samples were analyzed by appearance, UV-Vis,DLS and SEC-HPLC to assess stability/aggregation in the stressedsamples. The formulations used in the surfactant studies are summarizedin Table 7.

TABLE 7 Formulations for surfactant studies Tween-80 Buffer ExcipientConcentration (%) 30 mM Acetate, 150 mM NaCl 0 pH 5.0 0.005 0.020 250 mMSorbitol 0 0.005 0.020 30 mM Succinate, 150 mM NaCl 0 pH 6.0 0.005 0.020250 mM Sorbitol 0 0.005 0.020 30 mM Histidine, 150 mM NaCl 0 pH 6.50.005 0.020 250 mM Sorbitol 0 0.005 0.020 30 mM Phosphate, 150 mM NaCl 0pH 7.0 0.005 0.020 250 mM Sorbitol 0 0.005 0.020

Results. Surfactant was analysed for its effect on protein loss andaggregation. Polysorbate 80 (Tween 80) was assessed at two concentrationlevels for each of agitation and freeze/thaw.

Agitation stress samples showed significant opalescence without Tween80. Tween 80 was found to have an impact on agitation stress. The effectwas not concentration dependent at the concentrations evaluated.

Tween 80 had no impact on aggregation, at either concentration, infreeze/thaw.

In SEC (size exclusion chromatography) studies, Tween 80 had no impactat either concentration. Acetate and histidine had preferred bufferingproperties. Less aggregation was observed in acetate and histidine, andthus these were preferred buffers.

In DLS studies, Tween 80 protected against the effects of agitationalthough the effect was independent of concentration at theconcentrations studied. No effect of Tween was observed in freeze/thawexperiments, and sorbitol appeared to perform better.

Sample Preparation for Example 3. SAN-300 was formulated with andwithout Tween 80 (i.e., polysorbate 80) at a SAN-300 targetconcentration of ˜200 mg/mL. The protein samples were buffer exchangedusing Amicon Ultra concentrators (30K MWCO, Ultracel Membrane, Cat# UFC903008) into the buffer/excipient combinations (excluding surfactant)listed in table 7.

A total of ˜1600 mg (23 mL) of SAN-300 was used for eachbuffer/excipient combination and the volume was split into twoconcentrators which were diluted with the appropriate buffer to a volumeof 15 mL. The samples were concentrated to ˜7.5 mL and diluted in theappropriate buffer to a total volume of 15 mL. This process was repeatedfor a total of 4 cycles. The sample volumes were then reduced until thetarget concentration (˜2 mL per tube) was reached. The duplicateconcentrates were pooled, and the protein content determined induplicate by UV-Vis spectroscopy by diluting 50 μL into 49.95 mL of 0.9%SFI volumetrically and using an extinction coefficient of 1.53 mL/mg*cm.

The pooled samples were then split into three aliquots of 1.2 mL andTween 80 was spiked into the aliquoted samples at the specifiedconcentration. The formulated samples were subjected to stress viafreeze-thaw cycling and mechanical stress by agitation, in addition to asmall aliquot reserved as a no-stress control (stored at 2-8° C.) forSEC-HPLC analysis. For both forms of stress, 0.5 mL of sample weretransferred to type 1 borosilicate glass vials (2 mL size). Forfreeze-thaw cycling, the sample was frozen at −80° C. for ≥90 minutesand then allowed to thaw to room temperature. This was repeated for atotal of 5 cycles. The sample was then stored at 2° C. to 8° C. untilanalysis. For agitation stress, the samples were placed on a microplateshaker for 24 to 48 hours at room temperature. Samples were then storedat 2° C. to 8° C. until analysis.

Example 4. Pre-Formulation Design of Experiments (DOE)

The buffers in Table 8 were evaluated at 200 mg/mL SAN-300 for thepreformulation DOE (Design of Experiments). Samples 1 to 28 were forevaluation of Tween 80. Samples 29 to 36 were generated to test thesuitability of Tween-20 as an excipient. For the DOE, each axial pHsample was prepared in duplicate, with center point pH samples preparedin triplicate. For Tween-20 investigations, duplicate samples wereprepared at center point pHs.

TABLE 8 Buffers for preformulation DOE (Design of Experiments) Sam- pleNo. Buffer pH Excipient Surfactant 1 30 mM Acetate 4.5 150 mM NaCl 0.01%Tween 80 2 30 mM Acetate 4.5 150 mM NaCl 0.01% Tween 80 3 30 mM Acetate5.0 150 mM NaCl 0.01% Tween 80 4 30 mM Acetate 5.0 150 mM NaCl 0.01%Tween 80 5 30 mM Acetate 5.0 150 mM NaCl 0.01% Tween 80 6 30 mM Acetate5.5 150 mM NaCl 0.01% Tween 80 7 30 mM Acetate 5.5 150 mM NaCl 0.01%Tween 80 8 30 mM Acetate 4.5 250 mM Sorbitol 0.01% Tween 80 9 30 mMAcetate 4.5 250 mM Sorbitol 0.01% Tween 80 10 30 mM Acetate 5.0 250 mMSorbitol 0.01% Tween 80 11 30 mM Acetate 5.0 250 mM Sorbitol 0.01% Tween80 12 30 mM Acetate 5.0 250 mM Sorbitol 0.01% Tween 80 13 30 mM Acetate5.5 250 mM Sorbitol 0.01% Tween 80 14 30 mM Acetate 5.5 250 mM Sorbitol0.01% Tween 80 15 30 mM Histidine 6.0 150 mM NaCl 0.01% Tween 80 16 30mM Histidine 6.0 150 mM NaCl 0.01% Tween 80 17 30 mM Histidine 6.5 150mM NaCl 0.01% Tween 80 18 30 mM Histidine 6.5 150 mM NaCl 0.01% Tween 8019 30 mM Histidine 6.5 150 mM NaCl 0.01% Tween 80 20 30 mM Histidine 7.0150 mM NaCl 0.01% Tween 80 21 30 mM Histidine 7.0 150 mM NaCl 0.01%Tween 80 22 30 mM Histidine 6.0 250 mM Sorbitol 0.01% Tween 80 23 30 mMHistidine 6.0 250 mM Sorbitol 0.01% Tween 80 24 30 mM Histidine 6.5 250mM Sorbitol 0.01% Tween 80 25 30 mM Histidine 6.5 250 mM Sorbitol 0.01%Tween 80 26 30 mM Histidine 6.5 250 mM Sorbitol 0.01% Tween 80 27 30 mMHistidine 7.0 250 mM Sorbitol 0.01% Tween 80 28 30 mM Histidine 7.0 250mM Sorbitol 0.01% Tween 80 29 30 mM Acetate 5.0 150 mM NaCl 0.01% Tween20 30 30 mM Acetate 5.0 150 mM NaCl 0.01% Tween 20 31 30 mM Acetate 5.0250 mM Sorbitol 0.01% Tween 20 32 30 mM Acetate 5.0 250 mM Sorbitol0.01% Tween 20 33 30 mM Histidine 6.5 150 mM NaCl 0.01% Tween 20 34 30mM Histidine 6.5 150 mM NaCl 0.01% Tween 20 35 30 mM Histidine 6.5 250mM Sorbitol 0.01% Tween 20 36 30 mM Histidine 6.5 250 mM Sorbitol 0.01%Tween 20

Results.

One vial of each formulation was placed at 5° C. and one at 50° C.(stress condition) for the 28 day incubation. Data collected after 28days storage were analyzed for statistical significance.

Acetate data sets indicated that a preferred formulation containssorbitol and has a pH ˜5.50.

Histidine data sets indicated that pH ˜6.00 is preferred. With theexception of HPLC data, all other indicators supported sorbitol as apreferred excipient. The effects of sorbitol and NaCl in histidinesamples were more similar than was observed for the acetateformulations.

Size Exclusion data was essentially identical for NaCl and sorbitol,while the highly qualitative 50° C. CEX response data indicated thatNaCl is a preferred excipient for histidine formulations. CEXchromatograms also indicated a higher level of degradation in thepresence of acetate as compared to histidine.

These conclusions were from formulations that contained the surfactantPS-80 at a concentration of about 0.01%. To evaluate the effect of analternative surfactant, off-DOE samples were prepared at center pointpHs that contained about 0.01% PS-20. Evaluation of the data revealed noclear difference between the two surfactant types, as indicated by SEC(size-exclusion chromatography), CEX (cation exchange chromatography),DSC, and UV-Vis methods. However, DLS and appearance testing resultswere less optimal with PS-20. Light scattering measurements of 30 mMacetate, 150 mM NaCl, PS-20, pH 5.0, samples showed excessivepolydispersity, which was not observed in comparable PS-80-containingsamples. Polydispersity, however, was evident in respective PS-80,acetate/NaCl samples at pH 4.5. Furthermore, during appearance testingat 4 weeks, it was observed that a total of 9 samples (out of 72)contained apparent particulate matter. Of these, six were PS-20formulations (˜38% of 16 samples). Given no clear advantage of PS-20over PS-80, the latter surfactant was preferred for carrying on tofurther studies.

The sorbitol-containing acetate formulation was slightly preferred overthe histidine formulation under all conditions tested except HPLC. Thisfavorability for acetate was primarily supported by DLS data. This data,however, also indicated that the preferred acetate formulation waspredicted to have a higher percentage of aggregate species (by ˜1%)relative to the preferred histidine formulation. The increasedpropensity for aggregate formation in acetate could alone be enough tosupport the histidine/sorbitol formulation in further studies. However,one advantage of the acetate/sorbitol formulation was its reducedviscosity. In further evaluation of SAN-300, this reduced viscositycould allow for higher concentration formulations in addition to easingthe burden on tangential flow filtration systems.

Thus, the following candidate formulations were selected for forceddegradation and formulation development studies:

1. 30 mM acetate, 250 mM sorbitol, 0.01% PS-80, pH 5.5 and

2. 30 mM histidine, 250 mM sorbitol, 0.01% PS-80, pH 6.0.

Since for histidine formulations, polysorbate 20 results were similar topolysorbate 80, a histidine formulation was designed wherein polysorbate20 was substituted for the polysorbate 80 to avoid any yellowing effectthat sometimes occurs with polysorbate 80/Histidine formulations.

Sample Preparaton for Example 4. Samples were buffer exchanged andconcentrated using Amicon-15 concentrators (Cat. # UFC903024). Theconcentrators were pre-rinsed with the appropriate buffer by adding 5 mLof buffer to the filter, followed by spinning at ˜3200×g for 5 minutes.For each formulation, a total of 13 mL of SAN-300 (69 mg/mL) were splitbetween duplicate Amicon-15 concentrators and diluted to 15 mL with theappropriate formulation buffer. In the case of a single center pointsample for each formulation, a total of 19.5 mL of SAN-300 were splitbetween triplicate concentrators to account for the volume of samplenecessary for osmolality and viscosity testing. Tween-20 formulationswere prepared using 13 mL of SAN-300. For buffer exchange, theconcentrators were centrifuged until the volume reached ˜7.5 mL, and thesamples were diluted with formulation buffer to 15 mL for a total of 4rounds. A total of ˜33 g of protein was used for the study

Following buffer exchange of SAN-300 into the various buffers, thesamples were concentrated to <1.5 mL, and the contents of duplicate (ortriplicate) concentrators were pooled into a single fraction. A priorsurfactant screening study showed a protein loss of 20-32% during anidentical buffer exchange and concentration process. Assuming aworst-case 35% loss, the starting 13 mL of SAN-300 would produce ˜2.9 mLof 200 mg/mL concentrate. Material was mixed by pipetting up and downprior to transferring to 15 mL conical tubes. The protein concentrationin the samples was measured by UV-Vis spectroscopy using an extinctioncoefficient of 1.53 mL/mg*cm and a pathlength of 1 cm. To dilute thesamples to the target of ˜0.5 mg/mL, 50 μL of the concentrate wasdiluted into 25 mL of 0.9% NaCl volumetrically and in duplicate.Duplicate A₂₈₀ readings must be within 5% of each other. A thirddilution was prepared and measured where the A₂₈₀ readings were notwithin 5% of each other. The samples were diluted or furtherconcentrated as necessary to achieve the target concentration of 200mg/mL+/−10 mg/mL.

Following achievement of 200 mg/mL concentrations for each formulation,the appropriate volume of 10% PS-80 (Surfact-Amps, Thermo-Fisher, C/N28328) or 10% PS-20 (C/N 28320) was added to achieve a finalconcentration of about 0.01%. The formulations were sterile filteredusing Millipore Ultrafree-CL GV 0.22 μM sterile concentrators (Cat. #UFC40GVOS). To sterile filter, the entire volume of each formulation wastransferred to a separate sterile filter, only opening the top part ofthe filter. The Ultrafree-CL units were spun at −3200×g for 5 minutes oruntil the entire solution had passed through the 0.22 μM membrane.Following centrifugation, the filtering units were not reopened untilthe time of vialing, which was performed inside a biosafety cabinet(BSC).

Prior to vialing, ˜75 2.0 mL Vials (West Cat #68000314) and a similarnumber of FluroTec stoppers (West Cat #19500040) were triple rinsed inWFI (water for injection). Stoppers were double-bagged in autoclave bagsand autoclaved to sterilize. Vials were dried in an oven at 80° C. Afterdrying, the basket of vials was double wrapped in tin foil thendepyrogenated by heating at ˜200° C.

For vialing, a biosafety cabinet was used. Prior to use, the BSC wasturned on for at least 15 minutes then sprayed down with 70% IPA.Sterile gloves and arm covers were also used. All items entering thehood were sprayed with 70% IPA prior to entering. Filter unitscontaining sterile formulations were brought into the biosafety cabinet.A minimum of 1.0 mL filling volume was used. There were 2 vials performulation with the remainder to stay in the sterile filter to use asthe Time Zero sample. Appearance at Time Zero was performed using one ofthe vials for each formulation prior to staging.

Example 5A. Formulation Development Studies

For formulation development, SAN-300 samples were evaluated for thefollowing properties: syringeability, viscosity, osmolality, and filtercompatibility.

Syringeability Study.

The syringeability of high-concentration SAN-300 was evaluated at thetarget concentration. For this study, a total of 10 mL was used for eachcandidate formulation. The force (pounds-force (lbf)) required to expeleach solution was determined via use of Instron instrument using a 1 mLsyringe and 25 G, 27 G, and 30 G needles. Each data point was performedin triplicate, with fresh sample used for each measurement. Samples wereexpelled at a rate of 20 inches/minute (approximately 10 mL/min) andcollected in a glass vial. The post-expulsion samples were analyzed byDLS (undiluted), SEC, and appearance. A sample of pre-expulsionformulated material was analyzed as a control.

Results of the syringeability study are shown in Table 13.

TABLE 13 Formulation development for Syringability Average Maximum MeanMean Load Load Average Maximum Formulation Needle Sample (lbf) (lbf)Load (lbf) Load (lbf)  30 mM Acetate 25 Guage 1 1.57 1.59  1.45 ± 0.11 1.49 ± 0.09 220 mM Sorbitol 2 1.44 1.48 0.01% PS-80 3 1.35 1.41 pH 5.527 Guage 1 3.49 3.58  3.47 ± 0.08  3.54 ± 0.12 2 3.38 3.42 3 3.54 3.6430 Guage 1 11.64 11.97 10.72 ± 0.79 11.09 ± 0.77 2 10.26 10.60 3 10.2610.70  30 mM Histidine 25 Guage 1 1.26 1.28  1.28 ± 0.04  1.32 ± 0.04220 mM Sorbitol 2 1.25 1.30 0.01% PS-20 3 1.33 1.36 pH 6.0 27 Guage 12.92 3.04  2.88 ± 0.04  2.94 ± 0.08 2 2.86 2.89 3 2.86 2.90 30 Guage 113.12 13.28 11.01 ± 1.89 11.21 ± 1.89 2 9.45 9.59 3 10.47 10.74

Viscosity Measurements.

Acetate/Sorbitol/PS-80 and Histidine/Sorbitol/PS-80 samples (5° C.) fromthe DOE were pooled together, regardless of pH. The samples were nextdiluted to 190 mg/mL and 180 mg/mL in the appropriate buffer, and theviscosities and protein content measured (Table 14).

Viscosity for SAN-300 was measured using a Brookfield DV-III UltraProgrammable Rheometer. Prior to sample measurement, viscometerperformance was calibrated using a certified viscosity standard.Following the standard measurement, 0.5 mL of neat sample was loadedinto the viscometer. The viscosity measurements were performed atmultiple percentage torque values.

Undiluted samples displayed non-Newtonian behavior, as evidenced by thesmall drop in viscosity at higher shear speeds. The behavior of bothbuffers becomes more Newtonian as SAN-300 is diluted.

TABLE 14 Results of Viscosity Studies Target Vis- Vis- Vis- Conc. cositycosity cosity (mg/ 3 rpm 6 rpm 9 rpm Buffer Excipient pH mL) (cP) (cP)(cP) 30 mM Acetate 250 mM ~5.0 Neat 17.8 17.3 17.2 30 mM HistidineSorbitol ~6.5 Neat 24.7 24.2 23.8 30 mM Acetate ~5.0 190 14.0 13.7 13.630 mM Histidine ~6.5 190 18.0 17.6 17.5 30 mM Acetate ~5.0 180 11.1 11.011.0 30 mM Histidine ~6.5 180 14.1 13.7 13.7

Filter Compatibility Studies.

To assess membrane compatibility, 1 mL of SAN-300 solution was filledinto a 1 mL syringe (BD Cat. #. 309586) and ejected through thefollowing filter types:

-   -   i) 0.22 μM pore size PES membrane (Millipore Cat. #SLGPM33RS)    -   ii) 0.22 μM pore size PVDF membrane (Millipore Cat. # SLGVM33RS)    -   iii) 0.22 μM pore size Cellulose Acetate membrane (Whatman, Cat.        #10462200)

The appearance was recorded prior to and following filtration. Sampleswere analyzed by UV-Vis, DLS (undiluted), and SEC. Data were compared toan unprocessed control sample.

Table 15 shows protein loss following ejection through different filtertypes.

TABLE 15 Results of Filter Compatibility Studies Starting Final ProteinConc. Conc. Loss Buffer Excipient pH Condition (mg/mL) (mg/mL) (%) 30 mMAcetate 220 mM Sorbitol, 5.5 5° C. 189.1 186.4 1.4 0.01% PS-80 Control30 mM Histidine 250 mM Sorbitol, 6.0 5° C. 174.4 173.3 0.6 0.01% PS-20Control 30 mM Acetate 220 mM Sorbitol, 5.5 Cellulose 189.1 186.0 1.60.01% PS-80 Acetate 30 mM Histidine 250 mM Sorbitol, 6.0 Cellulose 174.4176.1 −1.0 0.01% PS-20 Acetate 30 mM Acetate 220 mM Sorbitol, 5.5 PES189.1 186.4 1.4 0.01% PS-80 30 mM Histidine 250 mM Sorbitol, 6.0 PES174.4 175.4 −0.6 0.01% PS-20 30 mM Acetate 220 mM Sorbitol, 5.5 PVDF189.1 185.3 2.0 0.01% PS-80 30 mM Histidine 250 mM Sorbitol, 6.0 PVDF174.4 174.8 −0.2 0.01% PS-20

Example 5B. Forced Degradation Studies

Forced degradation studies of SAN-300 were performed to ensure theability of analytical methods to detect and resolve potentialdegradation products in two different formulations. A total of 4.5 mL(9×0.5 mL vials) of concentrated SAN-300 was used per formulation.

Formulation Controls.

For formulation controls, 1 vial of each SAN-300 formulation was storedat 5° C. for the duration of the photo stress study (see below),followed by storage at 2° C. to 8′C until analysis.

Freeze/Thaw Stress.

For freeze/thaw studies, freezing was performed by placing 1 vial ofeach SAN-300 formulation at −80′C for ≥2 hours. The samples were thawedat room temperature and then returned to −80° C. for at least 90minutes. Samples were exposed to 5 freeze/thaw cycles and then stored at2° C. to 8° C. until analysis.

Heat Stress.

For heat-stress studies, 1 vial of each SAN-300 formulation was storedat 50° C. After 1 week, the samples were pulled for testing. Pulledsamples were stored at 2° C. to 8° C. until analysis.

Photo Stress.

Photostability studies were performed following ICH Q1B guidelines forexposure of the product to cool white light and near UV light. One vialof each SAN-300 formulation was exposed to 1.2 million lux hours ofwhite light and 200 W/m² of UV energy. First, the samples were exposedto 8.00 k lux of cool white light for 150 hours. Following thisexposure, the samples were exposed to 10.00 W/m² UV light for 20 hours.The chamber temperature was maintained at 5° C. for the duration of thestudy. A negative control for each formulation that is double wrappedwith aluminum foil was subjected to identical conditions (i.e., theformulation controls). Following stress, the samples were removed fromthe stability chamber and stored at 2° C. to 8° C. until analysis.

Controls for Hydrolysis and Agitation Studies.

To account for the effects of temperature in the hydrolysis andagitation stress studies, 1 vial of each SAN-300 formulation was storedat 25° C. for the duration of the hydrolysis/agitation studies, and thenstored at 2° C. to 8° C. until analysis.

Deamidation/Base Hydrolysis.

For base-catalyzed deamidation studies, 1 vial of each SAN-300formulation was titrated to pH ≥9.0 with 1 M Tris. The sample was thenplaced at 25° C. for three days. At the end of the incubation period,the sample was buffer exchanged back into the appropriate formulationbuffer using a 10 kDa MWCO concentrator (Millipore, Cat. No UFC801024)and stored at 2° C. to 8° C. until analysis.

Deamidation/Acid Hydrolysis.

For acid-catalyzed deamidation studies, 1 vial of each SAN-300formulation was titrated to pH 3.5 to pH 4.0 with 1 N HCl. The samplewas then placed at 25° C. for three days. At the end of the incubationperiod, the sample was buffer exchanged back into the appropriateformulation buffer using a 10 kDa MWCO concentrator and stored at 2° C.to 8° C. until analysis.

Agitation/Shear Stress.

For agitation studies, 1 vial of each SAN-300 formulation was placedvertically on a microplate shaker at ˜650 rpm for three days at roomtemperature. Samples were then stored at 2° C. to 8° C. until analysis.

Forced Oxidation Stress.

For forced oxidation studies, 1 vial of each SAN-300 formulation wasspiked with hydrogen peroxide to a final concentration of 0.04% (VN) andthen incubated at 37° C. for 4 hours. At the end of the incubationperiod, the sample was buffer exchanged back into the appropriateformulation buffer using a 10 kDa MWCO concentrator and stored at 2° C.to 8° C. until analysis.

TABLE 16 Results of Forced Degradation Studies Starting Final ProteinConc. Conc. Loss Buffer Excipent pH Condition (mg/mL) (mg/mL) (%) 30 mMAcetate 220 mM Sorbitol, 5.5 5° C. 189.1 186.4 1.4 0.01% PS-80 Control30 mM Histidine 250 mM Sorbitol, 6.0 5° C. 174.4 173.3 0.6 0.01% PS-20Control 30 mM Acetate 220 mM Sorbitol, 5.5 Form. 189.1 184.7 2.3 0.01%PS-80 Control 30 mM Histidine 250 mM Sorbitol, 6.0 Form. 174.4 175.1−0.4 0.01% PS-20 Control 30 mM Acetate 220 mM Sorbitol, 5.5 Photo 189.1181.3 4.1 0.01% PS-80 Stress 30 mM Histidine 250 mM Sorbitol, 6.0 Photo174.4 171.6 1.6 0.01% PS-20 Stress 30 mM Acetate 220 mM Sorbitol, 5.5Hydr. 189.1 186.2 1.5 0.01% PS-80 Control 30 mM Histidine 250 mMSorbitol, 6.0 Hydr. 174.4 175.7 −0.8 0.01% PS-20 Control 30 mM Acetate220 mM Sorbitol, 5.5 Acid 189.1  130.4^(a) 31.0 0.01% PS-80 Hydrolysis30 mM Histidine 250 mM Sorbitol, 6.0 Acid 174.4  121.7^(a) 30.2 0.01%PS-20 Hydrolysis 30 mM Acetate 220 mM Sorbitol, 5.5 Base 189.1 175.3^(a) 7.3 0.01% PS-80 Hydrolysis 30 mM Histidine 250 mM Sorbitol,6.0 Base 174.4  141.6^(a) 18.8 0.01% PS-20 Hydrolysis 30 mM Acetate 220mM Sorbitol, 5.5 Oxidation 189.1  163.9^(a) 13.3 0.01% PS-80 30 mMHistidine 250 mM Sorbitol, 6.0 Oxidation 174.4  158.6^(a) 9.1 0.01%PS-20 30 mM Acetate 220 mM Sorbitol, 5.5 Agitation 189.1 188.0 0.6 0.01%PS-80 30 mM Histidine 250 mM Sorbitol, 6.0 Agitation 174.4 176.2 −1.00.01% PS-20 30 mM Acetate 220 mM Sorbitol, 5.5 Freeze- 189.1 185.4 2.00.01% PS-80 Thaw 30 mM Histidine 250 mM Sorbitol, 6.0 Freeze- 174.4165.5 5.1 0.01% PS-20 Thaw 30 mM Acetate 220 mM Sorbitol, 5.5 Heat 189.1184.6 2.4 0.01% PS-80 Stress 30 mM Histidine 250 mM Sorbitol, 6.0 Heat174.4 170.7 2.1 0.01% PS-20 Stress ^(a)Values represent proteinconcentration measured at ~400 μl post-buffer exchange.

Useful formulations were as follows:

Formulation 1:

189.1 mg/mL SAN-300

30 mM Acetate

220 mM Sorbitol

0.01% polysorbate 80 (PS-80)

pH 5.5

Viscosity 3 rpm: 13.2 cP

Viscosity 5 rpm: 12.8 cP

Viscosity 7 rpm: 12.6 cP

Viscosity 9 rpm: 12.6 cP

Formulation 2:

174.4 mg/mL SAN-300

30 mM Histidine

250 mM Sorbitol

0.01% polysorbate 20 (PS-20)

pH 6.0

Viscosity 3 rpm: 10.4 cP

Viscosity 5 rpm: 10.2 cP

Viscosity 7 rpm: 10.1 cP

Viscosity 9 rpm: 10.0 cP

Example 5C. Sample Preparation for Formulation Development and ForcedDegradation Studies

Samples for use in formulation development and forced degradationstudies were prepared as follows:

1. 30 mM Acetate, 250 mM Sorbitol, 0.01% PS-80, pH 5.5

2. 30 mM Histidine, 250 mM Sorbitol, 0.01% PS-20, pH 6.0

DoE samples had concentrations of ˜215 mg/mL and viscosity of 18(acetate) and 21 (histidine). For subcutaneous formulations, atheoretical viscosity target <15 cps is desired, and thus theconcentrations were adjusted to bring viscosity into an acceptablerange:

-   -   Acetate ˜190 mg/mL, 13.7 cps    -   Histidine ˜180 mg/mL, 13.8 cps

Thus, the final SAN-300 concentration of the acetate solution was 190mg/mL, while the final SAN-300 concentration in histidine was 180 mg/mL.

Sample Preparation.

Buffer-exchange of SAN-300 into the candidate formulations was performedusing Amicon Ultra-15 concentrators (30 k MWCO, Ultracel Membrane, Cat#UFC 903096). Assuming a target concentration of 180 mg/mL to 190 mg/mLand a worst-case protein loss of 40%, a total of −90 mL of SAN-300 wasbuffer-exchanged into each candidate formulation (i.e., ˜12.4 g ofstarting material to be consumed in total), where a total of 12 Amiconconcentrators was used in parallel for each formulation to process therequired amount of SAN-300. The concentrators were rinsed with theappropriate buffer prior to the addition of protein. To eachconcentrator, 7.5 mL of SAN-300 (69 mg/mL) was added, and then dilutedto 15 mL with the appropriate buffer. The volume was reduced to ˜7.5 mLby centrifugation, followed by dilution with the appropriate buffer to15 mL. This process was repeated for a total of 4 cycles. Followingbuffer exchange, the samples were concentrated to the targetconcentration and pooled. Final SAN-300 concentration of the samples wasdetermined by UV-Vis spectroscopy using an extinction coefficient of1.53 mL/mg*cm.

Prior to final sample preparation, the osmolality measurements wereperformed using a freezing point depression osmometer. The Osmette XL5007 osmometer was calibrated using deionized water (zero mOsm/kg), 100mOsm/kg, and 500 mOsm/kg standard solutions before sample measurements.Following osmometer calibration, 0.25 mL of sample was used formeasurement. If needed, additional excipients may be evaluated to targetisotonic formulation composition (i.e., 280 to 350 mOsm/kg).

Samples were syringe filtered using 0.22 μm PVDF membranes (Millipore,Cat. # SLGVM33RS). Following filtration, samples were pooled and theconcentration of SAN-300 again determined by UV-Vis spectroscopy.Samples allocated for Forced Degradation were filled (0.5 mL) into 2 mLType 1 borosilicate glass vials (West Pharmaceuticals Cat #68000314) andstoppered with 13 mm Fluorotec stoppers (West Pharmaceuticals, Cat#19500040). A total of 9 vials was sealed for each formulation. Sampleallocated for Formulation Development studies were placed in a 40 mLconical tube.

Samples were exchanged into the appropriate buffers and slightlyover-concentrated, relative to the target SAN-300 concentration ((i)Acetate/Sorbitoll PS-80/pH 5.5: target 190 mg/mL Ab; (ii)Histidine/Sorbitol/PS-20/pH 6.0: target 180 mg/mL Ab) The propersurfactants were added, protein content was determined, and theviscosity measured (Table 9 and Table 10).

TABLE 9 Sample formulations. Avg. Diluted Final Final Conc. Conc. Conc.Buffer Excipient pH Sample (mg/mL) (mg/mL) (mg/mL) 30 mM 250 mM 5.5 10.44 218.9 217.4 Acetate Sorbitol 2 0.43 215.9 30 mM 6.0 1 0.42 210.5214.5 Histidine 2 0.44 218.5

TABLE 10 Starting concentrations and osmolality of sample formulationsConc. Osmolality Buffer (mg/mL) (mOsm/kg) 30 mM Acetate, 250 mMSorbitol, 217.4 384 0.01% PS-80, pH 5.5 30 mM Histidine, 250 mMSorbitol, 214.5 354 0.01% PS-20, pH 6.0

Samples were then diluted to obtain the target concentrations listedabove. For example, in order to obtain a suitable osmolality for theacetate formulation (280-350 mOsm/kg), this sample was diluted to thetarget concentration using 30 mM acetate, 0.01% PS-80, pH 5.5. Afterdilution, the final sorbitol concentration of this sample was 220 mM.

Osmolality was again measured for the final samples (Table 11).

TABLE 11 Target Concentration and osmolality of sample formulationsConc. Osmolality Buffer (mg/mL) (mOsm/kg) 30 mM Acetate, 250 mMSorbitol, 196.5 318 0.01% PS-80, pH 5.5 30 mM Histidine, 250 mMSorbitol, 174.8 341 0.01% PS-20, pH 6.0

Before vialing for the Forced Degradation study, samples weresyringe-filtered through a 0.22 μm PVDF membrane (Millipore, C/NSLGVM33RS), and the protein content was again determined (Table 12).

TABLE 12 Concentration and viscosity following syringe-filtering. Conc.Viscosity Viscosity Viscosity Viscosity (mg/ 3 rpm 5 rpm 7 rpm 9 rpmBuffer mL) (cP) (cP) (cP) (cP) 30 mM Acetate, 189.1 13.2 12.8 12.6 12.6250 mM Sorbitol, 0.01% PS-80, pH 5.5 30 mM Histidine, 174.4 10.4 10.210.1 10.0 250 mM Sorbitol, 0.01% PS-20, pH 6.0

Example 6: Production and Stability Testing of SAN-300 Formulations:Materials, Methods and Experimental Design

Overview

Long-term stability studies were undertaken for SAN-300, an anti-VLA1IgG1 monoclonal antibody, to evaluate several formulations. The proteinwas formulated in 30 mM histidine, 250 mM sorbitol, 0.01% PS-20, pH 6.0and 30 mM acetate, 220 mM sorbitol, 0.01% PS-80, pH 5.5 at both high(180-190 mg/mL) and low (120 mg/mL) concentrations for a total of fourformulations. These samples were prepared by tangential flow filtration,sealed in type I borosilicate vials, and staged at prospective storageconditions (−75° C. and 2-8° C.), an accelerated condition (30° C./65%RH), and a stressed condition (40° C./75% RH). Samples were maintainedunder these conditions to assess the chemical, physical, and structuralstability of the protein. Lower concentration formulations were testedfor a period of 6 months under all conditions. Both higher concentrationformulations were evaluated through 12 months under all conditions, withthe exception of samples stored at 40′C/75% RH, which were testedthrough 6 months. The results of the long term stability studiesdescribed in Examples 6-12 established that histidine was a superiorbuffering system to acetate, and that SAN-300 remained stable at −75° C.and 2-8° C. for up to 12 months at high concentration.

List of Abbreviations

A280, A320 Absorbance at 280, 320 nm

AU Absorbance Units

CE Capillary Electrophoresis

CEX Cation Exchange Chromatography

C/N Catalog Number

DI Deionized Water

dP Pressure Differential (P Feed−P Ret)

HC Heavy Chain

HMW High Molecular Weight

HPLC High Performance Liquid Chromatography

LC Light Chain

LMWI Low Molecular Weight Impurity

P Feed Feed Pressure

P Ret Retentate Pressure

PS-20, PS-80 Polysorbate-20, Polysorbate 80

RH Relative Humidity

RSD Relative Standard Deviation

SDS Sodium Dodecyl Sulfate

SEC Size Exclusion Chromatography

TFF Tangential Flow Filtration

TMP Transmembrane Pressure ((P Feed+P Ret)/2)

UV Ultraviolet

Vis Visible

WFI Water For Injection

Materials

The following materials were used in Examples 6-12.

SAN-300, Lot # CP4-04-109 (69 mg/mL)

SAN-300, Lot # CP4-04-106 (60 mg/mL)

Pellicon XL 30 kDa cassettes, Millipore, C/N PXB030A50

10% Tween-20 Surfact-Amp, Thermo, C/N 28320

10% Tween-80 Surfact-Amp, Thermo, C/N 28328

Colloidal Blue Staining Kit Stainer A&B, Invitrogen, C/N 46-7015

D-Sorbitol, Sigma, C/N 85529

DryEase® Mini-gel Drying System, Invitrogen, C/N N 12387

Gel Drying Solution, Invitrogen, C/N LC 1001

Hydrochloric Acid (6 N), J. T. Baker, C/N H31513 or equivalent

L-Histidine, J. T. Baker, C/N 2080-05

Mark 12 Molecular Marker, Invitrogen, C/N LC5677

NuPAGE® Sample Reducing Agent, Invitrogen, C/N NP0004

Sodium Acetate, Sigma, C/N S1429

Sodium Chloride, Sigma, C/N S 1679 or equivalent

Sodium Hydroxide (6 N), J. T. Baker, C/N H41521 or equivalent

Sodium Phosphate Dibasic Anhydrous, Sigma, C/N S9763 or equivalent

Sodium Phosphate Monobasic Monohydrate, Sigma, C/N S9638 or equivalent

Tris-Glycine Gels (4-20% Gradient), 15 well, Invitrogen, C/N EC60255BOX

Tris-Glycine SDS Sample Buffer, Invitrogen, C/N LC2676

UVettes, Eppendorf, C/N 952010051

HyClone WFI water, Thermo, C/N SH30221.10

CEX Column: ProPac WCX-10 CEX Column, 4×250 mm, Dionex, C/N 054993

CEX Guard Column: Propac WCX-10 OG Guard Column, 4×50 mm, Dionex, C/N054994

SEC Column: G3000SWx1 7.8×300 mm, 5 μm, Tosoh, C/N 08541

SEC Guard Column: SWx1 6×40 mm, 7 μm, Tosoh, C/N 08543

Viscosity Standard, Brookfield, C/N 10 cps

Vials (13 mm, 2 mL), West, C/N 68000314

Stoppers (13 mm), West, C/N 19500040

Lids (13 mm), West, C/N 54130240

Equipment

1100 HPLC System, Agilent

Sevenmulti pH/Conductivity Meter, Mettler Toledo

BioRad Power Supply, Power Pac Basic

DV-III Ultra Programmable Rheometer, Brookfield

GeneGenius Bioimaging System

HIAC Liquid Particle Counter, HACH, model 9703

Labscale TFF System, Millipore,

Observation Lamp, Eisai Machinery, model MIH-DX

Osmette™ XL Automatic Osmometer model 5007

S40 pH Meter, Mettler Toledo

Stability Chamber, Environmental Specialties, model ES2000

UV/Vis Spectrophotometer, Agilent, model 8453

Xcell Surelock Mini-Cell, Invitrogen, C/N EI00001

Methods

Protein Content.

50 μL of concentrated protein solution was diluted volumetrically into25.0 mL of 0.9% NaCl. Diluted samples were measured using UVettedisposable cuvettes in an Agilent UV/Vis spectrophotometer, model 8453.Protein concentration was determined according to the followingequations:

Correction Factor=A320+(A320−A360)

Corrected A280=A280−Correction Factor

Protein Concentration(mg/mL)=(Corrected A280*Dilution Factor)/1.53ml/mg*cm

If duplicate samples displayed >5% relative standard deviation (RSD), athird dilutionwas evaluated, and the outlying data point discarded.

pH.

pH measurements of all sample solutions were performed according toGTM-0015 “Determination of pH” using a calibrated SV40 pH Meter (MettlerToledo) with an automatic temperature compensation electrode.

Conductivity.

Conductivity measurements were performed using a calibrated SevenmultipH and Conductivity Meter.

Sample Preparation and Study Design

The indicated lot of SAN-300 drug substance was formulated into thefollowing buffers by tangential flow filtration (TFF) using a MilliporeLabscale TFF System fitted with three Millipore Pellicon XL 30 kDacassettes operating in series (150 cm2 total area). Transmembranepressure (TMP) was maintained at ≤20 psi for all TFF processes.

i) Lot # CP4-04-106 (60 mg/mL): 30 mM Acetate, 220 mM Sorbitol, pH 5.5

ii) Lot # CP4-104-109 (69 mg/mL): 30 mM Histidine, 250 mM Sorbitol, pH6.0 To monitor the progress during TFF processing, aliquots were removedat different stages for in-process pH, conductivity, and protein contenttesting (Table 17 and Table 18).

TABLE 17 Aliquot Withdrawal Schedule and In-Process Testing Results forTFF Processing of SAN-300 Drug Substance Protein Aliquot ContentConductivity Formulation Sample # Sample Point Removed (mg/mL) pH(mS/cm) 30 mM — Diafiltration Buffer — — 5.56 2.26 Acetate IP-1 DrugSubstance 3 × 1 mL 60.0 6.09 1.73 220 mM IP-2 Post-Concentration 1 mL111.1 — — Sorbitol Retentate pH 5.5 IP-3 Post-Concentration 3 × 1 mL 2.1— — Filtrate IP-4 After 5 Diafiltrations 3 × 1 mL — — — (Retentate) IP-5After 5 Diafiltrations 10 × 1 mL 2.8 5.50 2.38 (Filtrate) IP-6 After 7Diafiltrations 3 × 1 mL 113.2 — — (Retentate) IP-7 After 7Diafiltrations 10 × 1 mL 2.1 5.44 2.42 (Filtrate) IP-8 AfterOverconcentration 1 mL 231.2 — — IP-9 System Rinse — 56.6 — — IP-10Post-Rinse Addition — 193.4 — — 30 mM — Diafiltration Buffer — — 6.081.32 Histidine IP-1 Drug Substance 3 × 1 mL 69.0 NA^(a) NA^(a) 250 mMIP-2 Post-Concentration 1 mL 123.0 — — Sorbitol Retentate pH 6.0 IP-3Post-Concentration 3 × 1 mL 0.7 — — Filtrate IP-4 After 5 Diafiltrations3 × 1 mL — — — (Retentate) IP-5 After 5 Diafiltrations 10 × 1 mL −0.16.06 1.38 (Filtrate) IP-6 After 7 Diafiltrations 3 × 1 mL 141.2 — —(Retentate) IP-7 After 7 Diafiltrations 10 × 1 mL 1.3 5.97 1.32(Filtrate) IP-8 After Overconcentration 1 mL 219.1 — — IP-9 System Rinse— 37.1 — — IP-10 Post-Rinse Addition — 182.2 — — ^(a)Measurement was nottaken for sample

TABLE 18 Protein Content Determinations of Aliquots Withdrawn forIn-Process Testing Average A280 Diluted Final Final Formu- Condi- A280A320 A360 Correction Corrected Conc. Conc. Conc. % lation tion Sample(AU) (AU) (AU) (AU) (AU) (mg/mL) (mg/mL) (mg/mL) RSD 30 mM IP-1 10.21840 0.02684 0.01608 0.03761 0.18079 0.12 59.1 60.0 2.3 Acetate 20.18525 −0.00708 −0.01272 −0.00145 0.18670 0.12 61.0 220 mM IP-2 10.35282 0.00780 0.00070 0.01490 0.33792 0.22 110.4 111.1 0.8 Sorbitol 20.34576 −0.00018 −0.00419 0.00383 0.34193 0.22 111.7 pH 5.5 IP-3 1−0.00494 −0.00623 0.00004 −0.01250 0.00756 0.00 2.5 2.1 25.4 2 −0.01202−0.01333 0.00938 −0.01728 0.00526 0.00 1.7 IP-5 1 −0.01665 −0.01893−0.01271 −0.02515 0.00850 0.01 2.8 2.8 1.9 2 −0.01081 −0.01559 −0.01162−0.01955 0.00874 0.01 2.9 IP-6 1 0.34230 −0.00146 −0.00159 −0.001320.34362 0.22 112.3 113.2 1.1 2 0.34244 −0.00710 −0.00771 −0.006500.34894 0.23 114.0 IP-7 1 −0.01433 −0.01487 −0.01200 −0.01774 0.003410.00 1.1 2.1 64.7 2 −0.01927 −0.02167 −0.01493 −0.02842 0.00914 0.01 3.0IP-8 1 0.68642 −0.02048 −0.01783 −0.02313 0.70955 0.46 231.9 231.2 0.4 20.68393 −0.01673 −0.01182 −0.02164 0.70557 0.46 230.6 IP-9 1 0.190400.00407 −0.00859 0.01673 0.17367 0.11 56.8 56.6 0.4 (Rinse) 2 0.18056−0.00083 −0.00956 0.00790 0.17266 0.11 56.4 IP-10 1 0.58275 −1.2217E−02−2.1278E−02 −0.00316 0.58591 0.38 191.5 193.4 1.4 2 0.61120  7.4577E−04−1.2146E−02 0.01364 0.59756 0.39 195.3 30 mM IP-2 1 0.37486 −0.00234−0.00556 0.00089 0.37397 0.24 122.2 123.0 0.9 Histidine 2 0.387750.00684 0.00443 0.00924 0.37851 0.25 123.7 250 mM IP-3 1 0.00531 0.00209−0.00454 0.00872 −0.00340 0.00 −1.1 0.7 351.2 Sorbitol 2 −0.01455−0.01648 −0.01043 −0.02254 0.00799 0.01 2.6 pH 6.0 After 4th 1 0.37145−0.00682 −0.00769 −0.00596 0.37741 0.25 123.3 120.7 3.0 Diafil- 20.37566 0.00874 0.00340 0.01409 0.36157 0.24 118.2 tration IP-5 1−0.00936 −0.00685 −0.00431 −0.00939 0.00004 0.00 0.0 −0.1 −157.9 2−0.01815 −0.01492 −0.01237 −0.01748 −0.00068 0.00 −0.2 IP-6 1 0.40677−0.01602 −0.00584 −0.02621 0.43298 0.28 141.5 141.2 0.3 2 0.41610−0.01461 −0.01419 −0.01503 0.43113 0.28 140.9 IP-7 1 −0.01297 −0.01053−0.00233 −0.01873 0.00577 0.00 1.9 1.3 60.3 2 −0.00631 −0.00604 −0.00346−0.00863 0.00232 0.00 0.8 Conc. to 1 0.59934 0.00308 0.00170 0.004450.59489 0.39 194.4 194.4 0.0 115 mL 2 0.58662 −0.00413 −0.00013 −0.008130.59475 0.39 194.4 IP-8 1 0.66784 0.00237 0.00483 −0.00008 0.66792 0.44218.3 219.1 0.5 2 0.64941 −0.01297 −0.00253 −0.02340 0.67281 0.44 219.9IP-9 1 0.11225 −0.00660 −0.00911 −0.00409 0.11634 0.08 38.0 37.1 3.5(Rinse) 2 0.11000 −0.00567 −0.01068 −0.00067 0.11067 0.07 36.2 IP-10 10.54739 −0.01053 −0.00573 −0.01532 0.56271 0.37 183.9 182.2 1.3 20.54346 −0.00355 0.00168 −0.00878 0.55224 0.36 180.5

To begin, ˜450 mL of CP4-04-106 or ˜430 mL of CP4-04-109 wereconcentrated to roughly half the starting volume (Table 19). Feed andretentate pressure (P Feed and P Ret) were monitored during initialconcentration at several time points.

TABLE 19 Summary of Initial Concentration Data for TFF Processing ofSAN-300 Drug Substance Permeate P Feed P Ret dP TMP Flux Flux VolumeFormulation Time (psi) (psi) (psi) (psi) (mL/min) (LMH) (mL) 30 mMAcetate 5 25.0 5.0 20.0 15.0 4.0 16.0 20 220 mM Sorbitol 20 26.0 5.021.0 15.5 3.7 14.8 75 pH 5.5 35 27.0 5.0 22.0 16.0 3.5 14.1 128 45 29.05.0 24.0 17.0 3.1 12.4 159 65 33.0 5.0 28.0 19.0 2.9 11.4 216 30 mMHistidine 1 22.5 7.5 15.0 15.0 — — — 250 mM Sorbitol 8 22.5 7.5 15.015.0 — — 26 pH 6.0 34 30.0 5.0 25.0 17.5 — — 96 62 30.0 3.0 20.0 18.0 —— 173

The mass of permeate was recorded at each of these time points andpermeate volume determined. The pressure drop (dP; P Feed−P Ret) andtransmembrane pressure (TMP; (P Feed+P Ret)/2) were also calculated. Forthe acetate formulation, filtrate flow rate was recorded at each timepoint (Flux, mljmin), and this measurement was normalized for membranearea ((L*h−1)/m2).

The concentrated drug substance was next exchanged into the appropriateformulation buffer by seven rounds of continuous diafiltration (Table20). For each diavolume, feed pressure, retentate pressure andfiltration rate were measured, and the associated parameters calculatedas described above. Flux was observed to increase by ˜50% for theacetate formulation, and ˜30% for the histidine formulation by the fifthdiavolume.

TABLE 20 Summary of Diafiltration Data for TFF Processing of SAN-300Drug Substance P P Flux Total Formu- Dia- Feed Ret dP TMP (mL/ Flux Timelation volume (psi) (psi) (psi) (psi) min) (LMH) (hr:min) 30 mM 1 33.03.0 30.0 18.0 2.8 11.0 01:24 Acetate 2 34.0 5.0 29.0 19.5 3.0 12.0 02:37220 mM 3 33.0 5.0 28.0 19.0 3.0 12.0 03:40 Sorbitol 4 33.0 5.0 28.0 19.03.8 15.2 04:37 pH 5.5 5 34.0 5.0 29.0 19.5 4.2 16.9 05:32 6 34.0 5.029.0 19.5 4.3 17.0 06:22 7 34.0 5.0 29.0 19.5 4.7 18.8 07:12 30 mM 137.0 2.0 35.0 19.5 2.5 10.0 01:34 Histidine 2 36.0 3.0 33.0 19.5 2.610.4 02:53 250 mM 3 36.0 3.0 33.0 19.5 3.5 14.0 04:06 Sorbitol 4 37.03.0 34.0 20.0 3.2 12.9 05:14 pH 6.0 5 36.0 3.0 33.0 19.5 3.3 13.2 06:166 37.0 0.0 37.0 18.5 3.3 13.2 07:29 7 39.0 1.0 38.0 20.0 3.3 13.2 08:38

Following the completion of diafiltration, formulated drug substance wasoverconcentrated relative to the final SAN-300 target concentration(Table 17). The final pH and conductivity of the over-concentratedsolutions were nearly identical to the associated diafiltration buffer(Table 17). After removing the sample, the TFF system was flushed withdiafiltration buffer and the protein content of the flush determined.This flush was used to dilute the over-concentrated SAN-300 to a levelonly slightly above the final target (Table 17). The volume of thissolution was determined by weight using a density of 1.089 g/mL.Finally, the percent yield was estimated using protein contentdeterminations made throughout TFF processing (Table 21). While noapparent SAN-300 loss was observed for the acetate formulation, exchangeinto histidine buffer resulted in a yield of 89%.

TABLE 21 Estimated Percent Yield for SAN-300 TFF Processing Total VolumeConc. Protein Formulation Sample (mL) (mg/mL) (mg) 30 mM AcetatePost-Concentration 1.3 111.1 138.9 220 mM Sorbitol Aliquot^(a) 0.01%PS-80 Post-5 Diafiltrations 3.0 111.1^(b) 333.3 pH 5.5 Aliquot Post-7Diafiltrations 3.5 113.2 396.2 Aliquot^(c) Over-Concentration 1.5 231.2346.8 Aliquot^(c) Final Over- 109.7 231.2 25362.6 Concentrated SampleRinse^(b) 22.0 56.6 1245.2 Total (mg): 27823.0 Starting Drug 450.0 60.027000.0 Substance Percent Yield: 103.0 30 mM HistidinePost-Concentration 2.0 123.0 246.0 250 mM Sorbitol Aliquot^(a) 0.01%PS-20 4th Diafiltration 1.0 120.7 120.7 pH 6.0 Aliquot Post-5Diafiltrations 3.0 120.7^(b) 362.1 Aliquot Post-7 Diafiltrations 3.5141.2 494.2 Aliquot^(c) Conc. To 115 mL 0.5 194.4 97.2 AliquotOver-Concentration 1.5 219.1 328.7 Aliquot^(c) Final Over- 108.7 219.123816.2 Concentrated Sample Rinse^(b) 25.5 37.1 946.1 Total (mg):26411.1 Starting Drug 430.0 69.0 29670.0 Substance Percent Yield: 89.0^(a)Includes 1.0 mL sample withdrawn for A280 testing ^(b)Concentrationnot determined, the value shown is an estimate used to approximate theamount of material withdrawn for this aliquot ^(c)Includes 0.5 mL samplewithdrawn for A280 testingTo reach the final target concentration, a small volume of formulationbuffer including the sample-appropriate polysorbate (acetate, PS-80;histidine, PS-20) was added to achieve a surfactant concentration of0.01%. A 40 mL aliquot of formulated SAN-300 at the target concentrationwas removed and diluted to 120 mg/mL using formulation buffer including0.01% polysorbate. A total of four SAN-300 formulations were generatedat the indicated target concentrations:

High Concentration:

NB1206p86A: 190 mg/mL, 30 mM Acetate, 220 mM Sorbitol, 0.01% PS-80, pH5.5NB1206p86B: 180 mg/mL, 30 mM Histidine, 250 mM Sorbitol, 0.01% PS-20 pH6.0

Low Concentration:

NB1206p86C: 120 mg/mL 30 mM Acetate, 220 mM Sorbitol, 0.01% PS-80, pH5.5NB1206p86D: 120 mg/mL, 30 mM Histidine, 250 mM Sorbitol, 0.01% PS-20 pH6.0

Prior to vialing, the final protein content for all formulations wasmeasured before and after filtration through a 0.22 μm PES membrane. Theresults are shown in Table 22.

TABLE 22 Final Protein Content Determination for SAN-300 Formulationsused in Stability Study Target Average Conc. Correc- A280 Diluted FinalFinal Formu- (mg/ Filt- A280 A320 A360 tion Corrected Conc. Conc. Conc.% lation mL) ered Sample (AU) (AU) (AU) (AU) (AU) (mg/mL) (mg/mL)(mg/mL) RSD 30 mM 190 Pre- 1 0.56786 −0.01349 −0.01702 −0.00995 0.577810.38 188.8 189.4 0.4 Acetate 2 0.55664 −0.02798 −0.03137 −0.024590.58123 0.38 189.9 220 mM Post- 1 0.56776 −0.01310 −0.01250 −0.013690.58145 0.38 190.0 187.6 1.8 Sorbitol 2 0.57070 −0.00423 −0.012310.00385 0.56685 0.37 185.2 0.01% 120 Pre- 1 0.34587 −0.02212 −0.01862−0.02563 0.37150 0.24 121.4 119.8 1.8 PS-80 2 0.33867 −0.02524 −0.02718−0.02330 0.36197 0.24 118.3 pH 5.5 Post- 1 0.34845 −0.02428 −0.02173−0.02684 0.37529 0.25 122.6 121.7 1.1 2 0.34747 −0.02325 −0.02449−0.02200 0.36947 0.24 120.7 30 mM 180 Pre- 1 0.52190 −0.01683 −0.01887−0.01480 0.53670 0.35 175.4 174.1 1.0 Histidine 2 0.49998 −0.02657−0.02423 −0.02890 0.52888 0.35 172.8 250 m M Post- 1 0.54108 −0.00328−0.00087 −0.00569 0.54677 .036 178.7 177.4 1.0 Sorbitol 2 0.52670−0.01604 −0.01957 −0.01250 0.53920 0.35 176.2 0.01% Pre- 1 0.34107−0.01813 −0.01766 −0.01860 0.35967 0.24 117.5 116.9 0.8 PS-20 120 20.35011 −0.00864 −0.01161 −0.00567 0.35578 0.23 116.3 pH 6.0 Post- 10.34101 −0.01342 −0.01537 −0.01146 0.35247 0.23 115.2 115.5 0.3 20.33710 −0.01865 −0.02027 −0.01702 0.35412 0.23 115.7

The four formulations were vialed into sterile, depyrogenated type Iborosilicate glass vials at a volume of 1 mL, sealed using 13 mmFluroTec® stoppers, and stored at 2-8° C. until staging. For stabilitytesting, samples were maintained at prospective storage conditions (−75°C. and 2-8° C.), an accelerated condition (30° C./65% RH), and astressed condition (40° C./75% RH). In addition, some vials were storedin an inverted position at 2-8° C. to determine if container closureimpacts SAN-300 stability. The analytical testing schedule is shown inTable 23.

TABLE 23 Analytical Testing Schedule for SAN-300 Stability Study 1 3 6 912 Formulation Condition T₀ Month Months Months Months Months NB1206p86A−75° C. X^(a) — — X — X NB1206p86B  2-8° C. X^(b) X^(b) X X X (HighConc.)  2-8° C. — — X — X (Inverted) 30° C./65% RH X X X X X 40° C./75%RH X X X — — NB1206p86C −75° C. X^(a) — — X — — NB1206p86D  2-8° C. —X^(b) X — — (Low Conc.)  2-8° C. — — X — — (Inverted) 30° C./65% RH — XX — — 40° C./75% RH — X X — — X Testing included appearance, proteincontent, pH, HIAC, reduced SDS-PAGE, SEC, and CEX ^(a)Additionalosmolality and viscosity testing ^(b)Additional osmolality testing

Example 7: Viscosity and Osmolality of SAN-300 Formulations

The viscosity of SAN-300 formulations (as described in Example 6) wasassessed at at the initial time point. Osmolality of the formulationswas assessed at the initial time point and after 1 and 3 months ofstorage at 2-8° C.

Methods

Methods for Assessing Viscosity.

A shear rheometer was calibrated with Brookfield viscosity standardfluid #10, and 0.5 mL of sample was measured at various spindle speeds(shear rates). Samples displaying constant viscosity (cP) readings overall shear rates were considered Newtonian over this range, while sampleswith shear rate-dependent viscosity values would be considerednon-Newtonian.

Methods for Assessing Osmolality.

Osmolality measurements were performed using a freezing point depressionosmometer, which measures the decrease in a solution's freezing point assolute concentration increases. The Osmette XL 5007 osmometer wascalibrated using deionized water (zero mOsm/kg), 100 mOsm/kg, and 500mOsm/kg standard solutions.

Following the osmometer calibration, 250 μL of sample was measured.

Results

The viscosity and osmolality results are shown in Table 24.

TABLE 24 Summary of Viscosity and Osmolality Results for SAN-300Stability Study Sample Conc. Time Viscosity Osmolality Lot Formulation(mg/mL) Condition Point (cP) (mOsm/kg) NB1206p86A  30 mM Acetate 190Initial 13.7 295 220 mM Sorbitol 2-8° C. 1M — 318 0.01% PS-80 3M — 310NB1206p86C pH 5.5 120 Initial 4.4 299 2-8° C. 3M — 321 NB1206p86B  30 mMHistidine 180 Initial 11.9 289 250 mM Sorbitol 2-8° C. 1M — 331 0.01%PS-20 3M — 319 NB1206p86D pH 6.0 120 Initial 4.3 287 2-8° C. 3M — 316

Viscosity Results.

Formulation viscosity was evaluated for all formulations at the initialtime point. The results are shown in Table 24. Newtonian behavior wasobserved for all samples, where both high concentration histidine andacetate formulations displayed viscosities <15 cP (11.9 and 13.7 cP,respectively). Low concentration histidine and acetate formulationviscosities were 4.3 and 4.4 cP, respectively. All viscosities measuredwere consistent with historical values.

Osmolality Results.

Osmolality measurements were performed at the initial time point (Table24). Readings for both high-concentration acetate (295 mOsm/kg) andhistidine (289 mOsm/kg) formulations were somewhat lower than historicalvalues and, thus, re-evaluation of sample osmolality was performed at 1and 3 months using samples stored at 2-8° C. The resulting values forthe acetate formulation were 318 and 310 mOsm/kg for samples at 1 monthand 3 months, respectively, while histidine-containing samples showedosmolality of 331 and 319 mOsm/kg. These data were fully consistent withhistorical readings, and show that sample osmolality remained constantwithin this time-frame. The osmolality of low concentration acetate andhistidine formulations at the 3 month time point was 321 and 316mOsm/kg, respectively.

Example 9: Long Term Stability of SAN-300 Formulations: AppearanceProtein Content, and pH

The appearance, protein content, and pH of SAN-300 Formulations wasassessed to determine their long term stability using the experimentaldesign described in Example 7.

Methods

Appearance.

Prior to unsealing vials for analytical testing, sample appearance wasevaluated against a white and dark background. Each sample was testedagainst an identical vial filled with DI water for color, clarity(opalescence), and the presence of visible particulate matter.

Protein Content and pH.

Protein content and pH were assessed as described in Example 7.

Results

The results are shown in Table 25 below. All formulations maintainedconsistent appearance, protein content, and pH over the course of thestudy

TABLE 25A Acetate Formulation: Summary of Protein Content, pH, andAppearance Results for SAN-300 Stability Samples Protein Osmo- TimeContent lality Sample Lot Formulation Condition Point (mg/mL) pH(mOsm/kg) Appearance^(a) NB1206p86A 190 mg/mL Initial 185.9 5.6 295slightly yellow (•), slightly SAN-300 opalescent, no visible particles 30 mM Acetate −75° C. 6M 194.2 5.7 — slightly yellow (•),(), slightly220 mM Sorbitol opalescent, no visible particles 0.01% PS-80, 12M  181.65.7 — slightly yellow (•), slightly pH 5.5 opalescent, no visibleparticles 2-8° C. 1M 186.7 5.6 318 slightly yellow (•), slightlyopalescent, no visible particles 3M 184.9 5.7 310 slightly yellow (•),slightly opalescent, no visible particles 6M 192.0 5.6 — slightly yellow(•), slightly opalescent, no visible particles 9M 187.1 5.6 — slightlyyellow (•), slightly opalescent, no visible particles 12M  181.5 5.7 —slightly yellow (•), slightly opalescent, no visible particles 2-8° C.6M 194.1 5.6 — slightly yellow (•), slightly (Inverted) opalescent, novisible particles 12M  186.6 5.7 — slightly yellow (•), slightlyopalescent, no visible particles  30° C./ 1M 187.7 5.7 — slightly yellow(•), slightly 65% opalescent, no visible particles RH 3M 189.3 5.7 —slightly yellow (•), slightly opalescent, no visible particles 6M 189.55.7 — slightly yellow (•), slightly opalescent, no visible particles 9M192.9 5.7 — slightly yellow (•), slightly opalescent, no visibleparticles 12M  188.3 5.7 — slightly yellow (•), slightly opalescent, novisible particles  40° C./ 1M 189.5 5.7 — slightly yellow (•), slightly75% opalescent, no visible particles RH 3M 188.3 8.7 — slightly yellow(•), slightly opalescent, no visible particles 6M 193.8 5.7 — slightlyyellow (•), slightly opalescent, no visible particles Initial 120.9 5.6299 slightly yellow (−), slightly opalescent, no visible particles −75°C. 6M 122.3 5.6 — slightly yellow (−), slightly opalescent, no visibleparticles 120 g/mL 2-8° C. 3M 121.0 5.6 321 slightly yellow (−),slightly SAN-300 opalescent, no visible particles  30 mM Acetate 6M124.6 5.6 — slightly yellow (−), slightly 220 mM Sorbitol opalescent, novisible particles NB1206p86C 0.01% PS-80, 2-8° C. 6M 122.9 5.6 —slightly yellow (−), slightly pH 5.5 (Inverted) opalescent, no visibleparticles  30° C./ 3M 122.7 5.6 — slightly yellow (−), slightly 65%opalescent, no visible particles RH 6M 124.4 5.6 — slightly yellow (−),slightly opalescent, no visible particles  40° C./ 3M 124.4 5.6 —slightly yellow (−), slightly 75% opalescent, no visible particles RH 6M125.6 5.7 — slightly yellow (−), slightly opalescent, no visibleparticles ^(a)The degree of sample coloration increases from (−) to (•)to (+). Low concentration (120 mg/mL) samples were retroactively gradedas slightly yellow (−) for time points earlier than 6 months.

TABLE 25B Histidine Formulation: Summary of Protein Content, pH, andAppearance Results for SAN-300 Stability Samples (Continued) ProteinOsmo- Time Content lality Sample Lot Formulation Condition Point (mg/mL)pH (mOsm/kg) Appearance^(a) NB1206p86A 180 mg/mL Initial 174.1 6.2 289slightly yellow (•), slightly SAN-300 opalescent, no visible particles 30 mM Acetate −75° C. 6M 179.4 6.2 — slightly yellow (•), slightly 220mM Sorbitol opalescent, no visible particles 0.01% PS-20, 12M  173.8 6.3— slightly yellow (•), slightly pH 6.0 opalescent, no visible particles2-8° C. 1M 176.5 6.2 331 slightly yellow (•), slightly opalescent, novisible particles 3M 175.8 6.2 319 slightly yellow (•), slightlyopalescent, no visible particles 6M 180.1 6.2 — slightly yellow (•),slightly opalescent, no visible particles 9M 178.9 6.2 — slightly yellow(•), slightly opalescent, no visible particles 12M  170.9 6.3 — slightlyyellow (•), slightly opalescent, no visible particles 2-8° C. 6M 184.56.2 — slightly yellow (•), slightly (Inverted) opalescent, no visibleparticles 12M  170.1 6.3 — slightly yellow (•), slightly opalescent, novisible particles 30° C./ 1M 179.9 6.2 — slightly yellow (•), slightly65% opalescent, no visible particles RH 3M 179.5 6.2 — slightly yellow(•), slightly opalescent, no visible particles 6M 180.2 6.2 — slightlyyellow (•), slightly opalescent, no visible particles 9M 177.7 6.2 —slightly yellow (•), slightly opalescent, no visible particles 12M 172.2 6.2 — slightly yellow (•), slightly opalescent, no visibleparticles 40° C./ 1M 176.5 6.2 — slightly yellow (•), slightly 75%opalescent, no visible particles RH 3M 184.3 6.2 — slightly yellow (•),slightly opalescent, no visible particles 6M 180.6 6.2 — slightly yellow(•), slightly opalescent, no visible particles NB1206p86C 120 g/mLInitial 117.8 6.1 287 slightly yellow (−), slightly SAN-300 opalescent,no visible particles  30 mM Acetate −75° C. 6M 120.9 6.2 — slightlyyellow (−), slightly 220 mM Sorbitol opalescent, no visible particles0.01% PS-80, 2-8° C. 3M 119.4 6.1 316 slightly yellow (−), slightly pH6.0 opalescent, no visible particles 6M 120.7 6.2 — slightly yellow (−),slightly opalescent, no visible particles 2-8° C. 6M 122.5 6.2 —slightly yellow (−), slightly (Inverted) opalescent, no visibleparticles 30° C./ 3M 118.4 6.1 — slightly yellow (−), slightly 65%opalescent, no visible particles RH 6M 119.9 6.1 — slightly yellow (−),slightly opalescent, no visible particles 40° C./ 3M 121.0 6.1 —slightly yellow (−), slightly 75% opalescent, no visible particles RH 6M118.8 6.1 — slightly yellow (−), slightly opalescent, no visibleparticles ^(a)The degree of sample coloration increases from (−) to (•)to (+). Low concentration (120 mg/mL) samples were retroactively gradedas slightly yellow (−) for time points earlier than 6 months.

Appearance.

Visual inspection of unopened sample vials was used to evaluate samplecolor, clarity, and the presence of particulate matter. As shown inTable 25, all samples were slightly opalescent and essentially free ofvisible particles, where high concentration formulations were noticeablymore yellow than those at low concentration. While somewhat increasedyellow color was observed in histidine formulations maintained at highertemperatures (after 6 months at 40° C., 12 months at 30° C.),formulations generally displayed consistent appearance by visualevaluation over the course of the study.

Protein Content.

Protein content was assessed for all samples over the course of thestability study (Table 25). No detectable loss of SAN-300 was observedfor any of the formulations, regardless of storage conditions.

pH.

Formulation pH was measured for all study samples. The initial pHreadings for high concentration histidine and acetate formulations were6.2 and 5.6, respectively. As shown in Table 25, pH remained constantthroughout the duration of the study, not varying more than 0.1 unitsfrom the initial reading in any formulation.

Example 10: Long Term Stability of SAN-300 Formulations: ParticulateMatter

The particulate matter in SAN-300 Formulations was assessed to determinetheir long term stability using the experimental design described inExample 7.

Methods for Assessing Particulate Matter

A Liquid Particle Counting System (Hach Model 9703, Sensor Model:HRLD-150 (HIAC)) was used for determining particle size and abundance inSAN-300 samples. The data was obtained using a single 500 μL draw ofsample. Due to the small sample volumes used in this study, the resultsgenerated do not fulfill USP <788>“Particulate Matter in Injections”requirements.

Briefly, the HIAC system was allowed to warm up for approximately 30minutes, and both the syringe (1 mL) and system were flushed withdeionized water for at least 10 cycles before use. Environmentsuitability was tested by showing that 25 mL of deionized watercontained no more than 25 particles ≥10 μm in size. If environmentsuitability failed, the system was flushed with deionized water until apassing measurement was obtained. System suitability was confirmed byanalyzing a single 500 μL draw of 15 μm standard using 10 μm and 25 μmchannel sizes. If cumulative counts/mL for the 10 μm channel fell withinthe specification given for the standard, then the system was deemedsuitable for sample testing. Before each sample, the system was againflushed with deionized water, until a single 500 μL draw of deionizedwater showed no particles greater than 10 μm in size. Sample wasanalyzed using a single 500 μL draw, and cumulative counts/mL for 10 μmand 25 μm channels were determined and reported to the nearest wholenumber.

Results

Particle counting by HIAC was performed for all samples over the courseof the stability study. The results are shown in Table 26.

TABLE 26 Summary of HIAC Results for SAN-300 Stability Samples (timepoints are measured in months) Cumulative Time Counts/mL^(a) Sample LotFormulation Condition Point 10 μm 25 μm NB1206p86A 190 mg/mL Initial1492 22 SAN-300 −75° C.  6M 1446 200 30 mM Acetate 12M 1550 142 220 mMSorbitol  2-8° C.  1M 2540 154 0.01% PS-80,  3M 36 4 pH 5.5  6M 1200 186 9M 150 64 12M 966 68  2-8° C.  6M 22 2 (Inverted) 12M 1126 104 30°C./65% RH  1M 1682 140  3M 8 6  6M 44 0  9M 414 4 12M 940 28 40° C./75%RH  1M 2310 104  3M 42 6  6M 212 16 NB1206p86C 120 mg/mL Initial 154 0SAN-300 −75° C.  6M 48 2 30 mM Acetate  2-8° C.  3M 24 4 220 mM Sorbitol 6M 142 44 0.01% PS-80,  2-8° C.  6M 20 0 pH 5.5 (Inverted) 30° C./65%RH  3M 10 0  6M 58 8 40° C./75% RH  3M 4 0  6M 46 0 NB1206p86B 180 mg/mLInitial 802 10 SAN-300 −75° C.  6M 356 20 30 mM Histidine 12M 582 12 250mM Sorbitol  2-8° C.  1M 1464 46 0.01% PS-20,  3M 38 10 pH 6.0  6M 42646  9M 34 8 12M 478 8  2-8° C.  6M 432 28 (Inverted) 12M 930 0 30°C./65% RH  1M 2280 110  3M 118 42  6M 48 2  9M 2 0 12M 2 0 40° C./75% RH 1M 1818 48  3M 88 28  6M 198 10 NB1206p86D 120 mg/mL Initial 80 0SAN-300 −75° C.  6M 104 34 30 mM Histidine  2-8° C.  3M 52 12 250 mMSorbitol  6M 80 12 0.01% PS-20,  2-8° C.  6M 146 40 pH 6.0 (Inverted)30° C./65% RH  3M 46 6  6M 22 0 40° C./75% RH  3M 22 0  6M 82 4^(a)Determined by a single sample draw of 500 μLFor all formulations and conditions, particle counts were well below theparticle limits for injection set by USP <788>(6000 for 10 μm, and 600for 25 μm particles). All formulations adequately suppressed particleformation during long-term SAN-300 storage under both intended storageconditions (−75° C. and 2-8° C.) and accelerated or stressed conditions(30° C. or 40° C.).

Example 11: Long Term Stability of SAN-300 Formulations: Purity

The purity of SAN-300 Formulations was assessed with reduced SDS-PAGEand size exclusion chromatography using the experimental designdescribed in Example 7.

Methods

Reduced Polyacrylamide Gel Electrophoresis.

Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) was used toassess SAN-300 sample purity by size separation of sampleproteins/peptides. Samples, controls and reference standard wereprepared to 2.0 mg/mL in 1× Tris-Glycine SDS sample buffer (containingNuPAGE® sample reducing agent), centrifuged, and heat denatured for 1minute at 95° C. followed by an additional centrifugation step. Gelswere loaded at 20 μg per lane, and electrophoresis was performed for 60minutes at maximum voltage, 250 watts, and 30 mAmp/gel. Followingelectrophoresis, gels were stained for a minimum of 3 hours withColloidal Blue and destained overnight. Gels were dried with a DryEase®mini-gel drying system, imaged, and analyzed by densitometry using theGeneGenius Bioimaging system.

The percent heavy chain (HC), light chain (LC), and IgG were determinedfrom densitometry data for each SDS-PAGE sample, in addition to totallane density (raw volume). To better account for variability betweengels, the abundances of HC, LC, and IgG were reported relative to theinternal reference standard run on each gel. For visualization purposes,percent IgG loss was also reported. Material from both Lots of SAN-300(CP4-04-109 and CP4-04-106) used to generate stability samples were runat T₀ and deemed equivalent. CP4-04-109 was used as reference for theremainder of the study.

Size Exclusion Chromatography.

Size exclusion chromatography (SEC) was used to evaluate the quantity ofaggregates and degradation products present in SAN-300 samples. AnAgilent 1100 HPLC system was fitted with a TSKgel G3000SWx1 SEC column(Tosoh, 7.8 mm×30 cm, 5 μm particle size) and SWx1 guard column (Tosoh,6 mm×4 cm, 7 μm particle size). Samples were diluted to 1 mg/mL in SECmobile phase (100 mM sodium phosphate, 200 mM sodium chloride, pH 7.2)and 40 μL of sample was injected in duplicate. The system was run usinga flow rate of 1.0 mL/min, and eluted protein was detected by absorbancemeasured at 215 nm. The percent total chromatogram area was reported forthe monomer peak, in addition to each individual high molecular weight(HMW) species and low molecular weight impurity (LMWI). Material fromboth Lots of SAN-300 (CP4-04-109 and CP4-04-106) used to generatestability samples were run at T0 and deemed equivalent. CP4-04-109 wasused as reference for the remainder of the study. Samples were run inthe following sequence order: blank (1×), reference (1×), samples (2×),reference (1×), blank (1×), where a bracketing reference injection wasperformed after every 15 samples (30 injections).

Results

Reduced Polyacrylamide Gel Electrophoresis.

The purity of all stability samples was evaluated by reduced SDS-PAGE.The results are shown in Table 27.

TABLE 27 Summary of Reduced SDS-PAGE Results for SAN-300 StabilitySamples (time points are measured in months) NB1206p86A 190 mg/mLInitial 98.1 101.4 99.2 0.8 SAN-300 −75° C. 6M 101.8 102.1 101.9 −1.9 30 mM 12M  99.2 99.0 99.2 0.8 Acetate  2-8° C. 1M 94.3 99.7 96.0 4.0220 mM 3M 94.1 92.7 93.6 6.4 Sorbitol 6M 97.6 102.4 99.1 0.9 0.01% 9M97.6 95.9 97.1 2.9 PS-80, 12M  93.5 95.0 93.9 6.1 pH 5.5  2-8° C. 6M101.0 102.7 101.5 −1.5 (Inverted) 12M  94.4 94.3 94.4 5.6 30° C./ 1M95.8 99.9 97.1 2.9 65% 3M 88.9 82.3 86.6 13.4 RH 6M 89.6 82.8 87.5 12.59M 80.8 77.3 79.6 20.4 12M  79.3 73.9 77.7 22.3 40° C./ 1M 86.9 94.089.0 11.0 75% 3M 77.2 75.8 76.7 23.3 RH 6M 78.0 78.4 78.1 21.9NB1206p86C 120 mg/mL Initial 103.4 97.2 101.4 −1.4 SAN-300 −75° C. 6M98.2 105.8 100.7 −0.7  30 mM  2-8° C. 3M 98.2 96.7 97.7 2.3 Acetate 6M100.7 96.8 99.4 0.6 220 mM 2-8° C. 6M 98.9 97.8 100.7 2.2 Sorbitol(Inverted) 0.01% 30° C./65% 3M 95.7 92.2 94.6 5.4 PS-80, RH 6M 88.2 88.788.4 11.6 pH 5.5 40° C./75% 3M 83.3 77.5 81.5 18.5 RH 6M 85.3 79.3 83.316.7 NB1206p86B 180 mg/mL Initial 101.5 103.9 102.3 −2.3 SAN-300 −75° C.6M 97.5 105.3 100.1 −0.1  30 mM 12M  98.8 101.6 99.6 0.4 Histidine, 2-8° C. 1M 99.9 97.3 99.1 0.9 250 mM 3M 98.3 100.5 99.0 1.0 Sorbitol,6M 97.8 101.6 99.1 0.9 0.01% 9M 101.4 98.5 100.5 −0.5 PS-20, 12M  96.799.3 97.4 2.6 pH 6.0  2-8° C. 6M 100.7 99.0 100.1 −0.1 (Inverted) 12M 93.5 94.6 93.8 6.2 30° C./ 1M 95.8 92.0 94.5 5.5 65% 3M 92.2 94.6 93.07.0 RH 6M 88.3 93.2 89.9 10.1 9M 80.5 81.0 80.6 19.4 12M  80.9 76.3 79.520.5 40° C./ 1M 87.9 84.7 86.8 13.2 75% 3M 81.2 83.7 82.0 18.0 RH 6M71.3 76.2 72.9 27.1 NB1206p86D 120 mg/mL Initial 102.3 98.7 101.1 −1.1SAN-300 −75° C. 6M 97.2 99.1 97.8 2.2  30 mM  2-8° C. 3M 100.0 94.8 98.31.7 Histidine, 6M 97.4 98.3 97.7 2.3 250 mM  2-8° C. 6M 99.6 102.6 100.5−0.5 Sorbitol, (Inverted) 0.01% 30° C./65% 3M 93.1 91.4 92.6 7.4 PS-20,RH 6M 90.7 88.5 90.0 10.0 pH 6.0 40° C./75% 3M 83.5 88.1 85.0 15.0 RH 6M78.2 82.8 79.6 20.4 ^(a)Data are reported relative to the internalreference run on the same gel.Given the variability inherent to this method, the abundances of heavychain, light chain, and IgG in stability samples were reported relativeto values obtained for the internal reference run on each gel. Inaddition, the percent IgG loss was also reported.

Both high-concentration formulations trended comparably under allstorage conditions and remained stable after 12 months at 2-8° C.Histidine slightly outperformed acetate at a majority of time points for2-8° C. and 30° C. samples. Small reductions in IgG content (˜5%) wereobserved for upright 2-8° C. samples for both formulations after 12months, with comparable results for inverted samples held at thistemperature. Twelve month samples maintained at −75° C. for bothformulations were comparable to measurements at the initial time point.Lower SAN-300 concentration samples showed a small apparent increase instability, relative to associated high-concentration solutions. Whilethis concentration-dependent effect on intact IgG was nearlyundetectable at 2-8° C. at the six month time point, it was morepronounced at elevated temperatures (>5% at 40° C.).

Size Exclusion Chromatography (SEC).

The purity of SAN-300 stability study samples was evaluated by SEC(Table 28), where the percent abundances of all HMW and LMWI speciesobserved were reported.

TABLE 28 Summary of SEC Results for SAN-300 Stability Samples (timepoints are measured in months) Aggregate Aggregate Aggregate MonomerLMWI 1 LMWI 2 Time 3 Average 2 Average 1 Average Average Average AverageSample Lot Formulation Condition Point % Area % Area % Area % Area %Area % Area NB1206p86A 190 mg/mL Initial — 0.1 2.6 96.9 — 0.5 SAN-300−75° C.  6M — 0.1 2.6 — — 0.5  30 mM 12M  — <0.1 2.3 — — 0.5 Acetate2-8° C. 1M — 0.1 2.7 96.8 — 0.5 220 mM 3M — 0.1 3.0 96.4 — 0.5 Sorbitol6M — 0.1 3.2 96.2 — 0.5 0.01% PS-80, 9M — 0.1 3.1 96.3 — 0.5 pH 5.5 12M — 0.1 3.3 96.1 — 0.5 2-8° C. 6M — 0.1 3.4 96.0 — 0.5 (Inverted) 12M  —0.1 3.3 96.1 — 0.5 30° C./ 1M — 0.1 3.5 95.8 — 0.6 65% 3M — 0.2 4.4 94.5— 0.9 RH 6M — 0.3 5.2 93.3 — 1.3 9M — 0.2 5.2 92.9 — 1.6 12M  — 0.4 5.788.0 4.1 1.9 40° C./ 1M — 0.2 4.4 94.6 — 0.9 75% 3M — 0.6 6.2 91.2 — 2.0RH 6M 0.3 1.0 8.8 80.1 3.3 6.6 NB1206p86C 120 mg/mL Initial — 0.1 2.097.4 — 0.5 SAN-300 −75° C.  6M — <0.1 2.1 97.4 — 0.5  30 mM 2-8° C. 3M —<0.1 2.4 97.1 — 0.5 Acetate 6M — 0.1 2.7 96.8 — 0.5 220 mM 2-8° C. 6M —0.1 2.6 96.8 — 0.5 Sorbitol (Inverted) 0.01% PS-80, 30° C./65% 3M — 0.13.3 95.8 — 0.9 pH 5.5 RH 6M — 0.1 3.7 94.9 — 1.2 40° C./75% 3M — 0.2 4.693.3 — 1.9 RH 6M 0.1 0.5 6.0 83.4 3.0 7.0 NB1206p86B 180 mg/mL Initial —0.1 2.6 96.9 — 0.4 SAN-300 −75° C.  6M <0.1 0.1 2.8 96.6 — 0.5  30 mM12M  <0.1 0.1 2.5 97.0 — 0.4 Histidine, 2-8° C. 1M — 0.1 2.5 97.0 — 0.4250 mM 3M — 0.1 2.8 96.7 — 0.5 Sorbitol, 6M <0.1 0.1 3.1 96.3 — 0.50.01% 9M <0.1 0.1 2.7 96.6 — 0.5 PS-20, 12M  <0.1 0.1 2.8 96.6 — 0.5 pH6.0 2-8° C. 6M <0.1 0.1 2.9 96.5 — 0.5 (Inverted) 12M  <0.1 0.1 2.8 96.6— 0.5 30° C./ 1M — 0.1 2.9 96.5 — 0.5 65% 3M — 0.2 3.6 95.4 — 0.8 RH 6M<0.1 0.2 4.2 94.4 — 1.2 9M <0.1 0.2 4.5 93.7 — 1.6 12M <0.1 0.3 5.0 88.94.0 1.9 40° C./ 1M — 0.1 3.4 95.7 — 0.8 75%  3M — 0.4 5.0 92.9 — 1.7 RH6M 0.2 0.6 6.6 83.9 2.8 5.9 NB1206p86D 120 mg/mL Initial — 0.1 2.3 97.2— 0.4 SAN-300 −75° C.  6M <0.1 0.1 2.5 97.0 — 0.5  30 mM 2-8° C. 3M —0.1 2.3 97.2 — 0.5 Histidine, 6M <0.1 0.1 2.5 96.9 — 0.5 250 mM 2-8° C.6M <0.1 2.4 0.1 97.0 — 0.5 Sorbitol, (Inverted) 0.01% 30° C./ 3M — 0.12.7 96.3 — 0.8 PS-20, 65% 6M <0.1 0.1 3.2 95.4 — 1.2 pH 6.0 RH 40° C./3M — 0.2 3.7 94.4 — 1.8 75% 6M 0.1 0.3 4.8 85.6 2.9 6.3 RHSimilar to SDS-PAGE data, SEC results showed that high-concentrationSAN-300 formulated in histidine results in reduced degradation ofmonomer relative to acetate. At the 12 month time point, histidinesamples at 2-8° C. (96.6% monomer) were nearly indistinguishable frommaterial at the initial time point (96.9% monomer), while the acetateformulation displayed somewhat elevated levels of HMW material (FIG. 5).Data for inverted and frozen samples for both formulations werecomparable to results for the upright 2-8° C. samples. Samples underaccelerated and stressed conditions revealed more dramatic differencesbetween the performances of the two high-concentration formulations. Atthe 6 month time point for example, 40° C. histidine samples showedmonomer content of ˜84%, while counterpart acetate samples showed only˜80%. These differences in monomer content were associated almostentirely with aggregate content, as LMWI formation did not appear to bebuffer-dependent. As shown in the representative overlays presented inFIG. 6, a total of three HMW species were observed over the course ofthe study, where Aggregate 1 (dimer) represented the majority of HMWcontent. Formation of the higher-order Aggregates 2 and 3 was bothtemperature- and buffer-dependent, where histidine was again superior toacetate buffer. In addition to the SAN-300 fragment LMWI 2, observed inall samples to varying degrees, accelerated and stressed conditions ledto the formation of LMWI 1, which presented as a trailing shoulder offthe monomer peak.

Results for low-concentration formulations mirrored those describedabove, where acetate-buffered samples displayed reduced monomer contentcompared with corresponding histidine samples (Table 28). As would beexpected, both low concentration formulations had reduced propensity foraggregate formation relative to their high-concentration counterparts.This effect was strongly temperature dependent, where differences intotal aggregate between low and high-concentration samples were ˜0.5%for 2-8° C. samples and up to 3.5% for those at 40° C. Fragmentationinto LMWI was not SAN-300 concentration-dependent.

Example 12: Lone Term Stability of SAN-300 Formulations: ChargeHeterogeneity

The charge heterogeneity of SAN-300 formulations was assessed withcation exchange chromatography using the experimental design describedin Example 7.

Method

An Agilent 1100 HPLC system was fitted with a ProPac WCX-10 CEX column(Dionex, 4×250 mm) and a Propac WCX-10G Guard Column, (Dionex, 4×50 mm).SAN-300 samples were diluted to 1.0 mg/mL in mobile phase A (10 mMsodium phosphate, pH 7.5) and 75 μL was injected in duplicate. Agradient was run using buffer B (10 mM sodium phosphate, 100 mM sodiumchloride, pH 7.5) and buffer C (10 mM sodium phosphate, 2 M sodiumchloride, pH 7.5), where protein was detected by absorbance measured at280 nm.

The abundances of main peak, acidic variants, and basic variants werereported for each sample as percent total chromatogram peak area. Thetwo Lots of SAN-300 (CP4-04-109 and CP4-04-106) used to generateformulations for the present study displayed slightly different chargeprofiles as determined by CEX. To account for this variability, percentmain, acidic, and basic species were also reported relative to theLot-appropriate reference standard run within a given HPLC sequence.Samples were run in the following sequence order: blank (1×), CP4-04-109reference (1×), CP4-04-106 reference (1×), samples (2×), CP4-04-109reference (1×), CP4-04-106 reference, blank (1×), where bracketingreference injections were performed after every 15 samples (30injections).

Results

Charge heterogeneity was determined by CEX for all stability samples.The results are shown in Table 29 and Table 30. The percent abundancesof main peak, and total acidic and basic charge variants were reported.

TABLE 29 Summary of CEX Results for SAN-300 Stability Samples (timepoints are measured in months) Acidic Main Basic Peaks Peak Peaks TimeAverage Average Average Sample Lot Formulation Condition Point % Area %Area % Area NB1206p86A 190 mg/mL SAN-300 Initial 34.7 56.4 9.0 30 mMAcetate −75° C.  6M 34.8 56.2 9.0 220 mM Sorbitol 12M  34.8 55.8 9.40.01% PS-80, 2-8° C. 1M 34.4 53.5 12.1 pH 5.5 3M 33.6 54.5 11.9 6M 34.956.5 8.6 9M 33.5 57.4 9.0 12M  33.7 58.3 8.0 2-8° C. 6M 34.9 56.7 8.4(Inverted) 12M  34.2 57.9 8.0 30° C./ 1M 37.7 53.2 9.1 65% 3M 46.8 46.66.7 RH 6M 69.2 27.6 3.1 9M 78.4 17.4 4.2 12M  85.8 12.5 1.7 40° C./ 1M50.3 42.6 7.1 75% 3M 76.8 19.6 3.7 RH 6M NA^(a) NA^(a) NA^(a) NB1206p86C120 mg/mL SAN-300 Initial 34.6 56.9 8.6 30 mM Acetate −75° C.  6M 35.456.1 8.5 200 mM Sorbitol 2-8° C. 3M 34.9 55.0 10.1 0.01% PS-80, 6M 34.957.2 7.9 pH 5.5 2-8° C. 6M 35.1 57.1 7.8 (Inverted) 30° C./65% 3M 47.447.0 5.6 RH 6M 70.1 27.5 2.4 40° C./75% 3M 76.6 19.8 3.6 RH 6M NA^(a)NA^(a) NA^(a) NB1206p86B 180 mg/mL SAN-300 Initial 32.4 59.5 8.1 30 mMHistidine −75° C.  6M 33.3 58.3 8.4 250 mM Sorbitol 12M  32.8 58.6 8.60.01% PS-20, 2-8° C. 1M 32.6 55.8 11.6 pH 6.0 3M 33.2 57.3 9.5 6M 34.458.7 6.9 9M 32.5 60.7 6.8 12M  34.0 59.7 6.4 2-8° C. 6M 34.1 59.0 6.9(Inverted) 12M  34.3 59.0 6.7 30° C./ 1M 36.4 56.3 7.3 65% 3M 46.1 49.44.5 RH 6M 65.9 32.3 1.8 9M 75.2 22.8 2.0 12M  81.3 17.0 1.7 40° C./ 1M46.9 46.6 6.5 75% 3M 72.0 23.8 4.2 RH 6M NA^(a) NA^(a) NA^(a) NB1206p86D120 mg/mL SAN-300 Initial 32.3 59.3 8.5 30 mM Histidine −75° C.  6M 31.960.5 7.6 250 mM Sorbitol 2-8° C. 3M 31.3 58.7 10.0 0.01% PS-20, 6M 32.861.4 5.8 pH 6.0 2-8° C. 6M 32.3 61.9 5.8 (Inverted) 30° C./65% 3M 45.149.7 5.2 RH 6M 65.9 33.0 1.1 40° C./75% 3M 72.4 24.5 3.1 RH 6M NA^(a)NA^(a) NA^(a) ^(a)Due to excessive degradation, samples were notintegrated. Unlike other analytical methods used in the present study, asmall variation in charge heterogeneity was observed between the twoSAN-300 Lots used in preparation of the study samples. For this reason,CEX results were also reported as the percent change, relative to thelot specific reference standard run in a given HPLC sequence (see Table30).

TABLE 30 Summary of CEX Results for SAN-300 Stability Samples: Relativeto Internal Reference (time points are measured in months) Acidic MainBasic Peaks % Peak % Peaks % Change Change Change Time from from fromSample Lot Formulation Condition Point Ref Std Ref Std Ref StdNB1206p86A 190 mg/mL SAN-300 Initial 0.0 −0.4 2.3 30 mM Acetate −75° C. 6M 1.2 −1.5 5.0 220 mM Sorbitol 12M^(a) 3.2 −1.6 −1.8 0.01% PS-80, 2-8°C. 1M 0.3 0.0 −0.8 pH 5.5 3M 4.5 −4.3 9.5 6M 1.7 −1.0 −0.4 9M −0.1 1.3−6.3 12M^(a) −0.1 2.8 −16.0 2-8° C. 6M 1.7 −0.6 −2.7 (Inverted) 12M^(a)1.3 2.1 −16.9 30° C./ 1M 9.9 −0.6 −25.4 65% 3M 45.4 −18.3 −38.6 RH 6M10.7 −51.6 −63.6 9M 133.5 −69.3 −56.1 12M^(a) 154.3 −78.0 −81.8 40° C./1M 46.6 −20.4 −41.8 75% 3M 138.7 −65.7 −66.4 RH 6M NA NA NA NB1206p86C120 mg/mL SAN-300 Initial −0.2 0.5 −2.4 30 mM Acetate −75° C.  6M 3.0−1.7 −0.6 220 mM Sorbitol 2-8° C. 3M 8.4 −3.4 −7.1 0.01% PS-80, 6M 1.80.1 −8.0 pH 5.5 2-8° C. 6M 2.2 0.1 −9.3 (Inverted) 30° C./65% 3M 47.4−17.6 −48.1 RH 6M 104.1 −51.8 −71.6 40° C./75% 3M 138.1 −65.3 −66.5 RH6M NA NA NA NB1206p86B 180 mg/mL SAN-300 Initial 0.6 −0.1 −1.9 30 mMHistidine −75° C.  6M 4.2 −2.4 1.4 250 mM Sorbitol 12M 3.7 −0.9 −6.80.01% PS-20, 2-8° C. 1M 1.9 0.2 −5.7 pH 6.0 3M 4.3 0.7 −15.5 6M 7.6 −1.7−16.9 9M 4.5 2.3 −28.8 12M 7.4 0.8 −30.9 2-8° C. 6M 6.6 −1.3 −16.1(Inverted) 12M 8.3 −0.3 −26.6 30° C./ 1M 13.8 1.1 −40.7 65% 3M 44.8−13.1 −60.4 RH 6M 106.0 −45.9 −78.8 9M 141.5 −61.6 −79.2 12M 157.0 −71.3−81.2 40° C./ 1M 46.6 −16.3 −47.2 75% 3M 126.2 −58.2 −62.5 RH 6M NA NANA NB1206p86D 120 mg/mL Initial 0.2 −0.4 2.0 SAN-300 −75° C.  6M −0.31.2 −7.8 30 mM Histidine 2-8° C. 3M −1.7 3.2 −11.5 250 mM Sorbitol 6M2.6 2.8 −30.2 0.01% PS-20, 2-8° C. 6M 0.9 3.6 −29.9 pH 6.0 (Inverted)30° C./65% 3M 41.8 −12.7 −54.1 RH 6M 106.0 −44.8 −86.8 40° C./75% 3M127.5 −56.9 −72.7 RH 6M NA NA NA ^(a)Due to a pressure-failure, thefinal bracketing reference was not run. Values are calculated using asingle reference injection. ^(b)Due to excessive degradation, sampleswere not integratedThe two data sets were comparable.

Both high-concentration formulations retained their initial chargeheterogeneity profile after 12 months storage at −75° C. and 2-8° C.While results for formulations NB1206p86A and NB1206p86B were nearlyindistinguishable at intended storage conditions, accelerated andstressed conditions more clearly established that the histidine buffersystem led to reduced changes in SAN-300 charge heterogeneity. BothNB1206p86A and NB1206p86B showed similar trends at 30° C. and 40° C.,with the histidine formulation consistently retaining more of itsinitial charge profile. The shift to more acidic variants at elevatedtemperatures was not found to be concentration-dependent, aslow-concentration samples were indistinguishable from associatedhigh-concentration samples.

CONCLUSIONS

Both high-concentration formulations displayed excellent stability forup to 12 months under intended storage conditions (−75° C. and 2-8° C.).Results from SEC, SDS-PAGE and CEX indicate that compared with theacetate formulation, the histidine formulation provides better SAN-300stability.

Example 13: Exemplary Liquid Formulation

A liquid formulation containing 180 mg/mL of anti-VLA 1 monoclonalantibody having a light chain sequence of SEQ ID NO: 1 and a heavy chainsequence of SEQ ID NO:2 in 30 mM histidine, 250 mM sorbitol, 0.01%polysorbate 20, pH 6.0, with a final fill volume of 1 mL/vial wasproduced using methods described in Example 6. The formulation met eachof the criteria shown in Table 31. The formulation was packaged forstorage at 2-8° C. in a 2 ml. USP Type 1 borosilicate glass vial with a13 mm chlorobutyl based stopper with flourotech coating on plug and B2coating on the top and an aluminum over seal with flip top cap.

TABLE 31 Specifications Attribute Criterion General Appearance Clear toopalescent (see USP <631>) Slightly yellow to yellow Essentially freefrom visible particulate matter pH 5-7 (see USP <791>) Particulates ≥10μm particles: ≤6000 (see USP <788>) particles per container ≥25 μmparticles: ≤600 particles per container Osmolality 270-380 mOsm/Kg (seeUSP<785>) Protein 165-190 mg/mL Concentration (A280) Identity¹ ChargeProfile by pI of the main peak is ± 0.1 Imaging Capillary from that ofthe reference Isoelectric standard Focusing (icIEF) Potency (ELISA)Demonstrates Binding to Integrin α1 I domain Biological Potency (ELISA)80%-125% of Reference Potency Standard Purity and Impurities by TotalImpurities <15.0% impurities Reducing CE- SDS Impurities by Totalimpurities <15.0% Non-Reducing CE-SDS Aggregation by ≤10.0% TotalAggregation Size Exclusion Chromatography (SEC) Safety Endotoxin ≤90.0EU/mL Sterility Complies with USP requirements

1.-20. (canceled)
 21. A method of treating an inflammatory, immune, orautoimmune disorder in a patient comprising administering to the patientan effective amount of an aqueous antibody pharmaceutical compositioncomprising: (a) about 150 to about 210 mg/mL of an anti-VLA-1 (anti-VeryLate Antigen-1) antibody, said antibody having one or both of: a lightchain variable region having the amino acid sequence of SEQ ID NO:4 anda heavy chain variable region having the amino acid sequence of SEQ IDNO:5; (b) 25 to 35 mM histidine; (c) 170 to 288 mM sorbitol; and (d)0.008 to 0.012% polysorbate; and wherein the aqueous pharmaceuticalcomposition has a pH of 5 to
 7. 22. A method of treating an inflammatorydisorder in a patient, said method comprising administering to saidpatient an effective amount of the aqueous pharmaceutical compositioncomprising: (a) about 150 to about 210 mg/mL of an anti-VLA-1 (anti-VeryLate Antigen-1) antibody, said antibody having one or both of: a lightchain variable region having the amino acid sequence of SEQ ID NO:4 anda heavy chain variable region having the amino acid sequence of SEQ IDNO:5; (b) 25 to 35 mM histidine; (c) 170 to 288 mM sorbitol; and (d)0.008 to 0.012% polysorbate; and wherein the aqueous pharmaceuticalcomposition has a pH of 5 to
 7. 23. The method of claim 22, wherein saidinflammatory disorder is inflammatory bowel disease.
 24. The method ofclaim 22, wherein said inflammatory disorder is rheumatoid arthritis andthe patient is an adult patient.
 25. The method of claim 23, whereinsaid aqueous pharmaceutical composition is administered subcutaneously.26. The method of claim 23, wherein said aqueous pharmaceuticalcomposition is administered weekly.
 27. The method of claim 26, whereinsaid aqueous pharmaceutical composition is administered subcutaneously.28. The method of claim 23, wherein said aqueous pharmaceuticalcomposition is administered weekly for at least 6 weeks.
 29. The methodof claim 23, wherein said aqueous pharmaceutical composition isadministered to the patient at a dose of 2.0 mg/kg to 6.0 mg/kg.
 30. Themethod of claim 23, wherein said patient has demonstrated an inadequateresponse to a prior alternate treatment for the inflammatory disorder.31. The method of claim 21, wherein said inflammatory disorder isinflammatory bowel disease.
 32. The method of claim 21, wherein saidinflammatory disorder is rheumatoid arthritis and the patient is anadult patient.
 33. The method of claim 32, wherein said adult patienthas demonstrated an inadequate response to a prior alternate treatmentfor rheumatoid arthritis such that said patient fails to achieve ACR20after the prior alternate treatment.
 34. The method of claim 32, whereinsaid adult patient has demonstrated an inadequate response to a prioralternate treatment for rheumatoid arthritis such that said patientfails to achieve ACR50 after the prior alternate treatment.
 35. Themethod of claim 32, wherein said adult patient has demonstrated aninadequate response to a prior alternate treatment for rheumatoidarthritis such that said patient fails to achieve ACR70 after the prioralternate treatment.
 36. The method of claim 32, wherein said aqueouspharmaceutical composition is administered subcutaneously once weekly tosaid adult patient.
 37. The method of claim 32, wherein said prioralternate treatment comprises a biologic agent.
 38. The method of claim32, wherein said prior alternate treatment comprises an agent selectedfrom infliximab, adalimumab, certolizumab pegol, golimumab, etanerceptabatacept, rituximab, tocilizumab, tofacitinib, methotrexate,leflunomide, sulfasalazine, and hydroxychloroquine.